{"status": "ok", "message-type": "work-list", "message-version": "1.0.0", "message": {"facets": {}, "total-results": 932909, "items": [{"indexed": {"date-parts": [[2019, 11, 24]], "date-time": "2019-11-24T00:01:45Z", "timestamp": 1574553705320}, "reference-count": 0, "publisher": "Alphamed Press", "issue": "11", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["The Oncologist"], "published-print": {"date-parts": [[2014, 11, 1]]}, "DOI": "10.1634/theoncologist.2014-0032", "type": "journal-article", "created": {"date-parts": [[2014, 10, 18]], "date-time": "2014-10-18T04:03:59Z", "timestamp": 1413605039000}, "page": "1156-1168", "source": "Crossref", "is-referenced-by-count": 47, "title": ["Targeted Therapies in Metastatic Colorectal Cancer: A Systematic Review and Assessment of Currently Available Data"], "prefix": "10.1634", "volume": "19", "author": [{"given": "M. M.", "family": "Kirstein", "sequence": "first", "affiliation": []}, {"given": "A.", "family": "Lange", "sequence": "additional", "affiliation": []}, {"given": "A.", "family": "Prenzler", "sequence": "additional", "affiliation": []}, {"given": "M. P.", "family": "Manns", "sequence": "additional", "affiliation": []}, {"given": "S.", "family": "Kubicka", "sequence": "additional", "affiliation": []}, {"given": "A.", "family": "Vogel", "sequence": "additional", "affiliation": []}], "member": "638", "published-online": {"date-parts": [[2014, 10, 17]]}, "container-title": ["The Oncologist"], "language": "en", "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1634/theoncologist.2014-0032", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2016, 12, 23]], "date-time": "2016-12-23T00:15:56Z", "timestamp": 1482452156000}, "score": 61.82743, "issued": {"date-parts": [[2014, 10, 17]]}, "references-count": 0, "journal-issue": {"published-online": {"date-parts": [[2014, 11, 5]]}, "published-print": {"date-parts": [[2014, 11, 1]]}, "issue": "11"}, "URL": "http://dx.doi.org/10.1634/theoncologist.2014-0032", "ISSN": ["1083-7159", "1549-490X"], "issn-type": [{"value": "1083-7159", "type": "print"}, {"value": "1549-490X", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 12, 2]], "date-time": "2019-12-02T14:00:15Z", "timestamp": 1575295215492}, "reference-count": 57, "publisher": "Walter de Gruyter GmbH", "issue": "2", "license": [{"URL": "http://creativecommons.org/licenses/by-nc-nd/4.0", "start": {"date-parts": [[2018, 5, 7]], "date-time": "2018-05-07T00:00:00Z", "timestamp": 1525651200000}, "delay-in-days": 0, "content-version": "unspecified"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2018, 6, 27]]}, "abstract": "<jats:title>Abstract</jats:title>\n<jats:sec id=\"j_iss-2018-0012_s_999\">\n<jats:title id=\"d5257143e30295\">Introduction:</jats:title>\n<jats:p>Metastatic colorectal cancer (mCRC) is one of the most common cancers and the second leading cause of cancer worldwide. With the improvement of systemic and operative therapies, median overall survival (mOS) reached 30 months or longer. Here, we will review the use of the anti-vascular endothelial growth factor (VEGF) and anti-epidermal growth factor receptor (EGFR) antibodies in combination with doublet and triplet chemotherapy in patients with borderline and primary unresectable mCRC.</jats:p></jats:sec>\n<jats:sec id=\"j_iss-2018-0012_s_998\">\n<jats:title id=\"d5257143e30303\">Methods:</jats:title>\n<jats:p>Phases II and III trials were included in investigating chemotherapy in the first-line in combination with an anti-VEGF(R) or anti-EGFR in a cohort of patients with mCRC.</jats:p></jats:sec>\n<jats:sec id=\"j_iss-2018-0012_s_997\">\n<jats:title id=\"d5257143e30311\">Results:</jats:title>\n<jats:p>The VEGF-antibody bevacizumab has improved progression-free survival (PFS) in several phase III trials in combination with a chemotherapy doublet. More recently, a higher efficacy has been demonstrated in combination with an intensified chemotherapy including 5-fluoropyrimidine (5-FU), oxaliplatin, and irinotecan within the phase III TRIBE study. Similarly, high resectability rates have been shown in the phase II Olivia trial for patients with liver-limited disease with an intensified chemotherapeutic regime. However, this increase in efficacy was accompanied by an increase in toxicity as well. The efficacy of the EGFR-antibodies cetuximab and panitumumab has been shown in several phase III trials, but their use is restricted to patients whose tumors are RAS wildtype (WT). The phase II trials, CELIM and PLANET, demonstrated a favorable long-term survival for patients with initially non-resectable colorectal liver metastases who respond to conversion therapy with EGFR-antibodies and undergo secondary resection. The CLGB and FIRE-3 trials delivered an inconsistent finding whether anti-VEGF or -EGFR treatment is the better option in the first-line setting. However, there is increasing evidence from <jats:italic>post hoc</jats:italic> analyses of prospective clinical trials that patients with left-sided tumors benefit from EGFR-directed combination therapy in terms of prolongation of OS and PFS compared with limited, if any, benefit for those with right-sided tumors.</jats:p></jats:sec>\n<jats:sec id=\"j_iss-2018-0012_s_996\">\n<jats:title id=\"d5257143e30322\">Conclusion:</jats:title>\n<jats:p>Both anti-VEGF- and anti-EGFR-directed therapies represent efficient treatment options for patients with mCRC in the first line. For patients with RAS WT, left-sided tumor anti-EGFR-based treatment is recommended. Intensified regimens can be offered initially to unresectable patients in order to achieve resectability at a price of higher toxicity.</jats:p></jats:sec>", "DOI": "10.1515/iss-2018-0012", "type": "journal-article", "created": {"date-parts": [[2018, 5, 6]], "date-time": "2018-05-06T22:16:07Z", "timestamp": 1525644967000}, "page": "85-86", "source": "Crossref", "is-referenced-by-count": 0, "title": ["First-line molecular therapies in the treatment of metastatic colorectal cancer \u2013 a literature-based review of phases II and III trials"], "prefix": "10.1515", "volume": "3", "author": [{"given": "Arndt", "family": "Vogel", "sequence": "first", "affiliation": []}, {"given": "Martha M.", "family": "Kirstein", "sequence": "additional", "affiliation": []}], "member": "374", "reference": [{"key": "ref11", "volume": "5", "first-page": "153", "year": "2009", "article-title": "Impact of irinotecan and oxaliplatin on overall survival in patients with metastatic colorectal cancer: a population-based study", "journal-title": "J Oncol Pract", "DOI": "10.1200/JOP.0942001", "doi-asserted-by": "crossref"}, {"key": "ref241", "volume": "28", "first-page": "4697", "year": "2010", "article-title": "Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study", "journal-title": "J Clin Oncol", "DOI": "10.1200/JCO.2009.27.4860", "doi-asserted-by": "crossref"}, {"key": "ref151", "volume": "27", "first-page": "LBA21", "year": "2017", "article-title": "FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in metastatic colorectal cancer (mCRC): the phase II randomized MOMA trial", "journal-title": "Ann Oncol"}, {"key": "ref461", "volume": "107", "first-page": "pii:dju427", "year": "2015", "article-title": "Primary tumor location as a prognostic factor in metastatic colorectal cancer.", "journal-title": "J Natl Cancer Inst"}, {"key": "ref181", "volume": "51", "first-page": "1243", "year": "2015", "article-title": "FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer", "journal-title": "Eur J Cancer", "DOI": "10.1016/j.ejca.2015.04.007", "doi-asserted-by": "crossref"}, {"key": "ref251", "volume": "25", "first-page": "1346", "year": "2014", "article-title": "Final results from PRIME: randomized phase 3 study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer", "journal-title": "Ann Oncol", "DOI": "10.1093/annonc/mdu141", "doi-asserted-by": "crossref"}, {"key": "ref21", "volume": "11", "first-page": "753", "year": "2010", "article-title": "Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis", "journal-title": "Lancet Oncol", "DOI": "10.1016/S1470-2045(10)70130-3", "doi-asserted-by": "crossref"}, {"key": "ref351", "volume": "16", "first-page": "1557", "year": "2011", "article-title": "Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial", "journal-title": "Oncologist", "DOI": "10.1634/theoncologist.2011-0141", "doi-asserted-by": "crossref"}, {"key": "ref511", "volume": "26", "first-page": "5705", "year": "2008", "article-title": "Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer", "journal-title": "J Clin Oncol", "DOI": "10.1200/JCO.2008.18.0786", "doi-asserted-by": "crossref"}, {"key": "ref171", "volume": "34", "first-page": "492", "year": "2016", "article-title": "Overall response rate (ORR) in STEAM, a randomized, open-label, phase 2 trial of sequential and concurrent FOLFOXIRI-bevacizumab (BEV) vs FOLFOX-BEV for the first-line (1L) treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC)", "journal-title": "J Clin Oncol", "DOI": "10.1200/jco.2016.34.4_suppl.492", "doi-asserted-by": "crossref"}, {"key": "ref101", "volume": "14", "first-page": "1077", "year": "2013", "article-title": "Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial", "journal-title": "Lancet Oncol", "DOI": "10.1016/S1470-2045(13)70154-2", "doi-asserted-by": "crossref"}, {"key": "ref471", "year": "2016", "article-title": "Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials.", "journal-title": "JAMA Oncol"}, {"key": "ref31", "volume": "377", "first-page": "2103", "year": "2011", "article-title": "Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial", "journal-title": "Lancet", "DOI": "10.1016/S0140-6736(11)60613-2", "doi-asserted-by": "crossref"}, {"key": "ref391", "volume": "15", "first-page": "1065", "year": "2014", "article-title": "FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial", "journal-title": "Lancet Oncol", "DOI": "10.1016/S1470-2045(14)70330-4", "doi-asserted-by": "crossref"}, {"key": "ref301", "volume": "14", "first-page": "1208", "year": "2013", "article-title": "Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial", "journal-title": "Lancet Oncol", "DOI": "10.1016/S1470-2045(13)70447-9", "doi-asserted-by": "crossref"}, {"key": "ref331", "volume": "14", "first-page": "521", "year": "2014", "article-title": "Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer", "journal-title": "BMC Cancer", "DOI": "10.1186/1471-2407-14-521", "doi-asserted-by": "crossref"}, {"key": "ref501", "volume": "27", "first-page": "1386", "year": "2016", "article-title": "ESMO consensus guidelines for the management of patients with metastatic colorectal cancer", "journal-title": "Ann Oncol", "DOI": "10.1093/annonc/mdw235", "doi-asserted-by": "crossref"}, {"key": "ref111", "volume": "29", "first-page": "v158", "year": "2017", "article-title": "Randomized phase III study of fluoropyrimidine (FP) plus bevacizumab (BEV) vs. FP plus irinotecan (IRI) and BEV as first-line therapy for metastatic colorectal cancer (mCRC): German AIO KRK0110 (ML22011) study", "journal-title": "Ann Oncol"}, {"key": "ref201", "volume": "29", "first-page": "2011", "year": "2011", "article-title": "Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status", "journal-title": "J Clin Oncol", "DOI": "10.1200/JCO.2010.33.5091", "doi-asserted-by": "crossref"}, {"key": "ref371", "volume": "24", "first-page": "2062", "year": "2013", "article-title": "FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO)", "journal-title": "Ann Oncol", "DOI": "10.1093/annonc/mdt165", "doi-asserted-by": "crossref"}, {"key": "ref71", "volume": "26", "first-page": "2013", "year": "2008", "article-title": "Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study", "journal-title": "J Clin Oncol", "DOI": "10.1200/JCO.2007.14.9930", "doi-asserted-by": "crossref"}, {"key": "ref131", "volume": "35", "first-page": "3533", "year": "2017", "article-title": "\u201cCHARTA\u201d: FOLFOX/bevacizumab vs. FOLFOXIRI/bevacizumab in advanced colorectal cancer-final results, prognostic and potentially predictive factors from the randomized phase II trial of the AIO", "journal-title": "J Clin Oncol", "DOI": "10.1200/JCO.2017.35.15_suppl.3533", "doi-asserted-by": "crossref"}, {"key": "ref451", "volume": "61", "first-page": "847", "year": "2012", "article-title": "Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum", "journal-title": "Gut", "DOI": "10.1136/gutjnl-2011-300865", "doi-asserted-by": "crossref"}, {"key": "ref221", "volume": "48", "first-page": "1466", "year": "2012", "article-title": "Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials", "journal-title": "Eur J Cancer", "DOI": "10.1016/j.ejca.2012.02.057", "doi-asserted-by": "crossref"}, {"key": "ref141", "volume": "26", "first-page": "702", "year": "2015", "article-title": "Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial", "journal-title": "Ann Oncol", "DOI": "10.1093/annonc/mdu580", "doi-asserted-by": "crossref"}, {"key": "ref91", "volume": "28", "first-page": "3191", "year": "2010", "article-title": "Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study", "journal-title": "J Clin Oncol", "DOI": "10.1200/JCO.2009.27.7723", "doi-asserted-by": "crossref"}, {"key": "ref51", "volume": "350", "first-page": "2335", "year": "2004", "article-title": "Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer", "journal-title": "N Engl J Med", "DOI": "10.1056/NEJMoa032691", "doi-asserted-by": "crossref"}, {"key": "ref341", "volume": "103", "first-page": "1542", "year": "2010", "article-title": "Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial", "journal-title": "Br J Cancer", "DOI": "10.1038/sj.bjc.6605940", "doi-asserted-by": "crossref"}, {"key": "ref191", "volume": "360", "first-page": "1408", "year": "2009", "article-title": "Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer", "journal-title": "N Engl J Med", "DOI": "10.1056/NEJMoa0805019", "doi-asserted-by": "crossref"}, {"key": "ref561", "volume": "15", "first-page": "3184", "year": "2009", "article-title": "PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer", "journal-title": "Clin Cancer Res", "DOI": "10.1158/1078-0432.CCR-08-2961", "doi-asserted-by": "crossref"}, {"key": "ref291", "volume": "15", "first-page": "601", "year": "2014", "article-title": "Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the new EPOC randomised controlled trial", "journal-title": "Lancet Oncol", "DOI": "10.1016/S1470-2045(14)70105-6", "doi-asserted-by": "crossref"}, {"key": "ref361", "volume": "107", "first-page": "1932", "year": "2012", "article-title": "A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial", "journal-title": "Br J Cancer", "DOI": "10.1038/bjc.2012.509", "doi-asserted-by": "crossref"}, {"key": "ref551", "volume": "69", "first-page": "1851", "year": "2009", "article-title": "PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies", "journal-title": "Cancer Res", "DOI": "10.1158/0008-5472.CAN-08-2466", "doi-asserted-by": "crossref"}, {"key": "ref381", "volume": "28", "first-page": "4750", "year": "2017", "article-title": "mFOLFOXIRI + panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild-type metastatic colorectal cancer m(CRC): a randomized phase II VOLFI trial of the AIO (AIO-KRK0109)", "journal-title": "Ann Oncol"}, {"key": "ref411", "volume": "88", "first-page": "77", "year": "2017", "article-title": "Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer-central evaluation of FIRE-3", "journal-title": "Eur J Cancer"}, {"key": "ref601", "volume": "15", "first-page": "370", "year": "2017", "article-title": "Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology", "journal-title": "J Natl Compr Canc Netw", "DOI": "10.6004/jnccn.2017.0036", "doi-asserted-by": "crossref"}, {"key": "ref271", "volume": "25", "first-page": "1018", "year": "2014", "article-title": "Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study)", "journal-title": "Ann Oncol", "DOI": "10.1093/annonc/mdu088", "doi-asserted-by": "crossref"}, {"key": "ref41", "volume": "369", "first-page": "1023", "year": "2013", "article-title": "Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer", "journal-title": "N Engl J Med", "DOI": "10.1056/NEJMoa1305275", "doi-asserted-by": "crossref"}, {"key": "ref261", "volume": "11", "first-page": "38", "year": "2010", "article-title": "Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial", "journal-title": "Lancet Oncol", "DOI": "10.1016/S1470-2045(09)70330-4", "doi-asserted-by": "crossref"}, {"key": "ref281", "volume": "81", "first-page": "191", "year": "2017", "article-title": "First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: a randomised, phase II trial (PLANET-TTD)", "journal-title": "Eur J Cancer", "DOI": "10.1016/j.ejca.2017.04.024", "doi-asserted-by": "crossref"}, {"key": "ref01", "volume": "61", "first-page": "212", "year": "2011", "article-title": "Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths", "journal-title": "CA Cancer J Clin", "DOI": "10.3322/caac.20121", "doi-asserted-by": "crossref"}, {"key": "ref311", "volume": "8", "first-page": "v158", "year": "2017", "article-title": "Perioperative chemotherapy with or without cetuximab in patients (pts) with resectable colorectal liver metastasis (CRLM): mature analysis of overall survival (OS) in the new EPOC randomised controlled trial", "journal-title": "Ann Oncol"}, {"key": "ref491", "year": "2016", "article-title": "Prognostic survival associated with left-sided vs. right-sided colon cancer: a systematic review and meta-analysis.", "journal-title": "JAMA Oncol"}, {"key": "ref531", "volume": "101", "first-page": "465", "year": "2009", "article-title": "Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer", "journal-title": "Br J Cancer", "DOI": "10.1038/sj.bjc.6605164", "doi-asserted-by": "crossref"}, {"key": "ref81", "volume": "78", "first-page": "376", "year": "2010", "article-title": "Treatment of colorectal cancer with and without bevacizumab: a phase III study", "journal-title": "Oncology", "DOI": "10.1159/000320520", "doi-asserted-by": "crossref"}, {"key": "ref161", "volume": "17", "first-page": "408", "year": "2017", "article-title": "TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group", "journal-title": "BMC Cancer", "DOI": "10.1186/s12885-017-3360-z", "doi-asserted-by": "crossref"}, {"key": "ref581", "volume": "112", "first-page": "1888", "year": "2015", "article-title": "Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer", "journal-title": "Br J Cancer", "DOI": "10.1038/bjc.2015.173", "doi-asserted-by": "crossref"}, {"key": "ref541", "volume": "20", "first-page": "84", "year": "2009", "article-title": "PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients", "journal-title": "Ann Oncol"}, {"key": "ref321", "volume": "31", "first-page": "1931", "year": "2013", "article-title": "randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases", "journal-title": "J Clin Oncol", "DOI": "10.1200/JCO.2012.44.8308", "doi-asserted-by": "crossref"}, {"key": "ref521", "volume": "6", "first-page": "e15980", "year": "2011", "article-title": "Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in \u22652 line cetuximab-based therapy of colorectal cancer patients", "journal-title": "PLoS One", "DOI": "10.1371/journal.pone.0015980", "doi-asserted-by": "crossref"}, {"key": "ref211", "volume": "42", "first-page": "1540", "year": "2016", "article-title": "FOLFIRI plus cetuximab in patients with liver-limited or non-liver-limited RAS wild-type metastatic colorectal cancer: A retrospective subgroup analysis of the CRYSTAL study", "journal-title": "Eur J Surg Oncol", "DOI": "10.1016/j.ejso.2016.05.038", "doi-asserted-by": "crossref"}, {"key": "ref481", "volume": "28", "first-page": "1713", "year": "2017", "article-title": "Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials", "journal-title": "Ann Oncol", "DOI": "10.1093/annonc/mdx175", "doi-asserted-by": "crossref"}, {"key": "ref231", "volume": "30", "first-page": "1755", "year": "2012", "article-title": "Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study", "journal-title": "J Clin Oncol", "DOI": "10.1200/JCO.2011.38.0915", "doi-asserted-by": "crossref"}, {"key": "ref61", "volume": "23", "first-page": "3502", "year": "2005", "article-title": "Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer", "journal-title": "J Clin Oncol", "DOI": "10.1200/JCO.2005.10.017", "doi-asserted-by": "crossref"}, {"key": "ref121", "volume": "16", "first-page": "1306", "year": "2015", "article-title": "FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study", "journal-title": "Lancet Oncol", "DOI": "10.1016/S1470-2045(15)00122-9", "doi-asserted-by": "crossref"}, {"key": "ref571", "volume": "51", "first-page": "587", "year": "2015", "article-title": "Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis", "journal-title": "Eur J Cancer", "DOI": "10.1016/j.ejca.2015.01.054", "doi-asserted-by": "crossref"}, {"key": "ref401", "volume": "17", "first-page": "1426", "year": "2016", "article-title": "FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial", "journal-title": "Lancet Oncol", "DOI": "10.1016/S1470-2045(16)30269-8", "doi-asserted-by": "crossref"}], "container-title": ["Innovative Surgical Sciences"], "link": [{"URL": "http://www.degruyter.com/view/j/iss.2018.3.issue-2/iss-2018-0012/iss-2018-0012.xml", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.degruyter.com/view/j/iss.2018.3.issue-2/iss-2018-0012/iss-2018-0012.pdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 8, 19]], "date-time": "2019-08-19T10:38:51Z", "timestamp": 1566211131000}, "score": 43.179977, "issued": {"date-parts": [[2018, 5, 7]]}, "references-count": 57, "journal-issue": {"issue": "2"}, "URL": "http://dx.doi.org/10.1515/iss-2018-0012", "relation": {"cites": []}, "ISSN": ["2364-7485"], "issn-type": [{"value": "2364-7485", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 12, 20]], "date-time": "2019-12-20T15:27:03Z", "timestamp": 1576855623917}, "reference-count": 37, "publisher": "Elsevier BV", "issue": "1", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2016, 3, 1]], "date-time": "2016-03-01T00:00:00Z", "timestamp": 1456790400000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": ["clinicalkey.jp", "clinicalkey.com", "clinicalkey.es", "clinical-colorectal-cancer.com", "clinicalkey.com.au", "clinicalkey.fr", "elsevier.com", "sciencedirect.com"], "crossmark-restriction": true}, "short-container-title": ["Clinical Colorectal Cancer"], "published-print": {"date-parts": [[2016, 3]]}, "DOI": "10.1016/j.clcc.2015.10.002", "type": "journal-article", "created": {"date-parts": [[2015, 10, 25]], "date-time": "2015-10-25T07:58:54Z", "timestamp": 1445759934000}, "page": "1-6", "update-policy": "http://dx.doi.org/10.1016/elsevier_cm_policy", "source": "Crossref", "is-referenced-by-count": 19, "title": ["Metastatic Colorectal Cancer: A Systematic Review of the Value of Current Therapies"], "prefix": "10.1016", "volume": "15", "author": [{"given": "Daniel A.", "family": "Goldstein", "sequence": "first", "affiliation": []}, {"ORCID": "http://orcid.org/0000-0003-1953-6238", "authenticated-orcid": false, "given": "Simon B.", "family": "Zeichner", "sequence": "additional", "affiliation": []}, {"ORCID": "http://orcid.org/0000-0002-6651-6881", "authenticated-orcid": false, "given": "Catherine M.", "family": "Bartnik", "sequence": "additional", "affiliation": []}, {"given": "Eli", "family": "Neustadter", "sequence": "additional", "affiliation": []}, {"given": "Christopher R.", "family": "Flowers", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Clinical Colorectal Cancer"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S1533002815001176?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S1533002815001176?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 8, 31]], "date-time": "2019-08-31T23:01:20Z", "timestamp": 1567292480000}, "score": 40.3261, "issued": {"date-parts": [[2016, 3]]}, "references-count": 37, "journal-issue": {"published-print": {"date-parts": [[2016, 3]]}, "issue": "1"}, "alternative-id": ["S1533002815001176"], "URL": "http://dx.doi.org/10.1016/j.clcc.2015.10.002", "ISSN": ["1533-0028"], "issn-type": [{"value": "1533-0028", "type": "print"}], "assertion": [{"value": "Elsevier", "name": "publisher", "label": "This article is maintained by"}, {"value": "Metastatic Colorectal Cancer: A Systematic Review of the Value of Current Therapies", "name": "articletitle", "label": "Article Title"}, {"value": "Clinical Colorectal Cancer", "name": "journaltitle", "label": "Journal Title"}, {"value": "https://doi.org/10.1016/j.clcc.2015.10.002", "name": "articlelink", "label": "CrossRef DOI link to publisher maintained version"}, {"value": "article", "name": "content_type", "label": "Content Type"}, {"value": "Copyright \u00a9 2016 Elsevier Inc. All rights reserved.", "name": "copyright", "label": "Copyright"}]}, {"indexed": {"date-parts": [[2019, 12, 2]], "date-time": "2019-12-02T10:58:56Z", "timestamp": 1575284336367}, "reference-count": 0, "publisher": "Impact Journals, LLC", "issue": "30", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Oncotarget"], "published-print": {"date-parts": [[2018, 4, 20]]}, "DOI": "10.18632/oncotarget.25085", "type": "journal-article", "created": {"date-parts": [[2018, 4, 20]], "date-time": "2018-04-20T20:09:50Z", "timestamp": 1524254990000}, "source": "Crossref", "is-referenced-by-count": 14, "title": ["Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: a systematic review"], "prefix": "10.18632", "volume": "9", "author": [{"given": "Anjali V.", "family": "Sheahan", "sequence": "first", "affiliation": []}, {"given": "Andrew V.", "family": "Biankin", "sequence": "additional", "affiliation": []}, {"given": "Christopher R.", "family": "Parish", "sequence": "additional", "affiliation": []}, {"given": "Levon M.", "family": "Khachigian", "sequence": "additional", "affiliation": []}], "member": "7892", "published-online": {"date-parts": [[2018, 4, 2]]}, "container-title": ["Oncotarget"], "language": "en", "link": [{"URL": "http://www.oncotarget.com/fulltext/25085", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2018, 4, 20]], "date-time": "2018-04-20T20:10:11Z", "timestamp": 1524255011000}, "score": 34.37409, "issued": {"date-parts": [[2018, 4, 2]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2018, 4, 20]]}, "issue": "30"}, "alternative-id": ["25085"], "URL": "http://dx.doi.org/10.18632/oncotarget.25085", "ISSN": ["1949-2553"], "issn-type": [{"value": "1949-2553", "type": "electronic"}], "subject": ["Oncology"]}, {"indexed": {"date-parts": [[2019, 11, 21]], "date-time": "2019-11-21T01:04:55Z", "timestamp": 1574298295856}, "publisher-location": "Berlin, Heidelberg", "reference-count": 113, "publisher": "Springer Berlin Heidelberg", "isbn-type": [{"value": "9783540460909", "type": "print"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "DOI": "10.1007/978-3-540-46091-6_7", "type": "book-chapter", "created": {"date-parts": [[2007, 6, 8]], "date-time": "2007-06-08T12:39:52Z", "timestamp": 1181306392000}, "page": "61-80", "source": "Crossref", "is-referenced-by-count": 48, "title": ["Clinical, Biological, and Molecular Aspects of Metastasis in Colorectal Cancer"], "prefix": "10.1007", "author": [{"given": "Ulrike", "family": "Stein", "sequence": "first", "affiliation": []}, {"given": "Peter M.", "family": "Schlag", "sequence": "additional", "affiliation": []}], "member": "297", "reference": [{"key": "7_CR1", "unstructured": "Abdel-Aziz MM, Lotfy M, El-Kady IM, Abozaid M (2006) Mutant p53 protein in the serum of patients with colorectal cancer: Correlation with the level of carcinoembryonic antigen and serum epidermal growth factor receptor. Cancer Detect Prev Apr 20; [Epub ahead of print]"}, {"key": "7_CR2", "doi-asserted-by": "publisher", "first-page": "692", "DOI": "10.1054/bjoc.2001.1964", "volume": "85", "author": "H.J. Andreyev", "year": "2001", "unstructured": "Andreyev HJ, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ, Young J, Walsh T, Ward R, Hawkins N, Beranek M, Jandik P, Benamouzig R, Jullian E, Laurent-Puig P, Olschwang S, Muller O, Hoffmann I, Rabes HM, Zietz C, Troungos C, Valavanis C, Yuen ST, Ho JW, Croke CT, O\u2019Donoghue DP, Giaretti W, Rapallo A, Russo A, Bazan V, Tanaka M, Omura K, Azuma T, Ohkusa T, Fujimori T, Ono Y, Pauly M, Faber C, Glaesener R, de Goeij AF, Arends JW, Andersen SN, Lovig T, Breivik J, Gaudernack G, Clausen OP, De Angelis PD, Meling GI, Rognum TO, Smith R, Goh HS, Font A, Rosell R, Sun XF, Zhang H, Benhattar J, Losi L, Lee JQ, Wang ST, Clarke PA, Bell S, Quirke P, Bubb VJ, Piris J, Cruickshank NR, Morton D, Fox JC, Al-Mulla F, Lees N, Hall CN, Snary D, Wilkinson K, Dillon D, Costa J, Pricolo VE, Finkelstein SD, Thebo JS, Senagore AJ, Halter SA, Wadler S, Malik S, Krtolica K, Urosevic N (2001) Kirsten ras mutations in patients with colorectal cancer: the \u2018RASCAL II\u2019 study. Br J Cancer 85:692\u2013696", "journal-title": "Br J Cancer"}, {"key": "7_CR3", "doi-asserted-by": "publisher", "first-page": "412", "DOI": "10.1002/(SICI)1096-9896(200003)190:4<412::AID-PATH533>3.0.CO;2-P", "volume": "190", "author": "J.W. Arends", "year": "2000", "unstructured": "Arends JW (2000) Molecular interactions in the Vogelstein model of colorectal carcinoma. J Pathol 190:412\u2013416", "journal-title": "J Pathol"}, {"key": "7_CR4", "doi-asserted-by": "publisher", "first-page": "3758", "DOI": "10.1200/JCO.2004.08.066", "volume": "22", "author": "C. Aschele", "year": "2004", "unstructured": "Aschele C, Debernardis D, Lonardi S, Bandelloni R, Casazza S, Monfardini S, Gallo L (2004) Deleted in colon cancer protein expression in colorectal cancer metastases: a major predictor of survival in patients with unresectable metastatic disease receiving palliative fluorouracil-based chemotherapy. J Clin Oncol 22:3758\u20133765", "journal-title": "J Clin Oncol"}, {"key": "7_CR5", "doi-asserted-by": "publisher", "first-page": "821", "DOI": "10.2217/14796694.1.6.821", "volume": "1", "author": "R.C. Bates", "year": "2005", "unstructured": "Bates RC (2005) The alphavbeta6 integrin as a novel molecular target for colorectal cancer. Future Oncol 1:821\u2013828", "journal-title": "Future Oncol"}, {"key": "7_CR6", "doi-asserted-by": "publisher", "first-page": "365", "DOI": "10.4161/cbt.4.4.1655", "volume": "4", "author": "R.C. Bates", "year": "2005", "unstructured": "Bates RC, Mercurio AM (2005) The epithelial-mesenchymal transition (EMT) and colorectal cancer progression. Cancer Biol Ther 4:365\u2013370", "journal-title": "Cancer Biol Ther"}, {"key": "7_CR7", "doi-asserted-by": "publisher", "first-page": "339", "DOI": "10.1172/JCI200523183", "volume": "115", "author": "R.C. Bates", "year": "2005", "unstructured": "Bates RC, Bellovin DI, Brown C, Maynard E, Wu B, Kawakatsu H, Sheppard D, Oettgen P, Mercurio AM (2005) Transcriptional activation of integrin beta6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. J Clin Invest 115:339\u2013347", "journal-title": "J Clin Invest"}, {"key": "7_CR8", "doi-asserted-by": "publisher", "first-page": "748", "DOI": "10.1097/01.sla.0000160699.59061.92", "volume": "241", "author": "T.W. Bauer", "year": "2005", "unstructured": "Bauer TW, Fan F, Liu W, Johnson M, Parikh NU, Parry GC, Callahan J, Mazar AP, Gallick GE, Ellis LM (2005) Insulin like growth factor-I-mediated migration and invasion of human colon carcinoma cells requires activation of c-Met and urokinase plasminogen activator receptor. Ann Surg 241:748\u2013756", "journal-title": "Ann Surg"}, {"key": "7_CR9", "doi-asserted-by": "publisher", "first-page": "1393", "DOI": "10.1002/1097-0142(19920901)70:3+<1393::AID-CNCR2820701530>3.0.CO;2-P", "volume": "70", "author": "O.H. Beahrs", "year": "1992", "unstructured": "Beahrs OH (1992) Staging of cancer of the colon and rectum. Cancer 70:1393\u20131396", "journal-title": "Cancer"}, {"key": "7_CR10", "doi-asserted-by": "publisher", "first-page": "10938", "DOI": "10.1158/0008-5472.CAN-05-1947", "volume": "65", "author": "D.I. Bellovin", "year": "2005", "unstructured": "Bellovin DI, Bates RC, Muzikansky A, Rimm DL, Mercurio AM (2005) Altered localization of p120 catenin during epithelial to mesenchymal transition of colon carcinoma is prognostic for aggressive disease. Cancer Res 65:10938\u201310945", "journal-title": "Cancer Res"}, {"key": "7_CR11", "doi-asserted-by": "publisher", "first-page": "823", "DOI": "10.1038/418823a", "volume": "418", "author": "R. Bernards", "year": "2002", "unstructured": "Bernards R, Weinberg RA (2002) A progression puzzle. Nature 418:823", "journal-title": "Nature"}, {"key": "7_CR12", "doi-asserted-by": "publisher", "first-page": "915", "DOI": "10.1038/nrm1261", "volume": "4", "author": "C. Birchmeier", "year": "2003", "unstructured": "Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF (2003) Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4:915\u2013925", "journal-title": "Nat Rev Mol Cell Biol"}, {"key": "7_CR13", "first-page": "230", "volume": "212", "author": "W. Birchmeier", "year": "1997", "unstructured": "Birchmeier W, Brinkmann V, Niemann C, Meiners S, DiCesare S, Naundorf H, Sachs M (1997) Role of HGF/SF and c-Met in morphogenesis and metastasis of epithelial cells. Ciba Found Symp 212:230\u2013240", "journal-title": "Ciba Found Symp"}, {"key": "7_CR14", "doi-asserted-by": "publisher", "first-page": "68", "DOI": "10.1002/jso.20558", "volume": "94", "author": "N.C. Bird", "year": "2006", "unstructured": "Bird NC, Mangnall D, Majeed AW (2006) Biology of colorectal liver metastases: a review. J Surg Oncol 94:68\u201380", "journal-title": "J Surg Oncol"}, {"key": "7_CR15", "doi-asserted-by": "publisher", "first-page": "6524", "DOI": "10.1038/sj.onc.1206757", "volume": "22", "author": "T. Bogenrieder", "year": "2003", "unstructured": "Bogenrieder T, Herlyn M (2003) Axis of evil: molecular mechanisms of cancer metastasis. Oncogene 22:6524\u20136536", "journal-title": "Oncogene"}, {"key": "7_CR16", "doi-asserted-by": "publisher", "first-page": "231", "DOI": "10.1007/s00384-005-0762-1", "volume": "21", "author": "J. Bondi", "year": "2006", "unstructured": "Bondi J, Bukholm G, Nesland JM, Bakka A, Bukholm IR (2006) An increase in the number of adhesion proteins with altered expression is associated with an increased risk of cancer death for colon carcinoma patients. Int J Colorectal Dis 21:231\u2013237", "journal-title": "Int J Colorectal Dis"}, {"key": "7_CR17", "doi-asserted-by": "publisher", "first-page": "1078", "DOI": "10.1038/sj.bjc.6602405", "volume": "92", "author": "E.M. Boon", "year": "2005", "unstructured": "Boon EM, Kovarikova M, Derksen PW, van der Neut R (2005) MET signalling in primary colon epithelial cells leads to increased transformation irrespective of aberrant Wnt signalling. Br J Cancer 92:1078\u20131083", "journal-title": "Br J Cancer"}, {"key": "7_CR18", "doi-asserted-by": "publisher", "first-page": "630", "DOI": "10.1038/sj.bjc.6600511", "volume": "87", "author": "J.L. Boulay", "year": "2002", "unstructured": "Boulay JL, Mild G, Lowy A, Reuter J, Lagrange M, Terracciano L, Laffer U, Herrmann R, Rochlitz C (2002) SMAD4 is a predictive marker for 5-fluorouracilbased chemotherapy in patients with colorectal cancer. Br J Cancer 87:630\u2013634", "journal-title": "Br J Cancer"}, {"key": "7_CR19", "doi-asserted-by": "publisher", "first-page": "481", "DOI": "10.1093/annonc/mdi098", "volume": "16", "author": "P. Boyle", "year": "2005", "unstructured": "Boyle P, Ferlay J (2005) Cancer incidence and mortality in Europe, 2004. Ann Oncol 16:481\u2013488", "journal-title": "Ann Oncol"}, {"key": "7_CR20", "first-page": "2803", "volume": "6", "author": "S. Cascinu", "year": "2000", "unstructured": "Cascinu S, Staccioli MP, Gasparini G, Giordani P, Catalano V, Ghiselli R, Rossi C, Baldelli AM, Graziano F, Saba V, Muretto P, Catalano G (2000) Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer. Clin Cancer Res 6:2803\u20132807", "journal-title": "Clin Cancer Res"}, {"key": "7_CR21", "first-page": "115", "volume": "1756", "author": "P. Castagnola", "year": "2005", "unstructured": "Castagnola P, Giaretti W (2005) Mutant KRAS, chromosomal instability and prognosis in colorectal cancer. Biochim Biophys Acta 1756:115\u2013125", "journal-title": "Biochim Biophys Acta"}, {"key": "7_CR22", "doi-asserted-by": "crossref", "first-page": "118", "DOI": "10.1038/nrc1276", "volume": "4", "author": "U. Cavallaro", "year": "2004", "unstructured": "Cavallaro U, Christofori G (2004) Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer 4:118\u2013132", "journal-title": "Nat Rev Cancer"}, {"key": "7_CR23", "doi-asserted-by": "publisher", "first-page": "563", "DOI": "10.1038/nrc865", "volume": "2", "author": "A.F. Chambers", "year": "2002", "unstructured": "Chambers AF, Groom AC, MacDonald IC (2002) Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2:563\u2013572", "journal-title": "Nat Rev Cancer"}, {"key": "7_CR24", "doi-asserted-by": "crossref", "first-page": "4852", "DOI": "10.3748/wjg.v11.i31.4852", "volume": "11", "author": "Y.G. Cho", "year": "2005", "unstructured": "Cho YG, Kim CJ, Nam SW, Yoon SH, Lee SH, Yoo NJ, Lee JY, Park WS (2005) Overexpression of S100A4 is closely associated with progression of colorectal cancer. World J Gastroenterol 11:4852\u20134856", "journal-title": "World J Gastroenterol"}, {"key": "7_CR25", "doi-asserted-by": "publisher", "first-page": "444", "DOI": "10.1038/nature04872", "volume": "441", "author": "G. Christofori", "year": "2006", "unstructured": "Christofori G (2006) New signals from the invasive front. Nature 441:444\u2013450", "journal-title": "Nature"}, {"key": "7_CR26", "doi-asserted-by": "publisher", "first-page": "1283", "DOI": "10.1136/gut.2005.066514", "volume": "54", "author": "A. Conlin", "year": "2005", "unstructured": "Conlin A, Smith G, Carey FA, Wolf CR, Steele RJ (2005) The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma. Gut 54:1283\u20131286", "journal-title": "Gut"}, {"key": "7_CR27", "doi-asserted-by": "publisher", "first-page": "2883", "DOI": "10.1038/sj.onc.1202627", "volume": "18", "author": "H.C. Crawford", "year": "1999", "unstructured": "Crawford HC, Fingleton BM, Rudolph-Owen LA, Goss KJ, Rubinfeld B, Polakis P, Matrisian LM (1999) The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors. Oncogene 18:2883\u20132891", "journal-title": "Oncogene"}, {"key": "7_CR28", "doi-asserted-by": "publisher", "first-page": "9", "DOI": "10.1007/s10555-006-7886-9", "volume": "25", "author": "E.I. Deryugina", "year": "2006", "unstructured": "Deryugina EI, Quigley JP (2006) Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 25:9\u201334", "journal-title": "Cancer Metastasis Rev"}, {"key": "7_CR29", "doi-asserted-by": "publisher", "first-page": "365", "DOI": "10.1016/j.ejca.2004.11.005", "volume": "41", "author": "H. Doucas", "year": "2005", "unstructured": "Doucas H, Garcea G, Neal CP, Manson MM, Berry DP (2005) Changes in the Wnt signalling pathway in gastrointestinal cancers and their prognostic significance. Eur J Cancer 41:365\u2013379", "journal-title": "Eur J Cancer"}, {"key": "7_CR30", "doi-asserted-by": "publisher", "first-page": "89", "DOI": "10.2174/156800906776056518", "volume": "6", "author": "J.A. Eble", "year": "2006", "unstructured": "Eble JA, Haier J (2006) Integrins in cancer treatment. Curr Cancer Drug Targets 6:89\u2013105", "journal-title": "Curr Cancer Drug Targets"}, {"key": "7_CR31", "doi-asserted-by": "publisher", "first-page": "3", "DOI": "10.1053/j.seminoncol.2004.11.028", "volume": "31", "author": "L.M. Ellis", "year": "2004", "unstructured": "Ellis LM (2004) Angiogenesis and its role in colorectal tumor and metastasis formation. Semin Oncol 31:3\u20139", "journal-title": "Semin Oncol"}, {"key": "7_CR32", "doi-asserted-by": "publisher", "first-page": "1049", "DOI": "10.1016/j.gassur.2004.08.016", "volume": "8", "author": "A. Enns", "year": "2004", "unstructured": "Enns A, Gassmann P, Schluter K, Korb T, Spiegel HU, Senninger N, Haier J (2004) Integrins can directly mediate metastatic tumor cell adhesion within the liver sinusoids. J Gastrointest Surg 8:1049\u20131059", "journal-title": "J Gastrointest Surg"}, {"key": "7_CR33", "doi-asserted-by": "publisher", "first-page": "1065", "DOI": "10.1016/j.ejca.2004.12.031", "volume": "41", "author": "A. Enns", "year": "2005", "unstructured": "Enns A, Korb T, Schluter K, Gassmann P, Spiegel HU, Senninger N, Mitjans F, Haier J (2005) Alphavbeta5-integrins mediate early steps of metastasis formation. Eur J Cancer 41:1065\u20131072", "journal-title": "Eur J Cancer"}, {"key": "7_CR34", "doi-asserted-by": "publisher", "first-page": "3526", "DOI": "10.1200/JCO.2005.00.695", "volume": "23", "author": "S. Eschrich", "year": "2005", "unstructured": "Eschrich S, Yang I, Bloom G, Kwong KY, Boulware D, Cantor A, Coppola D, Kruhoffer M, Aaltonen L, Orntoft TF, Quackenbush J, Yeatman TJ (2005) Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol 23:3526\u20133535", "journal-title": "J Clin Oncol"}, {"key": "7_CR35", "doi-asserted-by": "publisher", "first-page": "1967", "DOI": "10.1016/j.cellsig.2006.03.005", "volume": "18", "author": "M. Fassetta", "year": "2006", "unstructured": "Fassetta M, D\u2019Alessandro L, Coltella N, Di Renzo MF, Rasola A (2006) Hepatocyte growth factor installs a survival platform for colorectal cancer cell invasive growth and overcomes p38 MAPK-mediated apoptosis. Cell Signal 18:1967\u20131976", "journal-title": "Cell Signal"}, {"key": "7_CR36", "doi-asserted-by": "publisher", "first-page": "639", "DOI": "10.1023/A:1013136303880", "volume": "18", "author": "K. Fazekas", "year": "2000", "unstructured": "Fazekas K, Csuka O, Koves I, Raso E, Timar J (2000) Experimental and clinicopathologic studies on the function of the HGF receptor in human colon cancer metastasis. Clin Exp Metastasis 18:639\u2013649", "journal-title": "Clin Exp Metastasis"}, {"key": "7_CR37", "doi-asserted-by": "publisher", "first-page": "759", "DOI": "10.1016/0092-8674(90)90186-I", "volume": "61", "author": "E.R. Fearon", "year": "1990", "unstructured": "Fearon ER, Vogelstein B (1990) A genetic model for colorectal tumorigenesis. Cell 61:759\u2013767", "journal-title": "Cell"}, {"key": "7_CR38", "doi-asserted-by": "publisher", "first-page": "145", "DOI": "10.1159/000087838", "volume": "69", "author": "P. Ferroni", "year": "2005", "unstructured": "Ferroni P, Spila A, Martini F, D\u2019Alessandro R, Mariotti S, Del Monte G, Graziano P, Buonomo O, Guadagni F, Roselli M (2005) Prognostic value of vascular endothelial growth factor tumor tissue content of colorectal cancer. Oncology 69:145\u2013153", "journal-title": "Oncology"}, {"key": "7_CR39", "doi-asserted-by": "publisher", "first-page": "453", "DOI": "10.1038/nrc1098", "volume": "3", "author": "I.J. Fidler", "year": "2003", "unstructured": "Fidler IJ (2003) The pathogenesis of cancer metastasis: the\u2019 seed and soil\u2019 hypothesis revisited. Nat Rev Cancer 3:453\u2013458", "journal-title": "Nat Rev Cancer"}, {"key": "7_CR40", "doi-asserted-by": "publisher", "first-page": "589", "DOI": "10.1002/path.1381", "volume": "200", "author": "K. Flatmark", "year": "2003", "unstructured": "Flatmark K, Pedersen KB, Nesland JM, Rasmussen H, Aamodt G, Mikalsen SO, Bjornland K, Fodstad O, Maelandsmo GM (2003) Nuclear localization of the metastasis-related protein S100A4 correlates with tumour stage in colorectal cancer. J Pathol 200:589\u2013595", "journal-title": "J Pathol"}, {"key": "7_CR41", "doi-asserted-by": "publisher", "first-page": "55", "DOI": "10.1038/35094067", "volume": "1", "author": "R. Fodde", "year": "2001", "unstructured": "Fodde R, Smits R, Clevers H (2001) APC, signal transduction and genetic instability in colorectal cancer. Nat Rev Cancer 1:55\u201367", "journal-title": "Nat Rev Cancer"}, {"key": "7_CR42", "doi-asserted-by": "crossref", "first-page": "1522", "DOI": "10.4161/cc.4.11.2129", "volume": "4", "author": "S.Y. Fuchs", "year": "2005", "unstructured": "Fuchs SY, Ougolkov AV, Spiegelman VS, Minamoto T (2005) Oncogenic beta-catenin signaling networks in colorectal cancer. Cell Cycle 4:1522\u20131539", "journal-title": "Cell Cycle"}, {"key": "7_CR43", "doi-asserted-by": "publisher", "first-page": "1216", "DOI": "10.1007/s10350-004-0552-9", "volume": "47", "author": "R. Gal", "year": "2004", "unstructured": "Gal R, Sadikov E, Sulkes J, Klein B, Koren R (2004) Deleted in colorectal cancer protein expression as a possible predictor of response to adjuvant chemotherapy in colorectal cancer patients. Dis Colon Rectum 47:1216\u20131224", "journal-title": "Dis Colon Rectum"}, {"key": "7_CR44", "doi-asserted-by": "publisher", "first-page": "677", "DOI": "10.1074/jbc.R500017200", "volume": "281", "author": "S.C. Garrett", "year": "2006", "unstructured": "Garrett SC, Varney KM, Weber DJ, Bresnick AR (2006) S100A4, a mediator of metastasis. J Biol Chem 281:677\u2013680", "journal-title": "J Biol Chem"}, {"key": "7_CR45", "doi-asserted-by": "publisher", "first-page": "118", "DOI": "10.1016/j.jss.2005.10.002", "volume": "131", "author": "L. Georgiou", "year": "2006", "unstructured": "Georgiou L, Minopoulos G, Lirantzopoulos N, Fiska-Demetriou A, Maltezos E, Sivridis E (2006) Angiogenesis and p53 at the invading tumor edge: prognostic markers for colorectal cancer beyond stage. J Surg Res 131:118\u2013123", "journal-title": "J Surg Res"}, {"key": "7_CR46", "doi-asserted-by": "publisher", "first-page": "97", "DOI": "10.1196/annals.1339.033", "volume": "1059", "author": "E.W. Gerner", "year": "2005", "unstructured": "Gerner EW, Ignatenko NA, Lance P, Hurley LH (2005) A comprehensive strategy to combat colon cancer targeting the adenomatous polyposis coli tumor suppressor gene. Ann N Y Acad Sci 1059:97\u2013105", "journal-title": "Ann N Y Acad Sci"}, {"key": "7_CR47", "doi-asserted-by": "publisher", "first-page": "1478", "DOI": "10.1053/gast.2002.36606", "volume": "123", "author": "S. Gongoll", "year": "2002", "unstructured": "Gongoll S, Peters G, Mengel M, Piso P, Klempnauer J, Kreipe H, von Wasielewski R (2002) Prognostic significance of calcium-binding protein S100A4 in colorectal cancer. Gastroenterology 123:1478\u20131484", "journal-title": "Gastroenterology"}, {"key": "7_CR48", "doi-asserted-by": "publisher", "first-page": "454", "DOI": "10.1093/carcin/bgi259", "volume": "27", "author": "D.L. Guo", "year": "2006", "unstructured": "Guo DL, Zhang J, Yuen ST, Tsui WY, Chan AS, Ho C, Ji J, Leung SY, Chen X (2006) Reduced expression of EphB2 that parallels invasion and metastasis in colorectal tumours. Carcinogenesis 27:454\u2013464", "journal-title": "Carcinogenesis"}, {"key": "7_CR49", "doi-asserted-by": "publisher", "first-page": "57", "DOI": "10.1016/S0092-8674(00)81683-9", "volume": "100", "author": "D. Hanahan", "year": "2000", "unstructured": "Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57\u201370", "journal-title": "Cell"}, {"key": "7_CR50", "doi-asserted-by": "publisher", "first-page": "1955", "DOI": "10.1038/sj.bjc.6602613", "volume": "92", "author": "D.M. Helfman", "year": "2005", "unstructured": "Helfman DM, Kim EJ, Lukanidin E, Grigorian M (2005) The metastasis associated protein S100A4: role in tumour progression and metastasis. Br J Cancer 92:1955\u20131958", "journal-title": "Br J Cancer"}, {"key": "7_CR51", "doi-asserted-by": "publisher", "first-page": "498", "DOI": "10.1002/jso.20460", "volume": "93", "author": "A.K. Hemandas", "year": "2006", "unstructured": "Hemandas AK, Salto-Tellez M, Maricar SH, Leong AF, Leow CK (2006) Metastasis-associated protein S100A4\u2014a potential prognostic marker for colorectal cancer. J Surg Oncol 93:498\u2013503", "journal-title": "J Surg Oncol"}, {"key": "7_CR52", "first-page": "336", "volume": "71", "author": "J.S. Hsieh", "year": "2005", "unstructured": "Hsieh JS, Lin SR, Chang MY, Chen FM, Lu CY, Huang TJ, Huang YS, Huang CJ, Wang JY (2005) APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance. Am Surg 71:336\u2013343", "journal-title": "Am Surg"}, {"key": "7_CR53", "first-page": "311", "volume": "15", "author": "Y. Ichikawa", "year": "2006", "unstructured": "Ichikawa Y, Ishikawa T, Momiyama N, Kamiyama M, Sakurada H, Matsuyama R, Hasegawa S, Chishima T, Hamaguchi Y, Fujii S, Saito S, Kubota K, Hasegawa S, Ike H, Oki S, Shimada H (2006) Matrilysin (MMP-7) degrades VE-cadherin and accelerates accumulation of beta-catenin in the nucleus of human umbilical vein endothelial cells. Oncol Rep 15:311\u2013315", "journal-title": "Oncol Rep"}, {"key": "7_CR54", "doi-asserted-by": "publisher", "first-page": "10330", "DOI": "10.1073/pnas.94.19.10330", "volume": "94", "author": "M. Ilyas", "year": "1997", "unstructured": "Ilyas M, Tomlinson IP, Rowan A, Pignatelli M, Bodmer WF (1997) Beta-catenin mutations in cell lines established from human colorectal cancers. Proc Natl Acad Sci U S A 94:10330\u201310334", "journal-title": "Proc Natl Acad Sci U S A"}, {"key": "7_CR55", "doi-asserted-by": "crossref", "first-page": "106", "DOI": "10.3322/canjclin.56.2.106", "volume": "56", "author": "A. Jemal", "year": "2006", "unstructured": "Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ (2006) Cancer statistics, 2006. CA Cancer J Clin 56:106\u2013130", "journal-title": "CA Cancer J Clin"}, {"key": "7_CR56", "doi-asserted-by": "publisher", "first-page": "6012", "DOI": "10.1158/1078-0432.CCR-05-0275", "volume": "11", "author": "W.G. Jiang", "year": "2005", "unstructured": "Jiang WG, Davies G, Martin TA, Parr C, Watkins G, Mason MD, Mokbel K, Mansel RE (2005) Targeting matrilysin and its impact on tumor growth in vivo: the potential implications in breast cancer therapy. Clin Cancer Res 11:6012\u20136019", "journal-title": "Clin Cancer Res"}, {"key": "7_CR57", "doi-asserted-by": "publisher", "first-page": "345", "DOI": "10.1023/A:1006304806799", "volume": "18", "author": "J.P. Johnson", "year": "1999", "unstructured": "Johnson JP (1999) Cell adhesion molecules in the development and progression of malignant melanoma. Cancer Metastasis Rev 18:345\u2013357", "journal-title": "Cancer Metastasis Rev"}, {"key": "7_CR58", "doi-asserted-by": "crossref", "first-page": "445", "DOI": "10.3727/096504005776568282", "volume": "15", "author": "L. Kaklamanis", "year": "2006", "unstructured": "Kaklamanis L, Trichas M, Amarantidis K, Spathari N, Micheli A, Karayiannakis A, Chatzaki E, Georgoulias V, Kakolyris S (2006) VEGF expression in the colorectal adenoma-carcinoma sequence. Oncol Res 15:445\u2013451", "journal-title": "Oncol Res"}, {"key": "7_CR59", "doi-asserted-by": "publisher", "first-page": "39", "DOI": "10.2174/1568006053005038", "volume": "5", "author": "T. Kawaguchi", "year": "2005", "unstructured": "Kawaguchi T (2005) Cancer metastasis: characterization and identification of the behavior of metastatic tumor cells and the cell adhesion molecules, including carbohydrates. Curr Drug Targets Cardiovasc Haematol Disord 5:39\u201364", "journal-title": "Curr Drug Targets Cardiovasc Haematol Disord"}, {"key": "7_CR60", "doi-asserted-by": "publisher", "first-page": "1784", "DOI": "10.1126/science.275.5307.1784", "volume": "275", "author": "V. Korinek", "year": "1997", "unstructured": "Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, Kinzler KW, Vogelstein B, Clevers H (1997) Constitutive transcriptional activation by a betacatenin-Tcf complex in APC-/- colon carcinoma. Science 275:1784\u20131787", "journal-title": "Science"}, {"key": "7_CR61", "doi-asserted-by": "publisher", "first-page": "1751", "DOI": "10.1136/gut.2005.071035", "volume": "54", "author": "S. Kurokawa", "year": "2005", "unstructured": "Kurokawa S, Arimura Y, Yamamoto H, Adachi Y, Endo T, Sato T, Suga T, Hosokawa M, Shinomura Y, Imai K (2005) Tumour matrilysin expression predicts metastatic potential of stage I (pT1) colon and rectal cancers. Gut 54:1751\u20131758", "journal-title": "Gut"}, {"key": "7_CR62", "doi-asserted-by": "publisher", "first-page": "2225", "DOI": "10.1073/pnas.040564697", "volume": "97", "author": "H. Lamlum", "year": "2000", "unstructured": "Lamlum H, Papadopoulou A, Ilyas M, Rowan A, Gillet C, Hanby A, Talbot I, Bodmer W, Tomlinson I (2000) APC mutations are sufficient for the growth of early colorectal adenomas. Proc Natl Acad Sci U S A 97:2225\u20132228", "journal-title": "Proc Natl Acad Sci U S A"}, {"key": "7_CR63", "doi-asserted-by": "publisher", "first-page": "5173", "DOI": "10.1158/0008-5472.CAN-05-3087", "volume": "66", "author": "Z.H. Li", "year": "2006", "unstructured": "Li ZH, Bresnick AR (2006) The S100A4 metastasis factor regulates cellular motility via a direct interaction with myosin-IIA. Cancer Res 66:5173\u20135180", "journal-title": "Cancer Res"}, {"key": "7_CR64", "doi-asserted-by": "publisher", "first-page": "739", "DOI": "10.1093/jjco/hyi195", "volume": "35", "author": "H.Z. Luo", "year": "2005", "unstructured": "Luo HZ, Zhou ZG, Yang L, Yu YY, Tian C, Zhou B, Zheng XL, Xia QJ, Li Y, Wang R (2005) Clinicopathologic and prognostic significance of MMP-7 (matrilysin) expression in human rectal cancer. Jpn J Clin Oncol 35:739\u2013744", "journal-title": "Jpn J Clin Oncol"}, {"key": "7_CR65", "doi-asserted-by": "publisher", "first-page": "1184", "DOI": "10.1158/1078-0432.CCR-05-1864", "volume": "12", "author": "M.S. Lyall", "year": "2006", "unstructured": "Lyall MS, Dundas SR, Curran S, Murray GI (2006) Profiling markers of prognosis in colorectal cancer. Clin Cancer Res 12:1184\u20131191", "journal-title": "Clin Cancer Res"}, {"key": "7_CR66", "doi-asserted-by": "crossref", "first-page": "67", "DOI": "10.1016/j.critrevonc.2005.03.005", "volume": "55", "author": "A. Mancuso", "year": "2005", "unstructured": "Mancuso A, Sternberg CN (2005) Colorectal cancer and antiangiogenic therapy: what can be expected in clinical practice? Crit Rev Oncol Hematol 55:67\u201381", "journal-title": "Crit Rev Oncol Hematol"}, {"key": "7_CR67", "doi-asserted-by": "crossref", "first-page": "191", "DOI": "10.1038/sj.bjc.6690033", "volume": "79", "author": "H.L. McLeod", "year": "1999", "unstructured": "McLeod HL, Murray GI (1999) Tumour markers of prognosis in colorectal cancer. Br J Cancer 79:191\u2013203", "journal-title": "Br J Cancer"}, {"key": "7_CR68", "doi-asserted-by": "publisher", "first-page": "27", "DOI": "10.1016/S0039-6109(05)70531-4", "volume": "77", "author": "K.W. Millikan", "year": "1997", "unstructured": "Millikan KW, Staren ED, Doolas A (1997) Invasive therapy of metastatic colorectal cancer to the liver. Surg Clin North Am 77:27\u201348", "journal-title": "Surg Clin North Am"}, {"key": "7_CR69", "doi-asserted-by": "publisher", "first-page": "799", "DOI": "10.1016/S0006-291X(03)01066-0", "volume": "306", "author": "M. Miyaki", "year": "2003", "unstructured": "Miyaki M, Kuroki T (2003) Role of Smad4 (DPC4) inactivation in human cancer. Biochem Biophys Res Commun 306:799\u2013804", "journal-title": "Biochem Biophys Res Commun"}, {"key": "7_CR70", "doi-asserted-by": "publisher", "first-page": "606", "DOI": "10.1007/BF02388215", "volume": "27", "author": "Y. Mohri", "year": "1997", "unstructured": "Mohri Y (1997) Prognostic significance of E-cadherin expression in human colorectal cancer tissue. Surg Today 27:606\u2013612", "journal-title": "Surg Today"}, {"key": "7_CR71", "doi-asserted-by": "publisher", "first-page": "1787", "DOI": "10.1126/science.275.5307.1787", "volume": "275", "author": "P.J. Morin", "year": "1997", "unstructured": "Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler KW (1997) Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 275:1787\u20131790", "journal-title": "Science"}, {"key": "7_CR72", "doi-asserted-by": "crossref", "first-page": "434", "DOI": "10.1038/sj.bjc.6602358", "volume": "92", "author": "A.J. Munro", "year": "2005", "unstructured": "Munro AJ, Lain S, Lane DP (2005) P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer 92:434\u2013444", "journal-title": "Br J Cancer"}, {"key": "7_CR73", "doi-asserted-by": "publisher", "first-page": "237", "DOI": "10.1385/MO:23:2:237", "volume": "23", "author": "W.A. Nasif", "year": "2006", "unstructured": "Nasif WA, Lotfy M, El-Sayed IH, El-Kenawy Ael-M, El-Shahat M, El-Hak NG (2006) Implications of CEA and p53 overexpression in the poor prognosis of colorectal cancer. Med Oncol 23:237\u2013244", "journal-title": "Med Oncol"}, {"key": "7_CR74", "doi-asserted-by": "publisher", "first-page": "1728", "DOI": "10.1016/j.ejca.2006.01.056", "volume": "42", "author": "C.P. Neal", "year": "2006", "unstructured": "Neal CP, Garcea G, Doucas H, Manson MM, Sutton CD, Dennison AR, Berry DP (2006) Molecular prognostic markers in resectable colorectal liver metastases: a systematic review. Eur J Cancer 42:1728\u20131743", "journal-title": "Eur J Cancer"}, {"key": "7_CR75", "first-page": "1111", "volume": "15", "author": "Y. Ogata", "year": "2006", "unstructured": "Ogata Y, Matono K, Mizobe T, Ishibashi N, Mori S, Akagi Y, Ikeda S, Ozasa H, Murakami H, Shirouzu K (2006) The expression of vascular endothelial growth factor determines the efficacy of post-operative adjuvant chemotherapy using oral fluoropyrimidines in stage II or III colorectal cancer. Oncol Rep 15:1111\u20131116", "journal-title": "Oncol Rep"}, {"key": "7_CR76", "first-page": "875", "volume": "52", "author": "M. Ogawa", "year": "2005", "unstructured": "Ogawa M, Ikeuchi K, Watanabe M, Etoh K, Kobayashi T, Takao Y, Anazawa S, Yamazaki Y (2005) Expression of matrix metalloproteinase 7, laminin and type IV collagen-associated liver metastasis in human colorectal cancer: immunohistochemical approach. Hepatogastroenterology 52:875\u2013880", "journal-title": "Hepatogastroenterology"}, {"key": "7_CR77", "doi-asserted-by": "publisher", "first-page": "60", "DOI": "10.1053/gast.2002.30306", "volume": "122", "author": "A.V. Ougolkov", "year": "2002", "unstructured": "Ougolkov AV, Yamashita K, Mai M, Minamoto T (2002) Oncogenic beta-catenin and MMP-7 (matrilysin) cosegregate in late-stage clinical colon cancer. Gastroenterology 122:60\u201371", "journal-title": "Gastroenterology"}, {"key": "7_CR78", "doi-asserted-by": "publisher", "first-page": "571", "DOI": "10.1016/S0140-6736(00)49915-0", "volume": "1", "author": "S. Paget", "year": "1889", "unstructured": "Paget S (1889) The distribution of secondary growths in cancer of the breast. Lancet 1:571\u2013573", "journal-title": "Lancet"}, {"key": "7_CR79", "doi-asserted-by": "publisher", "first-page": "448", "DOI": "10.1038/nrc1370", "volume": "4", "author": "K. Pantel", "year": "2004", "unstructured": "Pantel K, Brakenhoff RH (2004) Dissecting the metastatic cascade. Nat Rev Cancer 4:448\u2013456", "journal-title": "Nat Rev Cancer"}, {"key": "7_CR80", "doi-asserted-by": "publisher", "first-page": "74", "DOI": "10.3322/canjclin.55.2.74", "volume": "55", "author": "D.M. Parkin", "year": "2005", "unstructured": "Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74\u2013108", "journal-title": "CA Cancer J Clin"}, {"key": "7_CR81", "first-page": "3387", "volume": "25", "author": "M. Pesta", "year": "2005", "unstructured": "Pesta M, Holubec L Jr, Topolcan O, Cerna M, Rupert K, Holubec LS, Treska V, Kormunda S, Elgrova L, Finek J, Cerny R (2005) Quantitative estimation of matrix metalloproteinases 2 and 7 (MMP-2, MMP-7) and tissue inhibitors of matrix metalloproteinases 1 and 2 (TIMP-1, TIMP-2) in colorectal carcinoma tissue samples. Anticancer Res 25:3387\u20133391", "journal-title": "Anticancer Res"}, {"key": "7_CR82", "doi-asserted-by": "publisher", "first-page": "2060", "DOI": "10.1016/j.ejca.2005.04.039", "volume": "41", "author": "S. Popat", "year": "2005", "unstructured": "Popat S, Houlston RS (2005) A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis. Eur J Cancer 41:2060\u20132070", "journal-title": "Eur J Cancer"}, {"key": "7_CR83", "doi-asserted-by": "publisher", "first-page": "309", "DOI": "10.1038/nrc1322", "volume": "4", "author": "D.F. Ransohoff", "year": "2004", "unstructured": "Ransohoff DF (2004) Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer 4:309\u2013314", "journal-title": "Nat Rev Cancer"}, {"key": "7_CR84", "doi-asserted-by": "publisher", "first-page": "151", "DOI": "10.1002/jso.20413", "volume": "93", "author": "F. Roca", "year": "2006", "unstructured": "Roca F, Mauro LV, Morandi A, Bonadeo F, Vaccaro C, Quintana GO, Specterman S, de Kier Joffe EB, Pallotta MG, Puricelli LI, Lastiri J (2006) Prognostic value of E-cadherin, beta-catenin, MMPs (7 and 9), and TIMPs (1 and 2) in patients with colorectal carcinoma. J Surg Oncol 93:151\u2013160", "journal-title": "J Surg Oncol"}, {"key": "7_CR85", "doi-asserted-by": "publisher", "first-page": "7555", "DOI": "10.1073/pnas.87.19.7555", "volume": "87", "author": "N.R. Rodrigues", "year": "1990", "unstructured": "Rodrigues NR, Rowan A, Smith ME, Kerr IB, Bodmer WF, Gannon JV, Lane DP (1990) p53 mutations in colorectal cancer. Proc Natl Acad Sci U S A 87:7555\u20137559", "journal-title": "Proc Natl Acad Sci U S A"}, {"key": "7_CR86", "doi-asserted-by": "publisher", "first-page": "3352", "DOI": "10.1073/pnas.97.7.3352", "volume": "97", "author": "A.J. Rowan", "year": "2000", "unstructured": "Rowan AJ, Lamlum H, Ilyas M, Wheeler J, Straub J, Papadopoulou A, Bicknell D, Bodmer WF, Tomlinson IP (2000) APC mutations in sporadic colorectal tumors: a mutational \u201chotspot\u201d and interdependence of the \u201ctwo hits\u201d. Proc Natl Acad Sci U S A 97:3352\u20133357", "journal-title": "Proc Natl Acad Sci U S A"}, {"key": "7_CR87", "doi-asserted-by": "publisher", "first-page": "347", "DOI": "10.1002/jso.20393", "volume": "92", "author": "L.R. Rudmik", "year": "2005", "unstructured": "Rudmik LR, Magliocco AM (2005) Molecular mechanisms of hepatic metastasis in colorectal cancer. J Surg Oncol 92:347\u2013359", "journal-title": "J Surg Oncol"}, {"key": "7_CR88", "doi-asserted-by": "crossref", "first-page": "91", "DOI": "10.1038/sj.onc.1209005", "volume": "25", "author": "I.M. Seiden-Long", "year": "2006", "unstructured": "Seiden-Long IM, Brown KR, Shih W, Wigle DA, Radulovich N, Jurisica I, Tsao MS (2006) Transcriptional targets of hepatocyte growth factor signaling and Ki-ras oncogene activation in colorectal cancer. Oncogene 25:91\u2013102", "journal-title": "Oncogene"}, {"key": "7_CR89", "doi-asserted-by": "publisher", "first-page": "395", "DOI": "10.1007/s10555-005-5131-6", "volume": "24", "author": "D. Sheppard", "year": "2005", "unstructured": "Sheppard D (2005) Integrin-mediated activation of latent transforming growth factor beta. Cancer Metastasis Rev 24:395\u2013402", "journal-title": "Cancer Metastasis Rev"}, {"key": "7_CR90", "doi-asserted-by": "publisher", "first-page": "1727", "DOI": "10.1056/NEJM199612053352303", "volume": "335", "author": "D. Shibata", "year": "1996", "unstructured": "Shibata D, Reale MA, Lavin P, Silverman M, Fearon ER, Steele G Jr, Jessup JM, Loda M, Summerhayes IC (1996) The DCC protein and prognosis in colorectal cancer. N Engl J Med 335:1727\u20131732", "journal-title": "N Engl J Med"}, {"key": "7_CR91", "first-page": "517", "volume": "13", "author": "W. Shih", "year": "2005", "unstructured": "Shih W, Chetty R, Tsao MS (2005) Expression profiling by microarrays in colorectal cancer (review). Oncol Rep 13:517\u2013524", "journal-title": "Oncol Rep"}, {"key": "7_CR92", "doi-asserted-by": "publisher", "first-page": "1816", "DOI": "10.1038/sj.bjc.6603193", "volume": "94", "author": "M. Shioiri", "year": "2006", "unstructured": "Shioiri M, Shida T, Koda K, Oda K, Seike K, Nishimura M, Takano S, Miyazaki M (2006) Slug expression is an independent prognostic parameter for poor survival in colorectal carcinoma patients. Br J Cancer 94:1816\u20131822", "journal-title": "Br J Cancer"}, {"key": "7_CR93", "doi-asserted-by": "publisher", "first-page": "308", "DOI": "10.1016/j.ejso.2005.12.003", "volume": "32", "author": "S. Shiono", "year": "2006", "unstructured": "Shiono S, Ishii G, Nagai K, Murata Y, Tsuta K, Nitadori J, Kodama T, Ochiai A (2006) Immunohistochemical prognostic factors in resected colorectal lung metastases using tissue microarray analysis. Eur J Surg Oncol 32:308\u2013309", "journal-title": "Eur J Surg Oncol"}, {"key": "7_CR94", "doi-asserted-by": "crossref", "first-page": "1605", "DOI": "10.1002/(SICI)1097-0142(19960415)77:8<1605::AID-CNCR28>3.0.CO;2-2", "volume": "77", "author": "H. Shiozaki", "year": "1996", "unstructured": "Shiozaki H, Oka H, Inoue M, Tamura S, Monden M (1996) E-cadherin mediated adhesion system in cancer cells. Cancer 77:1605\u20131613", "journal-title": "Cancer"}, {"key": "7_CR95", "first-page": "103", "volume": "1756", "author": "N. Smakman", "year": "2005", "unstructured": "Smakman N, Borel Rinkes IH, Voest EE, Kranenburg O (2005) Control of colorectal metastasis formation by K-Ras. Biochim Biophys Acta 1756:103\u2013114", "journal-title": "Biochim Biophys Acta"}, {"key": "7_CR96", "doi-asserted-by": "publisher", "first-page": "296", "DOI": "10.1111/j.1463-1318.2005.00936.x", "volume": "8", "author": "D. Smith", "year": "2006", "unstructured": "Smith D, Ballal M, Hodder R, Selvachandran SN, Cade D (2006) The adenoma carcinoma sequence: an indoctrinated model for tumorigenesis, but is it always a clinical reality? Colorectal Dis 8:296\u2013301", "journal-title": "Colorectal Dis"}, {"key": "7_CR97", "first-page": "685", "volume": "163", "author": "A. Sory", "year": "1997", "unstructured": "Sory A, Minamoto T, Ohta T, Yamashita K, Sawaguchi K, Mai M, Misiuna P (1997) Does p53 overexpression cause metastases in early invasive colorectal adenocarcinoma? Eur J Surg 163:685\u2013692", "journal-title": "Eur J Surg"}, {"key": "7_CR98", "doi-asserted-by": "publisher", "first-page": "1486", "DOI": "10.1053/j.gastro.2006.08.041", "volume": "131", "author": "U. Stein", "year": "2006", "unstructured": "Stein U, Arlt F, Walther W, Smith J, Waldmann T, Harris ED, Mertins SD, Heizmann CW, Allard D, Birchmeier W, Schlag PM, Shoemaker RH. (2006) The metastasis-associated gene S100A4 is a novel target of beta-catenin/T-Cell factor signaling in colon cancer. Gastroenterology 131:1486\u20131500", "journal-title": "Gastroenterology"}, {"key": "7_CR99", "doi-asserted-by": "publisher", "first-page": "246", "DOI": "10.1159/000086781", "volume": "68", "author": "I. Storojeva", "year": "2005", "unstructured": "Storojeva I, Boulay JL, Ballabeni P, Buess M, Terracciano L, Laffer U, Mild G, Herrmann R, Rochlitz C (2005) Prognostic and predictive relevance of DNAM-1, SOCS6 and CADH-7 genes on chromosome 18q in colorectal cancer. Oncology 68:246\u2013255", "journal-title": "Oncology"}, {"key": "7_CR100", "first-page": "2309", "volume": "3", "author": "K. Takenaga", "year": "1997", "unstructured": "Takenaga K, Nakanishi H, Wada K, Suzuki M, Matsuzaki O, Matsuura A, Endo H (1997) Increased expression of S100A4, a metastasis-associated gene, in human colorectal adenocarcinomas. Clin Cancer Res 3:2309\u20132316", "journal-title": "Clin Cancer Res"}, {"key": "7_CR101", "first-page": "1480", "volume": "9", "author": "H. Takeuchi", "year": "2003", "unstructured": "Takeuchi H, Bilchik A, Saha S, Turner R, Wiese D, Tanaka M, Kuo C, Wang HJ, Hoon DS (2003) c-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases. Clin Cancer Res 9:1480\u20131488", "journal-title": "Clin Cancer Res"}, {"key": "7_CR102", "doi-asserted-by": "publisher", "first-page": "409", "DOI": "10.1038/sj.bjc.6600071", "volume": "86", "author": "S. Taylor", "year": "2002", "unstructured": "Taylor S, Herrington S, Prime W, Rudland PS, Barraclough R (2002) S100A4 (p9Ka) protein in colon carcinoma and liver metastases: association with carcinoma cells and T-lymphocytes. Br J Cancer 86:409\u2013416", "journal-title": "Br J Cancer"}, {"key": "7_CR103", "doi-asserted-by": "publisher", "first-page": "883", "DOI": "10.1007/s10350-006-0528-z", "volume": "49", "author": "W.S. Tsai", "year": "2006", "unstructured": "Tsai WS, Changchien CR, Yeh CY, Chen JS, Tang R, Chiang JM, Hsieh PS, Fan CW, Wang JY (2006) Preoperative plasma vascular endothelial growth factor but not nitrite is a useful complementary tumor marker in patients with colorectal cancer. Dis Colon Rectum 49:883\u2013894", "journal-title": "Dis Colon Rectum"}, {"key": "7_CR104", "doi-asserted-by": "publisher", "first-page": "999", "DOI": "10.1038/nm0803-999b", "volume": "9", "author": "L.J. Veer Van\u2019t", "year": "2003", "unstructured": "Van\u2019t Veer LJ, Weigelt B (2003) Road map to metastasis. Nat Med 9:999\u20131000", "journal-title": "Nat Med"}, {"key": "7_CR105", "doi-asserted-by": "publisher", "first-page": "1196", "DOI": "10.1056/NEJM200104193441603", "volume": "344", "author": "T. Watanabe", "year": "2001", "unstructured": "Watanabe T, Wu TT, Catalano PJ, Ueki T, Satriano R, Haller DG, Benson AB 3rd, Hamilton SR (2001) Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 344:1196\u20131206", "journal-title": "N Engl J Med"}, {"key": "7_CR106", "doi-asserted-by": "publisher", "first-page": "47", "DOI": "10.1186/1477-7819-3-47", "volume": "3", "author": "N.F. Watson", "year": "2005", "unstructured": "Watson NF, Madjd Z, Scrimegour D, Spendlove I, Ellis IO, Scholefield JH, Durrant LG (2005) Evidence that the p53 negative/Bcl-2 positive phenotype is an independent indicator of good prognosis in colorectal cancer: a tissue microarray study of 460 patients. World J Surg Oncol 3:47", "journal-title": "World J Surg Oncol"}, {"key": "7_CR107", "doi-asserted-by": "publisher", "first-page": "145", "DOI": "10.1083/jcb.121.1.145", "volume": "121", "author": "K.M. Weidner", "year": "1993", "unstructured": "Weidner KM, Sachs M, Birchmeier W (1993) The Met receptor tyrosine kinase transduces motility, proliferation, and morphogenic signals of scatter factor/hepatocyte growth factor in epithelial cells. J Cell Biol 121:145\u2013154", "journal-title": "J Cell Biol"}, {"key": "7_CR108", "unstructured": "Welch DR (2006) Defining a cancer metastasis. 97th Annual Meeting, American Association for Cancer Research, Education Book, pp 111\u2013115"}, {"key": "7_CR109", "doi-asserted-by": "publisher", "first-page": "302", "DOI": "10.1097/00130404-200307000-00013", "volume": "9", "author": "W. Xie", "year": "2003", "unstructured": "Xie W, Rimm DL, Lin Y, Shih WJ, Reiss M (2003) Loss of Smad signaling in human colorectal cancer is associated with advanced disease and poor prognosis. Cancer J 9:302\u2013312", "journal-title": "Cancer J"}, {"key": "7_CR110", "doi-asserted-by": "publisher", "first-page": "725", "DOI": "10.1097/00042737-200507000-00006", "volume": "17", "author": "Z. Ying-Tao", "year": "2005", "unstructured": "Ying-Tao Z, Yi-Ping G, Lu-Sheng S, Yi-Li W (2005) Proteomic analysis of differentially expressed proteins between metastatic and non-metastatic human colorectal carcinoma cell lines. Eur J Gastroenterol Hepatol 17:725\u2013732", "journal-title": "Eur J Gastroenterol Hepatol"}, {"key": "7_CR111", "doi-asserted-by": "publisher", "first-page": "409", "DOI": "10.1007/s10585-005-1617-4", "volume": "21", "author": "Z. Zeng", "year": "2004", "unstructured": "Zeng Z, Weiser MR, D\u2019Alessio M, Grace A, Shia J, Paty PB (2004) Immunoblot analysis of c-Met expression in human colorectal cancer: overexpression is associated with advanced stage cancer. Clin Exp Metastasis 21:409\u2013417", "journal-title": "Clin Exp Metastasis"}, {"key": "7_CR112", "first-page": "3073", "volume": "9", "author": "B. Zhang", "year": "2003", "unstructured": "Zhang B, Ougolkov A, Yamashita K, Takahashi Y, Mai M, Minamoto T (2003) beta-Catenin and ras oncogenes detect most human colorectal cancer. Clin Cancer Res 9:3073\u20133079", "journal-title": "Clin Cancer Res"}, {"key": "7_CR113", "doi-asserted-by": "publisher", "first-page": "101", "DOI": "10.1023/A:1025867130437", "volume": "23", "author": "S. Zucker", "year": "2004", "unstructured": "Zucker S, Vacirca J (2004) Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev 23:101\u2013117", "journal-title": "Cancer Metastasis Rev"}], "container-title": ["Targeted Therapies in Cancer", "Recent Results in Cancer Research"], "link": [{"URL": "http://www.springerlink.com/index/pdf/10.1007/978-3-540-46091-6_7", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 2, 17]], "date-time": "2019-02-17T07:21:35Z", "timestamp": 1550388095000}, "score": 34.054577, "issued": {"date-parts": [[null]]}, "ISBN": ["9783540460909"], "references-count": 113, "URL": "http://dx.doi.org/10.1007/978-3-540-46091-6_7", "relation": {"cites": []}}, {"indexed": {"date-parts": [[2019, 12, 2]], "date-time": "2019-12-02T07:28:57Z", "timestamp": 1575271737806}, "reference-count": 29, "publisher": "Elsevier BV", "issue": "1", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2014, 1, 1]], "date-time": "2014-01-01T00:00:00Z", "timestamp": 1388534400000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": ["ejcancer.info", "elsevier.com", "sciencedirect.com"], "crossmark-restriction": true}, "short-container-title": ["European Journal of Cancer"], "published-print": {"date-parts": [[2014, 1]]}, "DOI": "10.1016/j.ejca.2013.08.008", "type": "journal-article", "created": {"date-parts": [[2013, 9, 4]], "date-time": "2013-09-04T23:00:44Z", "timestamp": 1378335644000}, "page": "40-49", "update-policy": "http://dx.doi.org/10.1016/elsevier_cm_policy", "source": "Crossref", "is-referenced-by-count": 36, "title": ["A systematic review of cost-effectiveness of monoclonal antibodies for metastatic colorectal cancer"], "prefix": "10.1016", "volume": "50", "author": [{"given": "A.", "family": "Lange", "sequence": "first", "affiliation": []}, {"given": "A.", "family": "Prenzler", "sequence": "additional", "affiliation": []}, {"given": "M.", "family": "Frank", "sequence": "additional", "affiliation": []}, {"given": "M.", "family": "Kirstein", "sequence": "additional", "affiliation": []}, {"given": "A.", "family": "Vogel", "sequence": "additional", "affiliation": []}, {"given": "J.M.", "family": "von der Schulenburg", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["European Journal of Cancer"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0959804913007727?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0959804913007727?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 7, 23]], "date-time": "2019-07-23T09:41:25Z", "timestamp": 1563874885000}, "score": 33.86137, "issued": {"date-parts": [[2014, 1]]}, "references-count": 29, "journal-issue": {"published-print": {"date-parts": [[2014, 1]]}, "issue": "1"}, "alternative-id": ["S0959804913007727"], "URL": "http://dx.doi.org/10.1016/j.ejca.2013.08.008", "ISSN": ["0959-8049"], "issn-type": [{"value": "0959-8049", "type": "print"}], "subject": ["Cancer Research", "Oncology"], "assertion": [{"value": "Elsevier", "name": "publisher", "label": "This article is maintained by"}, {"value": "A systematic review of cost-effectiveness of monoclonal antibodies for metastatic colorectal cancer", "name": "articletitle", "label": "Article Title"}, {"value": "European Journal of Cancer", "name": "journaltitle", "label": "Journal Title"}, {"value": "https://doi.org/10.1016/j.ejca.2013.08.008", "name": "articlelink", "label": "CrossRef DOI link to publisher maintained version"}, {"value": "article", "name": "content_type", "label": "Content Type"}, {"value": "Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.", "name": "copyright", "label": "Copyright"}]}, {"indexed": {"date-parts": [[2019, 11, 22]], "date-time": "2019-11-22T17:56:51Z", "timestamp": 1574445411138}, "reference-count": 0, "publisher": "MultiMed Inc.", "issue": "S1", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Curr. Oncol."], "DOI": "10.3747/co.v17is1.615", "type": "journal-article", "created": {"date-parts": [[2010, 7, 15]], "date-time": "2010-07-15T16:45:14Z", "timestamp": 1279212314000}, "source": "Crossref", "is-referenced-by-count": 4, "title": ["Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer"], "prefix": "10.3747", "volume": "17", "author": [{"given": "M.", "family": "Fakih", "sequence": "first", "affiliation": []}, {"given": "M.", "family": "Vincent", "sequence": "additional", "affiliation": []}], "member": "2059", "published-online": {"date-parts": [[2010, 5, 6]]}, "container-title": ["Current Oncology"], "deposited": {"date-parts": [[2010, 7, 15]], "date-time": "2010-07-15T16:45:16Z", "timestamp": 1279212316000}, "score": 33.316887, "issued": {"date-parts": [[2010, 5, 6]]}, "references-count": 0, "journal-issue": {"published-online": {"date-parts": [[2010, 5, 6]]}, "issue": "S1"}, "URL": "http://dx.doi.org/10.3747/co.v17is1.615", "ISSN": ["1198-0052"], "issn-type": [{"value": "1198-0052", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 20]], "date-time": "2019-11-20T17:27:01Z", "timestamp": 1574270821943}, "reference-count": 150, "publisher": "Elsevier BV", "issue": "2", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2007, 4, 1]], "date-time": "2007-04-01T00:00:00Z", "timestamp": 1175385600000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Cancer Treatment Reviews"], "published-print": {"date-parts": [[2007, 4]]}, "DOI": "10.1016/j.ctrv.2006.08.006", "type": "journal-article", "created": {"date-parts": [[2007, 2, 3]], "date-time": "2007-02-03T07:46:33Z", "timestamp": 1170488793000}, "page": "146-160", "source": "Crossref", "is-referenced-by-count": 69, "title": ["Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma"], "prefix": "10.1016", "volume": "33", "author": [{"given": "Sean J.", "family": "Whittaker", "sequence": "first", "affiliation": []}, {"given": "Francine M.", "family": "Foss", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Cancer Treatment Reviews"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S030573720600168X?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S030573720600168X?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 4, 24]], "date-time": "2019-04-24T04:21:02Z", "timestamp": 1556079662000}, "score": 32.12897, "issued": {"date-parts": [[2007, 4]]}, "references-count": 150, "journal-issue": {"published-print": {"date-parts": [[2007, 4]]}, "issue": "2"}, "alternative-id": ["S030573720600168X"], "URL": "http://dx.doi.org/10.1016/j.ctrv.2006.08.006", "ISSN": ["0305-7372"], "issn-type": [{"value": "0305-7372", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 12, 4]], "date-time": "2019-12-04T21:53:43Z", "timestamp": 1575496423873}, "publisher-location": "New York, NY", "edition-number": "1", "reference-count": 0, "publisher": "Springer Publishing Company", "isbn-type": [{"value": "9780826138125", "type": "print"}, {"value": "9780826138132", "type": "electronic"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2019, 8]]}, "DOI": "10.1891/9780826138132.0015", "type": "book-chapter", "created": {"date-parts": [[2019, 8, 14]], "date-time": "2019-08-14T01:39:07Z", "timestamp": 1565746747000}, "source": "Crossref", "is-referenced-by-count": 0, "title": ["How I Treat Metastatic Colorectal Cancer With Maintenance Therapies"], "prefix": "10.1891", "author": [{"given": "Sakti", "family": "Chakrabarti", "sequence": "first", "affiliation": []}, {"given": "Joleen M.", "family": "Hubbard", "sequence": "additional", "affiliation": []}], "member": "793", "container-title": ["Handbook of Gastrointestinal Cancers"], "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1891/9780826138132.0015", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 8, 14]], "date-time": "2019-08-14T01:39:16Z", "timestamp": 1565746756000}, "score": 31.446014, "issued": {"date-parts": [[2019, 8]]}, "ISBN": ["9780826138125", "9780826138132"], "references-count": 0, "alternative-id": ["10.1891/9780826138132"], "URL": "http://dx.doi.org/10.1891/9780826138132.0015"}, {"indexed": {"date-parts": [[2019, 11, 22]], "date-time": "2019-11-22T04:15:39Z", "timestamp": 1574396139035}, "reference-count": 52, "publisher": "Wiley", "issue": "8", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2015, 9, 1]], "date-time": "2015-09-01T00:00:00Z", "timestamp": 1441065600000}, "delay-in-days": 1131, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2012, 8]]}, "DOI": "10.1111/j.1463-1318.2011.02817.x", "type": "journal-article", "created": {"date-parts": [[2011, 9, 8]], "date-time": "2011-09-08T07:23:02Z", "timestamp": 1315466582000}, "page": "920-930", "source": "Crossref", "is-referenced-by-count": 31, "title": ["Palliative excisional surgery for primary colorectal cancer in patients with incurable metastatic disease. Is there a survival benefit? A systematic review"], "prefix": "10.1111", "volume": "14", "author": [{"given": "S.", "family": "Anwar", "sequence": "first", "affiliation": []}, {"given": "M. B.", "family": "Peter", "sequence": "additional", "affiliation": []}, {"given": "J.", "family": "Dent", "sequence": "additional", "affiliation": []}, {"given": "N. A.", "family": "Scott", "sequence": "additional", "affiliation": []}], "member": "311", "published-online": {"date-parts": [[2012, 7, 27]]}, "reference": [{"key": "10.1111/j.1463-1318.2011.02817.x-BIB1|cit1", "author": "Campaign", "year": "2000", "volume-title": "Cancer Statistics: Large Bowel- UK Report"}, {"key": "10.1111/j.1463-1318.2011.02817.x-BIB2|cit2", "doi-asserted-by": "crossref", "first-page": "233", "DOI": "10.1016/S1072-7515(03)00390-9", "article-title": "Simultaneous liver and colorectal resections are safe for synchronous colorectal liver metastasis", "volume": "197", "author": "Martin", "year": "2003", "journal-title": "J Am Coll Surg"}, {"key": "10.1111/j.1463-1318.2011.02817.x-BIB3|cit3", "first-page": "285", "article-title": "A retrospective study of the natural history of patients with liver metastases from colorectal cancer", "volume": "2", "author": "Wood", "year": "1976", "journal-title": "Clin Oncol"}, {"key": "10.1111/j.1463-1318.2011.02817.x-BIB4|cit4", "doi-asserted-by": "crossref", "first-page": "229", "DOI": "10.1111/j.1445-2197.2004.02946.x", "article-title": "Is palliative resection of the primary tumour, in the presence of advanced rectal cancer, a safe and useful technique for symptom control?", "volume": "74", "author": "Al-Sanea", "year": "2004", "journal-title": "ANZ J Surg"}, {"key": "10.1111/j.1463-1318.2011.02817.x-BIB5|cit5", "doi-asserted-by": "crossref", "first-page": "1646", "DOI": "10.1007/BF02660770", "article-title": "How aggressive should we be in patients with stage IV colorectal cancer?", "volume": "46", "author": "Kuo", "year": "2003", "journal-title": "Dis Colon Rectum"}, {"key": "10.1111/j.1463-1318.2011.02817.x-BIB6|cit6", "doi-asserted-by": "crossref", "first-page": "722", "DOI": "10.1016/S1072-7515(03)00136-4", "article-title": "Elective bowel resection for incurable stage IV colorectal cancer: prognostic variables for asymptomatic patients", "volume": "196", "author": "Ruo", "year": "2003", "journal-title": "J Am Coll Surg"}, {"key": "10.1111/j.1463-1318.2011.02817.x-BIB7|cit7", "doi-asserted-by": "crossref", "first-page": "1776", "DOI": "10.1007/s10350-007-9025-2", "article-title": "Multivariate analysis of predictive factors for early postoperative death after colorectal surgery in patients with colorectal cancer and synchronous unresectable liver metastases", "volume": "50", "author": "Vibert", "year": "2007", "journal-title": "Dis Colon Rectum"}, {"key": "10.1111/j.1463-1318.2011.02817.x-BIB8|cit8", "doi-asserted-by": "crossref", "first-page": "211", "DOI": "10.1007/BF02633635", "article-title": "The rationale of palliative resection for primary cancer of the colon and rectum complicated by liver and lung metastasis", "volume": "7", "author": "Bacon", "year": "1964", "journal-title": "Dis Colon Rectum"}, {"key": "10.1111/j.1463-1318.2011.02817.x-BIB9|cit9", "doi-asserted-by": "crossref", "first-page": "36", "DOI": "10.1007/BF02616618", "article-title": "Surgery in patients with advanced carcinoma of the colon and rectum", "volume": "2", "author": "Lockhart-Mummery", "year": "1959", "journal-title": "Dis Colon Rectum"}, {"key": "10.1111/j.1463-1318.2011.02817.x-BIB10|cit10", "first-page": "697", "article-title": "Survival of patients after colonic resection for carcinoma with simultaneous liver metastases", "volume": "131", "author": "Cady", "year": "1970", "journal-title": "Surg Gynecol Obstet"}, {"key": "10.1111/j.1463-1318.2011.02817.x-BIB11|cit11", "doi-asserted-by": "crossref", "first-page": "637", "DOI": "10.1245/ASO.2005.06.012", "article-title": "Surgical resection of pimary tumourin pateints who present with stage IV colorectal cancer: an analysis of Surveillance, epidemiology and end results data, 1988-2000", "volume": "12", "author": "Cook", "year": "2005", "journal-title": "Ann Surg Oncol"}, {"key": "10.1111/j.1463-1318.2011.02817.x-BIB12|cit12", "doi-asserted-by": "crossref", "first-page": "559", "DOI": "10.1007/s00384-008-0456-6", "article-title": "Survival and symptomatic benefit from palliative primary tumour resection in aptients with metastatic colorectal cancer: a review", "volume": "23", "author": "Eisenberger", "year": "2008", "journal-title": "Int J Colorectal Dis"}, {"key": "10.1111/j.1463-1318.2011.02817.x-BIB13|cit13", "doi-asserted-by": "crossref", "first-page": "11", "DOI": "10.1007/BF02055675", "article-title": "Operation in patients with incurable colon cancer - is it worthwhile?", "volume": "40", "author": "Liu", "year": "1997", "journal-title": "Dis Colon Rectum"}, {"key": "10.1111/j.1463-1318.2011.02817.x-BIB14|cit14", "doi-asserted-by": "crossref", "first-page": "1246", "DOI": "10.1007/s11605-008-0506-y", "article-title": "Selective surgical treatment of patients with rectal carcinoma and unresectable synchronous metastases based on response to preoperative chemotherapy", "volume": "12", "author": "Stelzner", "year": "2008", "journal-title": "J Gastrointest Surg"}, {"key": "10.1111/j.1463-1318.2011.02817.x-BIB15|cit15", "doi-asserted-by": "crossref", "first-page": "197", "DOI": "10.1007/s00384-003-0551-7", "article-title": "Non-curative surgery for colorectal cancer: critical appraisal of outcomes", "volume": "19", "author": "Law", "year": "2004", "journal-title": "Int J Colorectal Dis"}, {"key": "10.1111/j.1463-1318.2011.02817.x-BIB16|cit16", "doi-asserted-by": "crossref", "first-page": "530", "DOI": "10.1001/archsurg.135.5.530", "article-title": "Initial presentation with stage IV colorectal cancer: how aggressive should we be?", "volume": "135", "author": "Rosen", "year": "2000", "journal-title": "Arch Surg"}, {"key": "10.1111/j.1463-1318.2011.02817.x-BIB17|cit17", "doi-asserted-by": "crossref", "first-page": "1352", "DOI": "10.1046/j.0007-1323.2001.01915.x", "article-title": "Non operative managemnet of the primary tumour in patients with incurable stage IV colorectal cancer", "volume": "88", "author": "Sarela", "year": "2001", "journal-title": "Br J Surg"}, {"key": "10.1111/j.1463-1318.2011.02817.x-BIB18|cit18", "doi-asserted-by": "crossref", "first-page": "954", "DOI": "10.1007/BF02574512", "article-title": "Radical resection of rectal cancer primary tumour provides effective local therapy in pateints with stage IV disease", "volume": "9", "author": "Nash", "year": "2002", "journal-title": "Ann Surg Oncol"}, {"key": "10.1111/j.1463-1318.2011.02817.x-BIB19|cit19", "doi-asserted-by": "crossref", "first-page": "797", "DOI": "10.1007/s00268-009-0366-y", "article-title": "Meta analysis of survival of pateints with stage IV Colorectal cancer managed with surgical resection versus chemotherapy alone", "volume": "34", "author": "Stillwell", "year": "2010", "journal-title": "World J sur"}, {"key": "10.1111/j.1463-1318.2011.02817.x-BIB20|cit20", "doi-asserted-by": "crossref", "first-page": "164", "DOI": "10.1016/j.ejso.2008.06.005", "article-title": "Primary tumour resection and survival in the palliative management of metastatic colorectal cancer", "volume": "35", "author": "Bajwa", "year": "2009", "journal-title": "Eur J Surg Oncol"}, {"key": "10.1111/j.1463-1318.2011.02817.x-BIB21|cit21", "doi-asserted-by": "crossref", "first-page": "2938", "DOI": "10.1200/JCO.2000.18.16.2938", "article-title": "Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer", "volume": "18", "author": "de Gramont", "year": "2000", "journal-title": "J Clin Oncol"}, {"key": "10.1111/j.1463-1318.2011.02817.x-BIB22|cit22", "doi-asserted-by": "crossref", "first-page": "1041", "DOI": "10.1016/S0140-6736(00)02034-1", "article-title": "Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial", "volume": "355", "author": "Douillard", "year": "2000", "journal-title": "Lancet"}, {"key": "10.1111/j.1463-1318.2011.02817.x-BIB23|cit23", "doi-asserted-by": "crossref", "first-page": "531", "DOI": "10.1136/bmj.321.7260.531", "article-title": "Palliative chemotherapy for advanced colorectal cancer: syatematic review and meta analysis, coloretal cancer collaborative group", "volume": "321", "author": "Simmonda", "year": "2000", "journal-title": "BMJ"}, {"key": "10.1111/j.1463-1318.2011.02817.x-BIB24|cit24", "doi-asserted-by": "crossref", "first-page": "649", "DOI": "10.1001/archsurg.1995.01430060087016", "article-title": "Increased tumor establishment and growth after laparotomy vs laparoscopy in a murine model", "volume": "130", "author": "Allendorf", "year": "1995", "journal-title": "Arch Surg"}, {"key": "10.1111/j.1463-1318.2011.02817.x-BIB25|cit25", "doi-asserted-by": "crossref", "first-page": "432", "DOI": "10.1067/S0039-6060(03)00136-3", "article-title": "Laparoscopic-assisted cecectomy is associated with decreased formation of postoperative pulmonary metastases compared with open cecectomy in a murine model", "volume": "134", "author": "Carter", "year": "2003", "journal-title": "Surgery"}, {"key": "10.1111/j.1463-1318.2011.02817.x-BIB26|cit26", "doi-asserted-by": "crossref", "first-page": "1016", "DOI": "10.1002/1097-0142(195409)7:5<1016::AID-CNCR2820070527>3.0.CO;2-G", "article-title": "Palliative surgery for cancer of the rectum and colon", "volume": "7", "author": "Stearns", "year": "1954", "journal-title": "Cancer"}, {"key": "10.1111/j.1463-1318.2011.02817.x-BIB27|cit27", "doi-asserted-by": "crossref", "first-page": "651", "DOI": "10.1007/s10434-999-0651-x", "article-title": "Nonoperative management of primary colorectal cancer in patients with stage IV disease", "volume": "6", "author": "Scoggins", "year": "1999", "journal-title": "Ann Surg Oncol"}, {"key": "10.1111/j.1463-1318.2011.02817.x-BIB28|cit28", "doi-asserted-by": "crossref", "first-page": "568", "DOI": "10.1136/gut.52.4.568", "article-title": "Intestinal complications after chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases", "volume": "52", "author": "Tebbutt", "year": "2003", "journal-title": "Gut"}, {"key": "10.1111/j.1463-1318.2011.02817.x-BIB29|cit29", "doi-asserted-by": "crossref", "first-page": "498", "DOI": "10.1111/j.1463-1318.2007.01384.x", "article-title": "Influence of palliative surgical resection on overall survival in patients with advanced colorectal cancer: a retrospective single institutional study", "volume": "10", "author": "Kaufman", "year": "2008", "journal-title": "Colorectal Dis"}, {"key": "10.1111/j.1463-1318.2011.02817.x-BIB30|cit30", "first-page": "433", "article-title": "Incurable colorectal carcinoma: the role of surgical palliation", "volume": "70", "author": "Cummins", "year": "2004", "journal-title": "Am Surg"}, {"key": "10.1111/j.1463-1318.2011.02817.x-BIB31|cit31", "doi-asserted-by": "crossref", "first-page": "434", "DOI": "10.1016/S0399-8320(04)94952-4", "article-title": "Colorectal cancer with non-resectable synchronous metastases: should the primary tumor be resected?", "volume": "28", "author": "Michel", "year": "2004", "journal-title": "Gastroenterol Clin Biol"}, {"key": "10.1111/j.1463-1318.2011.02817.x-BIB32|cit32", "doi-asserted-by": "crossref", "first-page": "352", "DOI": "10.1001/archsurg.143.4.352", "article-title": "First-line chemotherapy vs bowel tumor resection plus chemotherapy for patients with unresectable synchronous colorectal hepatic metastases", "volume": "143", "author": "Galizia", "year": "2008", "journal-title": "Arch Surg"}, {"key": "10.1111/j.1463-1318.2011.02817.x-BIB33|cit33", "doi-asserted-by": "crossref", "first-page": "1155", "DOI": "10.1002/bjs.5060", "article-title": "Treatment strategy for patients with colorectal cancer and synchronous irresectable liver metastases", "volume": "92", "author": "Benoist", "year": "2005", "journal-title": "Br J Surg"}, {"key": "10.1111/j.1463-1318.2011.02817.x-BIB34|cit34", "doi-asserted-by": "crossref", "first-page": "2567", "DOI": "10.1245/s10434-007-9444-2", "article-title": "Palliative resection of colorectal cancer: does it prolong survival?", "volume": "14", "author": "Costi", "year": "2007", "journal-title": "Ann Surg Oncol"}, {"key": "10.1111/j.1463-1318.2011.02817.x-BIB35|cit35", "doi-asserted-by": "crossref", "first-page": "846", "DOI": "10.1007/BF02051920", "article-title": "Palliative operations for colorectal cancer", "volume": "33", "author": "Makela", "year": "1990", "journal-title": "Dis Colon Rectum"}, {"key": "10.1111/j.1463-1318.2011.02817.x-BIB36|cit36", "doi-asserted-by": "crossref", "first-page": "430", "DOI": "10.1111/j.1463-1318.2007.01161.x", "article-title": "The role of primary tumour resection in patients with stage IV colorectal cancer", "volume": "9", "author": "Konyalian", "year": "2007", "journal-title": "Colorectal Dis"}, {"key": "10.1111/j.1463-1318.2011.02817.x-BIB37|cit37", "doi-asserted-by": "crossref", "first-page": "6634", "DOI": "10.3748/wjg.v12.i41.6634", "article-title": "Survival benefit in patients after palliative resection vs non-resection colon cancer surgery", "volume": "12", "author": "Beham", "year": "2006", "journal-title": "World J Gastroenterol"}, {"key": "10.1111/j.1463-1318.2011.02817.x-BIB38|cit38", "doi-asserted-by": "crossref", "first-page": "1116", "DOI": "10.1002/bjs.1800830827", "article-title": "Prognosis after surgery in patients with incurable rectal cancer: a population-based study", "volume": "83", "author": "Mahteme", "year": "1996", "journal-title": "Br J Surg"}, {"key": "10.1111/j.1463-1318.2011.02817.x-BIB39|cit39", "doi-asserted-by": "crossref", "first-page": "842", "DOI": "10.1007/BF02554846", "article-title": "Advanced rectal cancer. What is the best palliation?", "volume": "31", "author": "Longo", "year": "1988", "journal-title": "Dis Colon Rectum"}, {"key": "10.1111/j.1463-1318.2011.02817.x-BIB40|cit40", "doi-asserted-by": "crossref", "first-page": "336", "DOI": "10.1111/j.1463-1318.2007.01376.x", "article-title": "Palliative surgery for rectal cancer in a national cohort", "volume": "10", "author": "Sigurdsson", "year": "2008", "journal-title": "Colorectal Dis"}, {"key": "10.1111/j.1463-1318.2011.02817.x-BIB41|cit41", "doi-asserted-by": "crossref", "first-page": "107", "DOI": "10.1016/S0360-3016(00)00777-X", "article-title": "Effective pelvic symptom control using initial chemoradiation without colostomy in metastatic rectal cancer", "volume": "49", "author": "Crane", "year": "2001", "journal-title": "Int J Radiat Oncol Biol Phys"}, {"key": "10.1111/j.1463-1318.2011.02817.x-BIB42|cit42", "doi-asserted-by": "crossref", "first-page": "606", "DOI": "10.1007/BF02605756", "article-title": "Palliative operative management in rectal carcinoma", "volume": "24", "author": "Johnson", "year": "1981", "journal-title": "Dis Colon Rectum"}, {"key": "10.1111/j.1463-1318.2011.02817.x-BIB43|cit43", "doi-asserted-by": "crossref", "first-page": "1301", "DOI": "10.1007/s00384-007-0315-x", "article-title": "The prognostic factors of stage IV colorectal cancer and assessment of proper treatment according to the patient\u2019s status", "volume": "22", "author": "Yun", "year": "2007", "journal-title": "Int J Colorectal Dis"}, {"key": "10.1111/j.1463-1318.2011.02817.x-BIB44|cit44", "doi-asserted-by": "crossref", "first-page": "1425", "DOI": "10.1007/BF02070706", "article-title": "Multivariate analysis of the prognostic factors of patients with unresectable synchronous liver metastases from colorectal cancer", "volume": "40", "author": "Yamamura", "year": "1997", "journal-title": "Dis Colon Rectum"}, {"key": "10.1111/j.1463-1318.2011.02817.x-BIB45|cit45", "doi-asserted-by": "crossref", "first-page": "211", "DOI": "10.1002/jso.20196", "article-title": "Factors predicting survival in stage IV colorectal carcinoma patients after palliative treatment: a multivariate analysis", "volume": "89", "author": "Stelzner", "year": "2005", "journal-title": "J Surg Oncol"}, {"key": "10.1111/j.1463-1318.2011.02817.x-BIB46|cit46", "doi-asserted-by": "crossref", "first-page": "749", "DOI": "10.1007/BF02553304", "article-title": "Factors influencing survival in patients with hepatic metastases from adenocarcinoma of the colon or rectum", "volume": "25", "author": "Goslin", "year": "1982", "journal-title": "Dis Colon Rectum"}, {"key": "10.1111/j.1463-1318.2011.02817.x-BIB47|cit47", "doi-asserted-by": "crossref", "first-page": "1829", "DOI": "10.1093/annonc/mdn398", "article-title": "Managemnet of patients with asymptomatic colorectal cancer and synchronous irresectable metastasis", "volume": "19", "author": "Scheer", "year": "2008", "journal-title": "Ann Oncol"}, {"key": "10.1111/j.1463-1318.2011.02817.x-BIB48|cit48", "doi-asserted-by": "crossref", "first-page": "766", "DOI": "10.1245/s10434-006-9146-1", "article-title": "Asymptomatic colorectal cancer with unresectable liver metastasis: immediate colorectal resection or up front systemic chemotherapy", "volume": "14", "author": "Muratore", "year": "2007", "journal-title": "Ann Surg Oncol"}, {"key": "10.1111/j.1463-1318.2011.02817.x-BIB49|cit49", "doi-asserted-by": "crossref", "first-page": "355", "DOI": "10.1007/BF02603417", "article-title": "Palliative resection for colorectal carcinoma", "volume": "24", "author": "Joffe", "year": "1981", "journal-title": "Dis Colon Rectum"}, {"key": "10.1111/j.1463-1318.2011.02817.x-BIB50|cit50", "doi-asserted-by": "crossref", "first-page": "3475", "DOI": "10.1200/JCO.2004.10.218", "article-title": "Use of surgery among elderly patients with stage IV colorectal cancer", "volume": "22", "author": "Temple", "year": "2004", "journal-title": "J Clin Oncol"}, {"key": "10.1111/j.1463-1318.2011.02817.x-BIB51|cit51", "doi-asserted-by": "crossref", "first-page": "237", "DOI": "10.1159/000315730", "article-title": "Matastatic colorectal cancer: from improved surviival to poteential cure", "volume": "78", "author": "Gallagher", "year": "2010", "journal-title": "Oncology"}, {"key": "10.1111/j.1463-1318.2011.02817.x-BIB52|cit52", "doi-asserted-by": "crossref", "first-page": "214", "DOI": "10.1007/DCR.0b013e3182023bb0", "article-title": "Changing management and survival in patients with stage IV colorectal cancer", "volume": "54", "author": "Cameron", "year": "2011", "journal-title": "Dis Colon Rectum"}], "container-title": ["Colorectal Disease"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1463-1318.2011.02817.x", "content-type": "unspecified", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2017, 6, 20]], "date-time": "2017-06-20T05:57:29Z", "timestamp": 1497938249000}, "score": 31.034079, "subtitle": ["Palliative excisional surgery for primary colorectal cancer in patients with incurable metastatic disease"], "issued": {"date-parts": [[2012, 7, 27]]}, "references-count": 52, "journal-issue": {"published-print": {"date-parts": [[2012, 8]]}, "issue": "8"}, "URL": "http://dx.doi.org/10.1111/j.1463-1318.2011.02817.x", "relation": {"cites": []}, "ISSN": ["1462-8910"], "issn-type": [{"value": "1462-8910", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 12, 1]], "date-time": "2019-12-01T05:10:00Z", "timestamp": 1575177000070}, "reference-count": 132, "publisher": "Elsevier BV", "issue": "6", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2013, 10, 1]], "date-time": "2013-10-01T00:00:00Z", "timestamp": 1380585600000}, "delay-in-days": 0, "content-version": "tdm"}, {"URL": "http://creativecommons.org/licenses/by-nc-nd/3.0/", "start": {"date-parts": [[2013, 10, 30]], "date-time": "2013-10-30T00:00:00Z", "timestamp": 1383091200000}, "delay-in-days": 29, "content-version": "vor"}], "content-domain": {"domain": ["cancertreatmentreviews.com", "elsevier.com", "sciencedirect.com"], "crossmark-restriction": true}, "short-container-title": ["Cancer Treatment Reviews"], "published-print": {"date-parts": [[2013, 10]]}, "DOI": "10.1016/j.ctrv.2012.12.011", "type": "journal-article", "created": {"date-parts": [[2013, 1, 31]], "date-time": "2013-01-31T09:15:35Z", "timestamp": 1359623735000}, "page": "592-601", "update-policy": "http://dx.doi.org/10.1016/elsevier_cm_policy", "source": "Crossref", "is-referenced-by-count": 68, "title": ["Targeted therapy in metastatic colorectal cancer \u2013 An example of personalised medicine in action"], "prefix": "10.1016", "volume": "39", "author": [{"given": "V.", "family": "Heinemann", "sequence": "first", "affiliation": []}, {"given": "J.Y.", "family": "Douillard", "sequence": "additional", "affiliation": []}, {"given": "M.", "family": "Ducreux", "sequence": "additional", "affiliation": []}, {"given": "M.", "family": "Peeters", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Cancer Treatment Reviews"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0305737213000066?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0305737213000066?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 7, 9]], "date-time": "2019-07-09T02:37:54Z", "timestamp": 1562639874000}, "score": 30.406672, "issued": {"date-parts": [[2013, 10]]}, "references-count": 132, "journal-issue": {"published-print": {"date-parts": [[2013, 10]]}, "issue": "6"}, "alternative-id": ["S0305737213000066"], "URL": "http://dx.doi.org/10.1016/j.ctrv.2012.12.011", "ISSN": ["0305-7372"], "issn-type": [{"value": "0305-7372", "type": "print"}], "subject": ["Oncology", "Radiology Nuclear Medicine and imaging", "General Medicine"], "assertion": [{"value": "Elsevier", "name": "publisher", "label": "This article is maintained by"}, {"value": "Targeted therapy in metastatic colorectal cancer \u2013 An example of personalised medicine in action", "name": "articletitle", "label": "Article Title"}, {"value": "Cancer Treatment Reviews", "name": "journaltitle", "label": "Journal Title"}, {"value": "https://doi.org/10.1016/j.ctrv.2012.12.011", "name": "articlelink", "label": "CrossRef DOI link to publisher maintained version"}, {"value": "article", "name": "content_type", "label": "Content Type"}, {"value": "Copyright \u00a9 2013 Published by Elsevier Ltd.", "name": "copyright", "label": "Copyright"}]}, {"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T14:41:18Z", "timestamp": 1574779278699}, "reference-count": 99, "publisher": "Elsevier BV", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2016, 5, 1]], "date-time": "2016-05-01T00:00:00Z", "timestamp": 1462060800000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": ["clinicalkey.jp", "clinicalkey.com", "clinicalkey.es", "clinicalkey.com.au", "clinicalkey.fr", "ejcancer.com", "elsevier.com", "sciencedirect.com"], "crossmark-restriction": true}, "short-container-title": ["European Journal of Cancer"], "published-print": {"date-parts": [[2016, 5]]}, "DOI": "10.1016/j.ejca.2016.02.016", "type": "journal-article", "created": {"date-parts": [[2016, 3, 25]], "date-time": "2016-03-25T01:46:04Z", "timestamp": 1458870364000}, "page": "99-108", "update-policy": "http://dx.doi.org/10.1016/elsevier_cm_policy", "source": "Crossref", "is-referenced-by-count": 17, "title": ["Endometrial cancer\u2014targeted therapies myth or reality? Review of current targeted treatments"], "prefix": "10.1016", "volume": "59", "clinical-trial-number": [{"clinical-trial-number": "nct00910091", "registry": "10.18810/clinical-trials-gov"}, {"clinical-trial-number": "nct00977574", "registry": "10.18810/clinical-trials-gov"}, {"clinical-trial-number": "nct01367002", "registry": "10.18810/clinical-trials-gov"}, {"clinical-trial-number": "nct01396408", "registry": "10.18810/clinical-trials-gov"}, {"clinical-trial-number": "nct01770171", "registry": "10.18810/clinical-trials-gov"}, {"clinical-trial-number": "nct01797523", "registry": "10.18810/clinical-trials-gov"}, {"clinical-trial-number": "nct01877564", "registry": "10.18810/clinical-trials-gov"}, {"clinical-trial-number": "nct01935934", "registry": "10.18810/clinical-trials-gov"}, {"clinical-trial-number": "nct02025985", "registry": "10.18810/clinical-trials-gov"}, {"clinical-trial-number": "nct02065687", "registry": "10.18810/clinical-trials-gov"}, {"clinical-trial-number": "nct02491099", "registry": "10.18810/clinical-trials-gov"}], "author": [{"given": "Stephanie", "family": "Lheureux", "sequence": "first", "affiliation": []}, {"given": "Amit M.", "family": "Oza", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["European Journal of Cancer"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0959804916001313?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0959804916001313?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 9, 5]], "date-time": "2019-09-05T23:55:01Z", "timestamp": 1567727701000}, "score": 29.923548, "issued": {"date-parts": [[2016, 5]]}, "references-count": 99, "alternative-id": ["S0959804916001313"], "URL": "http://dx.doi.org/10.1016/j.ejca.2016.02.016", "ISSN": ["0959-8049"], "issn-type": [{"value": "0959-8049", "type": "print"}], "assertion": [{"value": "Elsevier", "name": "publisher", "label": "This article is maintained by"}, {"value": "Endometrial cancer\u2014targeted therapies myth or reality? Review of current targeted treatments", "name": "articletitle", "label": "Article Title"}, {"value": "European Journal of Cancer", "name": "journaltitle", "label": "Journal Title"}, {"value": "https://doi.org/10.1016/j.ejca.2016.02.016", "name": "articlelink", "label": "CrossRef DOI link to publisher maintained version"}, {"value": "article", "name": "content_type", "label": "Content Type"}, {"value": "\u00a9 2016 Elsevier Ltd. All rights reserved.", "name": "copyright", "label": "Copyright"}]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T18:58:36Z", "timestamp": 1574535516832}, "reference-count": 42, "publisher": "Wiley", "issue": "2", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2015, 9, 1]], "date-time": "2015-09-01T00:00:00Z", "timestamp": 1441065600000}, "delay-in-days": 1330, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2012, 2]]}, "DOI": "10.1111/j.1463-1318.2011.02765.x", "type": "journal-article", "created": {"date-parts": [[2011, 8, 16]], "date-time": "2011-08-16T15:17:09Z", "timestamp": 1313507829000}, "page": "e31-e47", "source": "Crossref", "is-referenced-by-count": 49, "title": ["A systematic review of treatment guidelines for metastatic colorectal cancer"], "prefix": "10.1111", "volume": "14", "author": [{"given": "M. S.", "family": "Edwards", "sequence": "first", "affiliation": []}, {"given": "S. D.", "family": "Chadda", "sequence": "additional", "affiliation": []}, {"given": "Z.", "family": "Zhao", "sequence": "additional", "affiliation": []}, {"given": "B. L.", "family": "Barber", "sequence": "additional", "affiliation": []}, {"given": "D. P.", "family": "Sykes", "sequence": "additional", "affiliation": []}], "member": "311", "published-online": {"date-parts": [[2012, 1, 10]]}, "reference": [{"key": "10.1111/j.1463-1318.2011.02765.x-BIB1|cit1", "doi-asserted-by": "crossref", "first-page": "2893", "DOI": "10.1002/ijc.25516", "article-title": "Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008", "volume": "127", "author": "Ferlay", "year": "2010", "journal-title": "Int J Cancer"}, {"issue": "Suppl. 4", "key": "10.1111/j.1463-1318.2011.02765.x-BIB2|cit2", "doi-asserted-by": "crossref", "first-page": "iv61", "DOI": "10.1093/annonc/mdp130", "article-title": "Advanced colorectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up", "volume": "20", "author": "Van Cutsem", "year": "2009", "journal-title": "Ann Oncol"}, {"key": "10.1111/j.1463-1318.2011.02765.x-BIB3|cit3", "doi-asserted-by": "crossref", "first-page": "202", "DOI": "10.3816/CCC.2006.n.036", "article-title": "Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab", "volume": "6", "author": "Yoo", "year": "2006", "journal-title": "Clin Colorectal Cancer"}, {"key": "10.1111/j.1463-1318.2011.02765.x-BIB4|cit4", "doi-asserted-by": "crossref", "first-page": "1311", "DOI": "10.1093/annonc/mdi246", "article-title": "Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates", "volume": "16", "author": "Folprecht", "year": "2005", "journal-title": "Ann Oncol"}, {"key": "10.1111/j.1463-1318.2011.02765.x-BIB5|cit5", "doi-asserted-by": "crossref", "first-page": "2938", "DOI": "10.1200/JCO.2000.18.16.2938", "article-title": "Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer", "volume": "18", "author": "De Gramont", "year": "2000", "journal-title": "J Clin Oncol"}, {"key": "10.1111/j.1463-1318.2011.02765.x-BIB6|cit6", "doi-asserted-by": "crossref", "first-page": "2335", "DOI": "10.1056/NEJMoa032691", "article-title": "Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer", "volume": "350", "author": "Hurwitz", "year": "2004", "journal-title": "N Engl J Med"}, {"key": "10.1111/j.1463-1318.2011.02765.x-BIB7|cit7", "doi-asserted-by": "crossref", "first-page": "2013", "DOI": "10.1200/JCO.2007.14.9930", "article-title": "Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study", "volume": "26", "author": "Saltz", "year": "2008", "journal-title": "J Clin Oncol"}, {"key": "10.1111/j.1463-1318.2011.02765.x-BIB8|cit8", "doi-asserted-by": "crossref", "first-page": "1408", "DOI": "10.1056/NEJMoa0805019", "article-title": "Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer", "volume": "360", "author": "Van Cutsem", "year": "2009", "journal-title": "N Engl J Med"}, {"key": "10.1111/j.1463-1318.2011.02765.x-BIB9|cit9", "doi-asserted-by": "crossref", "first-page": "1626", "DOI": "10.1200/JCO.2007.14.7116", "article-title": "Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer", "volume": "26", "author": "Amado", "year": "2008", "journal-title": "J Clin Oncol"}, {"key": "10.1111/j.1463-1318.2011.02765.x-BIB10|cit10", "doi-asserted-by": "crossref", "first-page": "4697", "DOI": "10.1200/JCO.2009.27.4860", "article-title": "Randomized phase III trial of panitmumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study", "volume": "28", "author": "Douillard", "year": "2010", "journal-title": "J Clin Oncol"}, {"key": "10.1111/j.1463-1318.2011.02765.x-BIB11|cit11", "doi-asserted-by": "crossref", "first-page": "4706", "DOI": "10.1200/JCO.2009.27.6055", "article-title": "Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer", "volume": "28", "author": "Peeters", "year": "2010", "journal-title": "J Clin Oncol"}, {"key": "10.1111/j.1463-1318.2011.02765.x-BIB12|cit12", "doi-asserted-by": "crossref", "first-page": "1757", "DOI": "10.1056/NEJMoa0804385", "article-title": "K-ras mutations and benefit from cetuximab in advanced colorectal cancer", "volume": "359", "author": "Karapetis", "year": "2008", "journal-title": "N Engl J Med"}, {"key": "10.1111/j.1463-1318.2011.02765.x-BIB13|cit13", "first-page": "CD005392", "article-title": "Anti-angiogenic therapies for metastatic colorectal cancer", "volume": "3", "author": "Wagner", "year": "2009", "journal-title": "Cochrane Database Syst Rev"}, {"issue": "Suppl. 1", "key": "10.1111/j.1463-1318.2011.02765.x-BIB14|cit14", "doi-asserted-by": "crossref", "first-page": "i20", "DOI": "10.1093/annonc/mdi827", "article-title": "ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of rectal cancer", "volume": "16", "author": "Tveit", "year": "2005", "journal-title": "Ann Oncol"}, {"issue": "Suppl. 1", "key": "10.1111/j.1463-1318.2011.02765.x-BIB15|cit15", "doi-asserted-by": "crossref", "first-page": "i18", "DOI": "10.1093/annonc/mdi803", "article-title": "ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of advanced colorectal cancer", "volume": "16", "author": "Van Cutsem", "year": "2005", "journal-title": "Ann Oncol"}, {"key": "10.1111/j.1463-1318.2011.02765.x-BIB16|cit16", "doi-asserted-by": "crossref", "first-page": "2037", "DOI": "10.1016/j.ejca.2007.07.017", "article-title": "Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group", "volume": "43", "author": "Nordlinger", "year": "2007", "journal-title": "Eur J Cancer"}, {"issue": "Suppl. 2", "key": "10.1111/j.1463-1318.2011.02765.x-BIB17|cit17", "doi-asserted-by": "crossref", "first-page": "ii31", "DOI": "10.1093/annonc/mdn078", "article-title": "Rectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up", "volume": "19", "author": "Glimelius", "year": "2008", "journal-title": "Ann Oncol"}, {"key": "10.1111/j.1463-1318.2011.02765.x-BIB18|cit18", "doi-asserted-by": "crossref", "first-page": "2212", "DOI": "10.1016/j.ejca.2006.04.012", "article-title": "Towards a pan-European consensus on the treatment of patients with colorectal liver metastases", "volume": "42", "author": "Van Cutsem", "year": "2006", "journal-title": "Eur J Cancer"}, {"issue": "Suppl. 4", "key": "10.1111/j.1463-1318.2011.02765.x-BIB19|cit19", "doi-asserted-by": "crossref", "first-page": "iv54", "DOI": "10.1093/annonc/mdp128", "article-title": "Rectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up", "volume": "20", "author": "Glimelius", "year": "2009", "journal-title": "Ann Oncol"}, {"issue": "Suppl. 2", "key": "10.1111/j.1463-1318.2011.02765.x-BIB20|cit20", "doi-asserted-by": "crossref", "first-page": "ii33", "DOI": "10.1093/annonc/mdn079", "article-title": "Advanced colorectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up", "volume": "19", "author": "Van Cutsem", "year": "2008", "journal-title": "Ann Oncol"}, {"issue": "Suppl. 2", "key": "10.1111/j.1463-1318.2011.02765.x-BIB21|cit21", "doi-asserted-by": "crossref", "first-page": "S27", "DOI": "10.1097/00001813-199708002-00006", "article-title": "An international, multidisciplinary approach to the management of advanced colorectal cancer", "volume": "8", "author": "Wilke", "year": "1997", "journal-title": "Anticancer Drugs"}, {"key": "10.1111/j.1463-1318.2011.02765.x-BIB22|cit22", "doi-asserted-by": "crossref", "first-page": "985", "DOI": "10.1093/annonc/mdn735", "article-title": "Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel", "volume": "20", "author": "Nordlinger", "year": "2009", "journal-title": "Ann Oncol"}, {"key": "10.1111/j.1463-1318.2011.02765.x-BIB23|cit23", "doi-asserted-by": "crossref", "first-page": "5", "DOI": "10.1093/annonc/mdn532", "article-title": "Treatment of the elderly colorectal cancer patient: SIOG expert recommendations", "volume": "20", "author": "Papamichael", "year": "2009", "journal-title": "Ann Oncol"}, {"key": "10.1111/j.1463-1318.2011.02765.x-BIB24|cit24", "doi-asserted-by": "crossref", "first-page": "1269", "DOI": "10.1007/s10350-004-0598-8", "article-title": "Practice parameters for colon cancer", "volume": "47", "author": "Otchy", "year": "2004", "journal-title": "Dis Colon Rectum"}, {"key": "10.1111/j.1463-1318.2011.02765.x-BIB25|cit25", "unstructured": "Society for Surgery of the Alimentary Tract (SSAT) Surgery for Hepatic Colorectal Metastases. 2004 Society for Surgery of the Alimentary Tract (SSAT) http://www.guideline.gov/summary/summary.aspx?doc_id=5699&nbr=003837&string=colorectal"}, {"key": "10.1111/j.1463-1318.2011.02765.x-BIB26|cit26", "doi-asserted-by": "crossref", "first-page": "1271", "DOI": "10.1245/s10434-006-9045-5", "article-title": "Improving resectability of hepatic colorectal metastases: expert consensus statement", "volume": "13", "author": "Abdalla", "year": "2006", "journal-title": "Ann Surg Oncol"}, {"key": "10.1111/j.1463-1318.2011.02765.x-BIB27|cit27", "doi-asserted-by": "crossref", "first-page": "1284", "DOI": "10.1245/s10434-006-9018-8", "article-title": "Chemotherapy and regional therapy of hepatic colorectal metastases: expert consensus statement", "volume": "13", "author": "Bartlett", "year": "2006", "journal-title": "Ann Surg Oncol"}, {"key": "10.1111/j.1463-1318.2011.02765.x-BIB28|cit28", "doi-asserted-by": "crossref", "first-page": "225", "DOI": "10.1097/01.RVI.0000195330.47954.48", "article-title": "Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy", "volume": "17", "author": "Brown", "year": "2006", "journal-title": "J Vasc Interv Radiol"}, {"key": "10.1111/j.1463-1318.2011.02765.x-BIB29|cit29", "doi-asserted-by": "crossref", "first-page": "1261", "DOI": "10.1245/s10434-006-9023-y", "article-title": "Selection of patients for resection of hepatic colorectal metastases: expert consensus statement", "volume": "13", "author": "Charnsangavej", "year": "2006", "journal-title": "Ann Surg Oncol"}, {"key": "10.1111/j.1463-1318.2011.02765.x-BIB30|cit30", "unstructured": "Herman J Messersmith WA Johnstone PA et\u00a0al. Expert Panel on Radiation Oncology - Rectal/Anal Cancer ACR Appropriateness Criteria\u00ae Rectal Cancer - Metastatic Disease At Presentation. 2007 American College of Radiology (ACR) http://www.guideline.gov/summary/summary.aspx?doc_id=13620&nbr=006981&string=colorectal"}, {"key": "10.1111/j.1463-1318.2011.02765.x-BIB31|cit31", "doi-asserted-by": "crossref", "first-page": "263", "DOI": "10.1002/jso.21053", "article-title": "Consensus statement on the loco regional treatment of colorectal cancer with peritoneal dissemination", "volume": "98", "author": "Esquivel", "year": "2008", "journal-title": "J Surg Oncol"}, {"issue": "Suppl. 7", "key": "10.1111/j.1463-1318.2011.02765.x-BIB32|cit32", "doi-asserted-by": "crossref", "first-page": "S219", "DOI": "10.1016/j.jvir.2009.04.033", "article-title": "Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy", "volume": "20", "author": "Brown", "year": "2009", "journal-title": "J Vasc Interv Radiol"}, {"key": "10.1111/j.1463-1318.2011.02765.x-BIB33|cit33", "unstructured": "Engstrom PF Arnoletti JP Benson AB 3rd et\u00a0al. 2011 NCCN Clinical Practice Guidelines in Oncology: Colon Cancer http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site"}, {"key": "10.1111/j.1463-1318.2011.02765.x-BIB34|cit34", "unstructured": "Engstrom PF Arnoletti JP Benson AB 3rd et\u00a0al. 2011 NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site"}, {"key": "10.1111/j.1463-1318.2011.02765.x-BIB35|cit35", "unstructured": "Alberta Health Services Clinical Practice Guideline Metastatic Colorectal Cancer, 2009 http://www.cancerboard.ab.ca/NR/rdonlyres/C2CB311E-D7B0-4D55-9318-499120A26579/0/GI003ColorectalMetastaticAug2009.pdf"}, {"key": "10.1111/j.1463-1318.2011.02765.x-BIB36|cit36", "doi-asserted-by": "crossref", "first-page": "723", "DOI": "10.1007/s12094-007-0129-x", "article-title": "Guidelines for the detection and treatment of liver metastases of colorectal cancer", "volume": "9", "author": "Abad", "year": "2007", "journal-title": "Clin Transl Oncol"}, {"key": "10.1111/j.1463-1318.2011.02765.x-BIB37|cit37", "unstructured": "Association for Coloproctology of Great Britain and Ireland 2007 3rd edition Guidelines for the Management of Colorectal Cancer http://www.acpgbi.org.uk/assets/documents/COLO_guides.pdf"}, {"key": "10.1111/j.1463-1318.2011.02765.x-BIB38|cit38", "unstructured": "Welch S, the Gastrointestinal Cancer Disease Site Group The Role of Bevacizumab (Avastin\u00ae) Combined with Chemotherapy in the Treatment of Patients with Advanced Colorectal Cancer: Guideline Recommendations. 2008 http://www.cancercare.on.ca/pdf/pebc2-25s.pdf"}, {"key": "10.1111/j.1463-1318.2011.02765.x-BIB39|cit39", "unstructured": "NHS National Institute for Health and Clinical Excellence (NICE) Cetuximab for the First-Line Treatment of Metastatic Colorectal Cancer. NICE Technology Appraisal Guidance. 2009 http://www.nice.org.uk/nicemedia/pdf/TA176Guidance.pdf"}, {"key": "10.1111/j.1463-1318.2011.02765.x-BIB40|cit40", "doi-asserted-by": "crossref", "first-page": "663", "DOI": "10.1200/JCO.2008.20.8397", "article-title": "Fluorouracil, leucovorin, and oxaliplatin with and without Erbitux in the first-line treatment of metastatic colorectal cancer", "volume": "27", "author": "Bokemeyer", "year": "2009", "journal-title": "J Clin Oncol"}, {"key": "10.1111/j.1463-1318.2011.02765.x-BIB41|cit41", "unstructured": "AGREE Collaboration Appraisal of Guidelines for Research and Evaluation (AGREE) Instrument http://www.agreecollaboration.org"}, {"key": "10.1111/j.1463-1318.2011.02765.x-BIB42|cit42", "unstructured": "The ADAPTE Collaboration Resource Toolkit for Guideline Adaptation (Version 1). The ADAPTE Collaboration http://www.adapte.org"}], "container-title": ["Colorectal Disease"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1463-1318.2011.02765.x", "content-type": "unspecified", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2017, 6, 20]], "date-time": "2017-06-20T04:46:53Z", "timestamp": 1497934013000}, "score": 29.866205, "subtitle": ["Treatment guidelines for mCRC"], "issued": {"date-parts": [[2012, 1, 10]]}, "references-count": 42, "journal-issue": {"published-print": {"date-parts": [[2012, 2]]}, "issue": "2"}, "URL": "http://dx.doi.org/10.1111/j.1463-1318.2011.02765.x", "relation": {"cites": []}, "ISSN": ["1462-8910"], "issn-type": [{"value": "1462-8910", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 12, 3]], "date-time": "2019-12-03T18:05:03Z", "timestamp": 1575396303232}, "reference-count": 105, "publisher": "IntechOpen", "isbn-type": [{"value": "9781789850598", "type": "print"}, {"value": "9781789850604", "type": "electronic"}], "license": [{"URL": "https://creativecommons.org/licenses/by/3.0/legalcode", "start": {"date-parts": [[2019, 2, 6]], "date-time": "2019-02-06T00:00:00Z", "timestamp": 1549411200000}, "delay-in-days": 0, "content-version": "unspecified"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "DOI": "10.5772/intechopen.80690", "type": "book-chapter", "created": {"date-parts": [[2019, 2, 6]], "date-time": "2019-02-06T07:47:57Z", "timestamp": 1549439277000}, "source": "Crossref", "is-referenced-by-count": 0, "title": ["Predictive Biomarkers for Monoclonal Antibody Therapies Targeting EGFR (Cetuximab, Panitumumab) in the Treatment of Metastatic Colorectal Cancer"], "prefix": "10.5772", "author": [{"given": "Anuratha", "family": "Sakthianandeswaren", "sequence": "first", "affiliation": []}, {"given": "Polly", "family": "Sabljak", "sequence": "additional", "affiliation": []}, {"given": "Meg", "family": "J. Elliott", "sequence": "additional", "affiliation": []}, {"given": "Michelle", "family": "Palmieri", "sequence": "additional", "affiliation": []}, {"given": "Oliver", "family": "M. Sieber", "sequence": "additional", "affiliation": []}], "member": "3774", "published-online": {"date-parts": [[2019, 2, 6]]}, "reference": [{"key": "ref=1", "unstructured": "Surveillance, Epidemiology, and End Results Program SEER Facts and Figures. Colorectal Cancer. National Cancer Institute. 2018. [cited Jul 20, 2018]. Available from: https://seer.cancer.gov/statfacts/html/colorect.html"}, {"key": "ref=2", "unstructured": "Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, et\u00a0al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Annals of Oncology. 2016;27(8):1386-1422", "DOI": "10.1093/annonc/mdw235", "doi-asserted-by": "crossref"}, {"key": "ref=3", "unstructured": "Zhao B, Wang L, Qiu H, Zhang M, Sun L, Peng P, et\u00a0al. Mechanisms of resistance to anti-EGFR therapy in colorectal cancer. Oncotarget. 2017;8(3):3980-4000", "DOI": "10.18632/oncotarget.14012", "doi-asserted-by": "crossref"}, {"key": "ref=4", "unstructured": "Brand TM, Iida M, Wheeler DL. Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biology & Therapy. 2011;11(9):777-792", "DOI": "10.4161/cbt.11.9.15050", "doi-asserted-by": "crossref"}, {"key": "ref=5", "unstructured": "Tebbutt N, Pedersen MW, Johns TG.\u00a0Targeting the ERBB family in cancer: couples therapy. Nature Reviews. Cancer. 2013;13(9):663-673", "DOI": "10.1038/nrc3559", "doi-asserted-by": "crossref"}, {"key": "ref=6", "unstructured": "Sigismund S, Avanzato D, Lanzetti L.\u00a0Emerging functions of the EGFR in cancer. Molecular Oncology. 2018;12(1):3-20", "DOI": "10.1002/1878-0261.12155", "doi-asserted-by": "crossref"}, {"key": "ref=7", "unstructured": "Spano JP, Lagorce C, Atlan D, Milano G, Domont J, Benamouzig R, et\u00a0al. Impact of EGFR expression on colorectal cancer patient prognosis and survival. Annals of Oncology. 2005;16(1):102-108", "DOI": "10.1093/annonc/mdi006", "doi-asserted-by": "crossref"}, {"key": "ref=8", "unstructured": "Goldstein NS, Armin M. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: Implications for a standardized scoring system. Cancer. 2001;92(5):1331-1346", "DOI": "10.1002/1097-0142(20010901)92:5<1331::AID-CNCR1455>3.0.CO;2-M", "doi-asserted-by": "crossref"}, {"key": "ref=9", "unstructured": "Yang BB, Lum P, Chen A, Arends R, Roskos L, Smith B, et\u00a0al. Pharmacokinetic and pharmacodynamic perspectives on the clinical drug development of panitumumab. Clinical Pharmacokinetics. 2010;49(11):729-740", "DOI": "10.2165/11535970-000000000-00000", "doi-asserted-by": "crossref"}, {"key": "ref=10", "unstructured": "Inoue Y, Hazama S, Iwamoto S, Miyake Y, Matsuda C, Tsunedomi R, et\u00a0al. FcgammaR and EGFR polymorphisms as predictive markers of cetuximab efficacy in metastatic colorectal cancer. Molecular Diagnosis & Therapy. 2014;18(5):541-548", "DOI": "10.1007/s40291-014-0103-6", "doi-asserted-by": "crossref"}, {"key": "ref=11", "unstructured": "Kurai J, Chikumi H, Hashimoto K, Yamaguchi K, Yamasaki A, Sako T, et\u00a0al. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clinical Cancer Research. 2007;13(5):1552-1561", "DOI": "10.1158/1078-0432.CCR-06-1726", "doi-asserted-by": "crossref"}, {"key": "ref=12", "unstructured": "Price TJ, Peeters M, Kim TW, Li J, Cascinu S, Ruff P, et\u00a0al. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): A randomised, multicentre, open-label, non-inferiority phase 3 study. The Lancet Oncology. 2014;15(6):569-579", "DOI": "10.1016/S1470-2045(14)70118-4", "doi-asserted-by": "crossref"}, {"key": "ref=13", "unstructured": "Linardou H, Briasoulis E, Dahabreh IJ, Mountzios G, Papadimitriou C, Papadopoulos S, et\u00a0al. All about KRAS for clinical oncology practice: Gene profile, clinical implications and laboratory recommendations for somatic mutational testing in colorectal cancer. Cancer Treatment Reviews. 2011;37(3):221-233", "DOI": "10.1016/j.ctrv.2010.07.008", "doi-asserted-by": "crossref"}, {"key": "ref=14", "unstructured": "Van Emburgh BO, Sartore-Bianchi A, Di Nicolantonio F, Siena S, Bardelli A.\u00a0Acquired resistance to EGFR-targeted therapies in colorectal cancer. Molecular Oncology. 2014;8(6):1084-1094", "DOI": "10.1016/j.molonc.2014.05.003", "doi-asserted-by": "crossref"}, {"key": "ref=15", "unstructured": "Malumbres M, Barbacid M.\u00a0RAS oncogenes: the first 30 years. Nature Reviews. Cancer. 2003;3(6):459-465", "DOI": "10.1038/nrc1097", "doi-asserted-by": "crossref"}, {"key": "ref=16", "unstructured": "Catalogue of Somatic Mutations in Cancer. Wellcome Trust Sanger Institute. 2018 [cited Jul 20, 2018]. Available from: http://www.sanger.ac.uk/genetics/CGP/cosmic/"}, {"key": "ref=17", "unstructured": "Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zubel A, et\u00a0al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Annals of Oncology. 2011;22(7):1535-1546", "DOI": "10.1093/annonc/mdq632", "doi-asserted-by": "crossref"}, {"key": "ref=18", "unstructured": "Van Cutsem E, Kohne CH, Lang I, Folprecht G, Nowacki MP, Cascinu S, et\u00a0al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. Journal of Clinical Oncology. 2011;29(15):2011-2019", "DOI": "10.1200/JCO.2010.33.5091", "doi-asserted-by": "crossref"}, {"key": "ref=19", "unstructured": "Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et\u00a0al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. Journal of Clinical Oncology. 2008;26(10):1626-1634", "DOI": "10.1200/JCO.2007.14.7116", "doi-asserted-by": "crossref"}, {"key": "ref=20", "unstructured": "Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, et\u00a0al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. Journal of Clinical Oncology. 2009;27(12):2091-2096", "DOI": "10.1200/JCO.2009.21.9170", "doi-asserted-by": "crossref"}, {"key": "ref=21", "unstructured": "Allegra CJ, Rumble RB, Hamilton SR, Mangu PB, Roach N, Hantel A, et\u00a0al. Extended RAS gene mutation testing in metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015. Journal of Clinical Oncology. 2016;34(2):179-185", "DOI": "10.1200/JCO.2015.63.9674", "doi-asserted-by": "crossref"}, {"key": "ref=22", "unstructured": "Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, et\u00a0al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. The New England Journal of Medicine. 2008;359(17):1757-1765", "DOI": "10.1056/NEJMoa0804385", "doi-asserted-by": "crossref"}, {"key": "ref=23", "unstructured": "Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et\u00a0al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. The New England Journal of Medicine. 2013;369(11):1023-1034", "DOI": "10.1056/NEJMoa1305275", "doi-asserted-by": "crossref"}, {"key": "ref=24", "unstructured": "Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, et\u00a0al. Final results from a randomized phase 3 study of FOLFIRI {+/\u2212} panitumumab for second-line treatment of metastatic colorectal cancer. Annals of Oncology. 2014;25(1):107-116", "DOI": "10.1093/annonc/mdt523", "doi-asserted-by": "crossref"}, {"key": "ref=25", "unstructured": "Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, et\u00a0al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. Journal of Clinical Oncology. 2009;27(5):663-671", "DOI": "10.1200/JCO.2008.20.8397", "doi-asserted-by": "crossref"}, {"key": "ref=26", "unstructured": "Guerrero S, Casanova I, Farre L, Mazo A, Capella G, Mangues R.\u00a0K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. Cancer Research. 2000;60(23):6750-6756"}, {"key": "ref=27", "unstructured": "De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, et\u00a0al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. Journal of the American Medical Association. 2010;304(16):1812-1820", "DOI": "10.1001/jama.2010.1535", "doi-asserted-by": "crossref"}, {"key": "ref=28", "unstructured": "Tejpar S, Celik I, Schlichting M, Sartorius U, Bokemeyer C, Van Cutsem E.\u00a0Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. Journal of Clinical Oncology. 2012;30(29):3570-3577", "DOI": "10.1200/JCO.2012.42.2592", "doi-asserted-by": "crossref"}, {"key": "ref=29", "unstructured": "Gajate P, Sastre J, Bando I, Alonso T, Cillero L, Sanz J, et\u00a0al. Influence of KRAS p.G13D mutation in patients with metastatic colorectal cancer treated with cetuximab. Clinical Colorectal Cancer. 2012;11(4):291-296", "DOI": "10.1016/j.clcc.2012.02.003", "doi-asserted-by": "crossref"}, {"key": "ref=30", "unstructured": "Peeters M, Douillard JY, Van Cutsem E, Siena S, Zhang K, Williams R, et\u00a0al. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: Assessment as prognostic and predictive biomarkers of response to panitumumab. Journal of Clinical Oncology. 2013;31(6):759-765", "DOI": "10.1200/JCO.2012.45.1492", "doi-asserted-by": "crossref"}, {"key": "ref=31", "unstructured": "Segelov E, Thavaneswaran S, Waring PM, Desai J, Robledo KP, Gebski VJ, et\u00a0al. Response to cetuximab with or without irinotecan in patients with refractory metastatic colorectal cancer harboring the KRAS G13D mutation: Australasian gastro-intestinal trials group ICECREAM study. Journal of Clinical Oncology. 2016;34(19):2258-2264", "DOI": "10.1200/JCO.2015.65.6843", "doi-asserted-by": "crossref"}, {"key": "ref=32", "unstructured": "Van Cutsem E, Lenz HJ, Kohne CH, Heinemann V, Tejpar S, Melezinek I, et\u00a0al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. Journal of Clinical Oncology. 2015;33(7):692-700", "DOI": "10.1200/JCO.2014.59.4812", "doi-asserted-by": "crossref"}, {"key": "ref=33", "unstructured": "Sorich MJ, Wiese MD, Rowland A, Kichenadasse G, McKinnon RA, Karapetis CS.\u00a0Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Annals of Oncology. 2015;26(1):13-21", "DOI": "10.1093/annonc/mdu378", "doi-asserted-by": "crossref"}, {"key": "ref=34", "unstructured": "Bokemeyer C, Kohne CH, Ciardiello F, Lenz HJ, Heinemann V, Klinkhardt U, et\u00a0al. FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer. European Journal of Cancer. 2015;51(10):1243-1252", "DOI": "10.1016/j.ejca.2015.04.007", "doi-asserted-by": "crossref"}, {"key": "ref=35", "unstructured": "Peeters M, Oliner KS, Price TJ, Cervantes A, Sobrero AF, Ducreux M, et\u00a0al. Analysis of KRAS/NRAS mutations in a phase III study of panitumumab with FOLFIRI compared with FOLFIRI alone as second-line treatment for metastatic colorectal cancer. Clinical Cancer Research. 2015;21(24):5469-5479", "DOI": "10.1158/1078-0432.CCR-15-0526", "doi-asserted-by": "crossref"}, {"key": "ref=36", "unstructured": "Schwartzberg LS, Rivera F, Karthaus M, Fasola G, Canon JL, Hecht JR, et\u00a0al. PEAK: A randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6\u00a0in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. Journal of Clinical Oncology. 2014;32(21):2240-2247", "DOI": "10.1200/JCO.2013.53.2473", "doi-asserted-by": "crossref"}, {"key": "ref=37", "unstructured": "Stintzing S, Modest DP, Rossius L, Lerch MM, von Weikersthal LF, Decker T, et\u00a0al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): A post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. The Lancet Oncology. 2016;17(10):1426-1434", "DOI": "10.1016/S1470-2045(16)30269-8", "doi-asserted-by": "crossref"}, {"key": "ref=38", "unstructured": "De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et\u00a0al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. The Lancet Oncology. 2010;11(8):753-762", "DOI": "10.1016/S1470-2045(10)70130-3", "doi-asserted-by": "crossref"}, {"key": "ref=39", "unstructured": "Stintzing S, Tejpar S, Gibbs P, Thiebach L, Lenz HJ.\u00a0Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes. European Journal of Cancer. 2017;84:69-80", "DOI": "10.1016/j.ejca.2017.07.016", "doi-asserted-by": "crossref"}, {"key": "ref=40", "unstructured": "Loupakis F, Yang D, Yau L, Feng S, Cremolini C, Zhang W, et\u00a0al. Primary tumor location as a prognostic factor in metastatic colorectal cancer. Journal of the National Cancer Institute. 2015;107(3):dju427", "DOI": "10.1093/jnci/dju427", "doi-asserted-by": "crossref"}, {"key": "ref=41", "unstructured": "Nitsche U, Stogbauer F, Spath C, Haller B, Wilhelm D, Friess H, et\u00a0al. Right sided colon cancer as a distinct histopathological subtype with reduced prognosis. Digestive Surgery. 2016;33(2):157-163", "DOI": "10.1159/000443644", "doi-asserted-by": "crossref"}, {"key": "ref=42", "unstructured": "Sinicrope FA, Mahoney MR, Yoon HH, Smyrk TC, Thibodeau SN, Goldberg RM, et\u00a0al. Analysis of molecular markers by anatomic tumor site in stage III colon carcinomas from adjuvant chemotherapy trial NCCTG N0147 (alliance). Clinical Cancer Research. 2015;21(23):5294-5304", "DOI": "10.1158/1078-0432.CCR-15-0527", "doi-asserted-by": "crossref"}, {"key": "ref=43", "unstructured": "Rowan A, Halford S, Gaasenbeek M, Kemp Z, Sieber O, Volikos E, et\u00a0al. Refining molecular analysis in the pathways of colorectal carcinogenesis. Clinical Gastroenterology and Hepatology. 2005;3(11):1115-1123", "DOI": "10.1016/S1542-3565(05)00618-X", "doi-asserted-by": "crossref"}, {"key": "ref=44", "unstructured": "Missiaglia E, Jacobs B, D'Ario G, Di Narzo AF, Soneson C, Budinska E, et\u00a0al. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Annals of Oncology. 2014;25(10):1995-2001", "DOI": "10.1093/annonc/mdu275", "doi-asserted-by": "crossref"}, {"key": "ref=45", "unstructured": "Lee MS, McGuffey EJ, Morris JS, Manyam G, Baladandayuthapani V, Wei W, et\u00a0al. Association of CpG island methylator phenotype and EREG/AREG methylation and expression in colorectal cancer. British Journal of Cancer. 2016;114(12):1352-1361", "DOI": "10.1038/bjc.2016.87", "doi-asserted-by": "crossref"}, {"key": "ref=46", "unstructured": "Tejpar S, Stintzing S, Ciardiello F, Tabernero J, Van Cutsem E, Beier F, et\u00a0al. Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: Retrospective analyses of the CRYSTAL and FIRE-3 trials. JAMA Oncology. 2017;3(2):194-201", "DOI": "10.1001/jamaoncol.2016.3797", "doi-asserted-by": "crossref"}, {"key": "ref=47", "unstructured": "Venook A, Niedzwiecki D, Innocenti F, Fruth B, Greene C, O'Neil B, et\u00a0al. Impact of primary (1\u00b0) tumor location on overall survival (OS) and progression free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): analysis of CALGB/SWOG 80405 (Alliance). Journal of Clinical Oncology. 2016;34:3504", "DOI": "10.1200/JCO.2016.34.15_suppl.3504", "doi-asserted-by": "crossref"}, {"key": "ref=48", "unstructured": "Boeckx N, Koukakis R, Op de Beeck K, Rolfo C, Van Camp G, Siena S, et\u00a0al. Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies. Annals of Oncology. 2017;28(8):1862-1868", "DOI": "10.1093/annonc/mdx119", "doi-asserted-by": "crossref"}, {"key": "ref=49", "unstructured": "Holch JW, Ricard I, Stintzing S, Modest DP, Heinemann V.\u00a0The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials. European Journal of Cancer. 2017;70:87-98", "DOI": "10.1016/j.ejca.2016.10.007", "doi-asserted-by": "crossref"}, {"key": "ref=50", "unstructured": "Modest DP, Stintzing S, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, et\u00a0al. Exploring the effect of primary tumor sidedness on therapeutic efficacy across treatment lines in patients with metastatic colorectal cancer: analysis of FIRE-3 (AIOKRK0306). Oncotarget. 2017;8(62):105749-105760", "DOI": "10.18632/oncotarget.22396", "doi-asserted-by": "crossref"}, {"key": "ref=51", "unstructured": "Boeckx AT N, Op de Beeck K, Kafatos G, Deschoolmeester V, Rolfo C, et\u00a0al. Primary tumor sidedness impacts on prognosis and treatment outcome: results from three randomized studies of panitumumab plus chemotherapy versus chemotherapy or chemotherapy plus bevacizumab in 1st and 2nd line RAS/BRAF WT mCRC Ann Oncol. 2016;27(suppl 6):vi15-vi42", "DOI": "10.1093/annonc/mdw363.37", "doi-asserted-by": "crossref"}, {"key": "ref=52", "unstructured": "Brule SY, Jonker DJ, Karapetis CS, O'Callaghan CJ, Moore MJ, Wong\u00a0R, et\u00a0al. Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. European Journal of Cancer. 2015;51(11):1405-1414", "DOI": "10.1016/j.ejca.2015.03.015", "doi-asserted-by": "crossref"}, {"key": "ref=53", "unstructured": "Clinical Practice Guidelines in Oncology Colon cancer: National Comprehensive Cancer Network (NCCN). 2018. [cited Jul 20, 2018]. Available from: https://www.nccn.org"}, {"key": "ref=54", "unstructured": "Petrelli F, Ardito R, Ghidini A, Zaniboni A, Ghidini M, Barni S, et\u00a0al. Different toxicity of cetuximab and panitumumab in metastatic colorectal cancer treatment: A systematic review and meta-analysis. Oncology. 2018;94(4):191-199", "DOI": "10.1159/000486338", "doi-asserted-by": "crossref"}, {"key": "ref=55", "unstructured": "Lacouture ME.\u00a0Mechanisms of cutaneous toxicities to EGFR inhibitors. Nature Reviews. Cancer. 2006;6(10):803-812", "DOI": "10.1038/nrc1970", "doi-asserted-by": "crossref"}, {"key": "ref=56", "unstructured": "AAMPP I.\u00a0Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial. Journal of Clinical Oncology. 2007;25(18S; June 20 suppl)"}, {"key": "ref=57", "unstructured": "Sobrero AF, Maurel J, Fehrenbacher\u00a0L, et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. Journal of Clinical Oncology. 2008 May 10;26(14):2311-2319", "DOI": "10.1200/JCO.2007.13.1193", "doi-asserted-by": "crossref"}, {"key": "ref=58", "unstructured": "Sobrero AF, Peeters M, Price\u00a0TJ, et\u00a0al. Final results from study 181: Randomized phase III study of FOLFIRI with or without panitumumab (pmab) for the treatment of second-line metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. 2012;30(suppl 4):387", "DOI": "10.1200/jco.2012.30.4_suppl.387", "doi-asserted-by": "crossref"}, {"key": "ref=59", "unstructured": "Douillard YJSS, Tabernero J, et\u00a0al. Final skin toxicity (ST) and patient-reported outcomes (PRO) results from PRIME: A randomized phase III study of panitumumab (pmab) plus FOLFOX4 (CT) for first-line metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. 2012;30(suppl 4):531", "DOI": "10.1200/jco.2012.30.4_suppl.531", "doi-asserted-by": "crossref"}, {"key": "ref=60", "unstructured": "Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et\u00a0al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. The New England Journal of Medicine. 2004;351(4):337-345", "DOI": "10.1056/NEJMoa033025", "doi-asserted-by": "crossref"}, {"key": "ref=61", "unstructured": "Price T, Kim TW, Li J, Cascinu S, Ruff P, Suresh AS, et\u00a0al. Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer. European Journal of Cancer. 2016;68:51-59", "DOI": "10.1016/j.ejca.2016.08.010", "doi-asserted-by": "crossref"}, {"key": "ref=62", "unstructured": "Douillard JY, Rong A, Sidhu R.\u00a0RAS mutations in colorectal cancer. The New England Journal of Medicine. 2013;369(22):2159-2160", "DOI": "10.1056/NEJMc1312697", "doi-asserted-by": "crossref"}, {"key": "ref=63", "unstructured": "Stintzing SKC, Laubender RP, et\u00a0al. Cetuximab-related skin toxicity in metastatic colorectal cancer (mCRC) patients and its correlation with molecular markers: Results from the German AIO CRC 0104 trial. Journal of Clinical Oncology. 2102;30(suppl 4):491", "DOI": "10.1200/jco.2012.30.4_suppl.491", "doi-asserted-by": "crossref"}, {"key": "ref=64", "unstructured": "Hu J, Zhang Z, Zheng R, Cheng L, Yang M, Li L, et\u00a0al. On-treatment markers as predictors to guide anti-EGFR MoAb treatment in metastatic colorectal cancer: a systematic review with meta-analysis. Cancer Chemotherapy and Pharmacology. 2017;79(2):275-285", "DOI": "10.1007/s00280-016-3196-2", "doi-asserted-by": "crossref"}, {"key": "ref=65", "unstructured": "Mouradov D, Sloggett C, Jorissen RN, Love CG, Li S, Burgess AW, et\u00a0al. Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer. Cancer Research. 2014;74(12):3238-3247", "DOI": "10.1158/0008-5472.CAN-14-0013", "doi-asserted-by": "crossref"}, {"key": "ref=66", "unstructured": "Shen WD, Chen HL, Liu PF.\u00a0EGFR gene copy number as a predictive biomarker for resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer treatment: A meta-analysis. Chinese Journal of Cancer Research. 2014;26(1):59-71"}, {"key": "ref=67", "unstructured": "Ketzer S, Schimmel K, Koopman M, Guchelaar HJ.\u00a0Clinical pharmacokinetics and pharmacodynamics of the epidermal growth factor receptor inhibitor panitumumab in the treatment of colorectal cancer. Clinical Pharmacokinetics. 2018;57(4):455-473", "DOI": "10.1007/s40262-017-0590-9", "doi-asserted-by": "crossref"}, {"key": "ref=68", "unstructured": "Jiang Z, Li C, Li F, Wang X. EGFR gene copy number as a prognostic marker in colorectal cancer patients treated with cetuximab or panitumumab: A systematic review and meta-analysis. PLoS One. 2013;8(2):e56205", "DOI": "10.1371/journal.pone.0056205", "doi-asserted-by": "crossref"}, {"key": "ref=69", "unstructured": "Yang ZY, Shen WX, Hu XF, Zheng DY, Wu XY, Huang YF, et\u00a0al. EGFR gene copy number as a predictive biomarker for the treatment of metastatic colorectal cancer with anti-EGFR monoclonal antibodies: A meta-analysis. Journal of Hematology & Oncology. 2012;5:52", "DOI": "10.1186/1756-8722-5-52", "doi-asserted-by": "crossref"}, {"key": "ref=70", "unstructured": "Li XD, Miao SY, Wang GL, Yang L, Shu YQ Yin YM.\u00a0Amphiregulin and epiregulin expression in colorectal carcinoma and the correlation with clinicopathological characteristics. Onkologie. 2010;33(7):353-358", "DOI": "10.1159/000315380", "doi-asserted-by": "crossref"}, {"key": "ref=71", "unstructured": "Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, et\u00a0al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. Journal of Clinical Oncology. 2007;25(22):3230-3237", "DOI": "10.1200/JCO.2006.10.5437", "doi-asserted-by": "crossref"}, {"key": "ref=72", "unstructured": "Oliveras-Ferraros C, Cufi S, Queralt B, Vazquez-Martin A, Martin-Castillo B, de Llorens R, et\u00a0al. Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells. British Journal of Cancer. 2012;106(8):1406-1414", "DOI": "10.1038/bjc.2012.103", "doi-asserted-by": "crossref"}, {"key": "ref=73", "unstructured": "Yoshida M, Shimura T, Sato M, Ebi M, Nakazawa T, Takeyama H, et\u00a0al. A novel predictive strategy by immunohistochemical analysis of four EGFR ligands in metastatic colorectal cancer treated with anti-EGFR antibodies. Journal of Cancer Research and Clinical Oncology. 2013;139(3):367-378", "DOI": "10.1007/s00432-012-1340-x", "doi-asserted-by": "crossref"}, {"key": "ref=74", "unstructured": "Baker JB, Dutta D, Watson D, Maddala T, Munneke BM, Shak S, et\u00a0al. Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer. British Journal of Cancer. 2011;104(3):488-495", "DOI": "10.1038/sj.bjc.6606054", "doi-asserted-by": "crossref"}, {"key": "ref=75", "unstructured": "Jacobs B, De Roock W, Piessevaux H, Van Oirbeek R, Biesmans B, De Schutter J, et\u00a0al. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. Journal of Clinical Oncology. 2009;27(30):5068-5074", "DOI": "10.1200/JCO.2008.21.3744", "doi-asserted-by": "crossref"}, {"key": "ref=76", "unstructured": "Jonker DJ, Karapetis CS, Harbison C, O'Callaghan CJ, Tu D, Simes RJ, et\u00a0al. Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer. British Journal of Cancer. 2014;110(3):648-655", "DOI": "10.1038/bjc.2013.753", "doi-asserted-by": "crossref"}, {"key": "ref=77", "unstructured": "Pentheroudakis G, Kotoula V, De Roock W, Kouvatseas G, Papakostas P, Makatsoris T, et\u00a0al. Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: Interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes. BMC Cancer. 2013;13:49", "DOI": "10.1186/1471-2407-13-49", "doi-asserted-by": "crossref"}, {"key": "ref=78", "unstructured": "Saridaki Z, Tzardi M, Papadaki C, Sfakianaki M, Pega F, Kalikaki A, et\u00a0al. Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in \u22652 line cetuximab-based therapy of colorectal cancer patients. PLoS One. 2011;6(1):e15980", "DOI": "10.1371/journal.pone.0015980", "doi-asserted-by": "crossref"}, {"key": "ref=79", "unstructured": "Llovet P, Sastre J, Ortega JS, Bando I, Ferrer M, Garcia-Alfonso P, et\u00a0al. Prognostic value of BRAF, PI3K, PTEN, EGFR copy number, amphiregulin and epiregulin status in patients with KRAS Codon 12 wild-type metastatic colorectal cancer receiving first-line chemotherapy with anti-EGFR therapy. Molecular Diagnosis & Therapy. 2015;19(6):397-408", "DOI": "10.1007/s40291-015-0165-0", "doi-asserted-by": "crossref"}, {"key": "ref=80", "unstructured": "Seligmann JF, Elliott F, Richman SD, Jacobs B, Hemmings G, Brown S, et\u00a0al. Combined epiregulin and amphiregulin expression levels as a predictive biomarker for panitumumab therapy benefit or lack of benefit in patients with RAS wild-type advanced colorectal cancer. JAMA Oncology. 2016", "DOI": "10.1001/jamaoncol.2015.6065", "doi-asserted-by": "crossref"}, {"key": "ref=81", "unstructured": "Karthaus M, Hofheinz RD, Mineur L, Letocha H, Greil R, Thaler J, et\u00a0al. Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer. British Journal of Cancer. 2016;115(10):1215-1222", "DOI": "10.1038/bjc.2016.343", "doi-asserted-by": "crossref"}, {"key": "ref=82", "unstructured": "Jing C, Jin YH, You Z, Qiong Q Jun Z.\u00a0Prognostic value of amphiregulin and epiregulin mRNA expression in metastatic colorectal cancer patients. Oncotarget. 2016;7(34):55890-55899", "DOI": "10.18632/oncotarget.10151", "doi-asserted-by": "crossref"}, {"key": "ref=83", "unstructured": "Tie J, Gibbs P, Lipton L, Christie M, Jorissen RN, Burgess AW, et\u00a0al. Optimizing targeted therapeutic development: Analysis of a colorectal cancer patient population with the BRAF(V600E) mutation. International Journal of Cancer. 2011;128(9):2075-2084", "DOI": "10.1002/ijc.25555", "doi-asserted-by": "crossref"}, {"key": "ref=84", "unstructured": "Sepulveda AR, Hamilton SR, Allegra CJ, Grody W, Cushman-Vokoun AM, Funkhouser WK, et\u00a0al. Molecular biomarkers for the evaluation of colorectal cancer: Guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. The Journal of Molecular Diagnostics. 2017;19(2):187-225", "DOI": "10.1016/j.jmoldx.2016.11.001", "doi-asserted-by": "crossref"}, {"key": "ref=85", "unstructured": "Rowland A, Dias MM, Wiese MD, Kichenadasse G, McKinnon RA, Karapetis CS, et\u00a0al. Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. British Journal of Cancer. 2015;112(12):1888-1894", "DOI": "10.1038/bjc.2015.173", "doi-asserted-by": "crossref"}, {"key": "ref=86", "unstructured": "Nosho K, Kawasaki T, Ohnishi M, Suemoto Y, Kirkner GJ, Zepf D, et\u00a0al. PIK3CA mutation in colorectal cancer: Relationship with genetic and epigenetic alterations. Neoplasia. 2008;10(6):534-541", "DOI": "10.1593/neo.08336", "doi-asserted-by": "crossref"}, {"key": "ref=87", "unstructured": "Day FL, Jorissen RN, Lipton L, Mouradov D, Sakthianandeswaren A, Christie M, et\u00a0al. PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancer. Clinical Cancer Research. 2013;19(12):3285-3296", "DOI": "10.1158/1078-0432.CCR-12-3614", "doi-asserted-by": "crossref"}, {"key": "ref=88", "unstructured": "Zhao L, Vogt PK.\u00a0Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proceedings of the National Academy of Sciences of the United States of America. 2008;105(7):2652-2657", "DOI": "10.1073/pnas.0712169105", "doi-asserted-by": "crossref"}, {"key": "ref=89", "unstructured": "Wu S, Gan Y, Wang X, Liu J, Li M, Tang Y.\u00a0PIK3CA mutation is associated with poor survival among patients with metastatic colorectal cancer following anti-EGFR monoclonal antibody therapy: a meta-analysis. Journal of Cancer Research and Clinical Oncology. 2013;139(5):891-900", "DOI": "10.1007/s00432-013-1400-x", "doi-asserted-by": "crossref"}, {"key": "ref=90", "unstructured": "Huang L, Liu Z, Deng D, Tan A, Liao M, Mo Z, et\u00a0al. Anti-epidermal growth factor receptor monoclonal antibody-based therapy for metastatic colorectal cancer: A meta-analysis of the effect of PIK3CA mutations in KRAS wild-type patients. Archives of Medical Science. 2014;10(1):1-9", "DOI": "10.5114/aoms.2014.40728", "doi-asserted-by": "crossref"}, {"key": "ref=91", "unstructured": "Yang ZY, Wu XY, Huang YF, Di MY, Zheng DY, Chen JZ, et\u00a0al. Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: A systematic review with meta-analysis. International Journal of Cancer. 2013;133(8):1914-1925", "DOI": "10.1002/ijc.28153", "doi-asserted-by": "crossref"}, {"key": "ref=92", "unstructured": "Therkildsen C, Bergmann TK, Henrichsen-Schnack T, Ladelund S, Nilbert M.\u00a0The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis. Acta Oncologica. 2014;53(7):852-864", "DOI": "10.3109/0284186X.2014.895036", "doi-asserted-by": "crossref"}, {"key": "ref=93", "unstructured": "Mohamed A, Twardy B, AbdAllah N, Akhras A, Ismail H, Zordok M, et\u00a0al. Clinical impact of PI3K/BRAF mutations in RAS wild metastatic colorectal cancer: Meta-analysis results. Journal of Gastrointestinal Cancer. 2018. DOI: 10.1007/s12029-018-0062-y", "DOI": "10.1007/s12029-018-0062-y", "doi-asserted-by": "crossref"}, {"key": "ref=94", "unstructured": "Mao C, Yang ZY, Hu XF, Chen Q, Tang JL.\u00a0PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis. Annals of Oncology. 2012;23(6):1518-1525", "DOI": "10.1093/annonc/mdr464", "doi-asserted-by": "crossref"}, {"key": "ref=95", "unstructured": "Zhou XP, Loukola A, Salovaara R, Nystrom-Lahti M, Peltomaki P, de la Chapelle A, et\u00a0al. PTEN mutational spectra, expression levels, and subcellular localization in microsatellite stable and unstable colorectal cancers. The American Journal of Pathology. 2002;161(2):439-447", "DOI": "10.1016/S0002-9440(10)64200-9", "doi-asserted-by": "crossref"}, {"key": "ref=96", "unstructured": "Goel A, Arnold CN, Niedzwiecki D, Carethers JM, Dowell JM, Wasserman L, et\u00a0al. Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. Cancer Research. 2004;64(9):3014-3021", "DOI": "10.1158/0008-5472.CAN-2401-2", "doi-asserted-by": "crossref"}, {"key": "ref=97", "unstructured": "Frattini M, Saletti P, Romagnani E, Martin V, Molinari F, Ghisletta M, et\u00a0al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. British Journal of Cancer. 2007;97(8):1139-1145", "DOI": "10.1038/sj.bjc.6604009", "doi-asserted-by": "crossref"}, {"key": "ref=98", "unstructured": "Perrone F, Lampis A, Orsenigo M, Di Bartolomeo M, Gevorgyan A, Losa M, et\u00a0al. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Annals of Oncology. 2009;20(1):84-90", "DOI": "10.1093/annonc/mdn541", "doi-asserted-by": "crossref"}, {"key": "ref=99", "unstructured": "Sartore-Bianchi A, Martini M, Molinari F, Veronese S, Nichelatti M, Artale S, et\u00a0al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Research. 2009;69(5):1851-1857", "DOI": "10.1158/0008-5472.CAN-08-2466", "doi-asserted-by": "crossref"}, {"key": "ref=100", "unstructured": "Negri FV, Bozzetti C, Lagrasta CA, Crafa P, Bonasoni MP, Camisa R, et\u00a0al. PTEN status in advanced colorectal cancer treated with cetuximab. British Journal of Cancer. 2010;102(1):162-164", "DOI": "10.1038/sj.bjc.6605471", "doi-asserted-by": "crossref"}, {"key": "ref=101", "unstructured": "Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, et\u00a0al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. Journal of Clinical Oncology. 2009;27(35):5924-5930", "DOI": "10.1200/JCO.2008.21.6796", "doi-asserted-by": "crossref"}, {"key": "ref=102", "unstructured": "Tol J, Dijkstra JR, Klomp M, Teerenstra S, Dommerholt M, Vink-Borger ME, et\u00a0al. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. European Journal of Cancer. 2010;46(11):1997-2009", "DOI": "10.1016/j.ejca.2010.03.036", "doi-asserted-by": "crossref"}, {"key": "ref=103", "unstructured": "Ulivi P, Capelli L, Valgiusti M, Zoli W, Scarpi E, Chiadini E, et\u00a0al. Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: a single center study. Journal of Translational Medicine. 2012;10:87", "DOI": "10.1186/1479-5876-10-87", "doi-asserted-by": "crossref"}, {"key": "ref=104", "unstructured": "Loupakis F, Pollina L, Stasi I, Ruzzo A, Scartozzi M, Santini D, et\u00a0al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. Journal of Clinical Oncology. 2009;27(16):2622-2629", "DOI": "10.1200/JCO.2008.20.2796", "doi-asserted-by": "crossref"}, {"key": "ref=105", "unstructured": "Wang ZH, Gao QY, Fang JY.\u00a0Loss of PTEN expression as a predictor of resistance to anti-EGFR monoclonal therapy in metastatic colorectal cancer: evidence from retrospective studies. Cancer Chemotherapy and Pharmacology. 2012;69(6):1647-1655", "DOI": "10.1007/s00280-012-1886-y", "doi-asserted-by": "crossref"}], "container-title": ["Advances in the Molecular Understanding of Colorectal Cancer"], "link": [{"URL": "http://www.intechopen.com/download/pdf/63348", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 16]], "date-time": "2019-11-16T05:17:24Z", "timestamp": 1573881444000}, "score": 29.804571, "issued": {"date-parts": [[2019, 2, 6]]}, "ISBN": ["9781789850598", "9781789850604"], "references-count": 105, "URL": "http://dx.doi.org/10.5772/intechopen.80690", "relation": {"cites": []}}, {"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T03:51:28Z", "timestamp": 1574740288490}, "publisher-location": "Hoboken, NJ, USA", "reference-count": 86, "publisher": "John Wiley & Sons, Inc.", "isbn-type": [{"value": "9781118468579", "type": "print"}, {"value": "9781118468678", "type": "electronic"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "DOI": "10.1002/9781118468678.ch17", "type": "book-chapter", "created": {"date-parts": [[2015, 10, 31]], "date-time": "2015-10-31T03:56:51Z", "timestamp": 1446263811000}, "page": "169-176", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Lymphoma and Targeted Therapies"], "prefix": "10.1002", "author": [{"given": "Sonali M.", "family": "Smith", "sequence": "first", "affiliation": []}, {"given": "Julie M.", "family": "Vose", "sequence": "additional", "affiliation": []}], "member": "311", "published-online": {"date-parts": [[2015, 10, 30]]}, "reference": [{"key": "10.1002/9781118468678.ch17-BIB1|cit1", "doi-asserted-by": "crossref", "first-page": "15", "DOI": "10.1146/annurev-med-050311-201823", "article-title": "Antibody-drug conjugates in cancer therapy", "volume": "64", "author": "Sievers", "year": "2013", "journal-title": "Annu Rev Med"}, {"issue": "19", "key": "10.1002/9781118468678.ch17-BIB2|cit2", "doi-asserted-by": "crossref", "first-page": "1812", "DOI": "10.1056/NEJMoa1002965", "article-title": "Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas", "volume": "363", "author": "Younes", "year": "2010", "journal-title": "N Engl J Med"}, {"issue": "19", "key": "10.1002/9781118468678.ch17-BIB3|cit3", "doi-asserted-by": "crossref", "first-page": "2190", "DOI": "10.1200/JCO.2011.38.0402", "article-title": "Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma: Results of a phase II study", "volume": "30", "author": "Pro", "year": "2012", "journal-title": "J Clin Onc"}, {"issue": "18", "key": "10.1002/9781118468678.ch17-BIB4|cit4", "doi-asserted-by": "crossref", "first-page": "2183", "DOI": "10.1200/JCO.2011.38.0410", "article-title": "Results of a pivotal phase II study of Brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma", "volume": "30", "author": "Younes", "year": "2012", "journal-title": "J Clin Onc"}, {"issue": "6", "key": "10.1002/9781118468678.ch17-BIB5|cit5", "doi-asserted-by": "crossref", "first-page": "886", "DOI": "10.1080/10428190902943077", "article-title": "Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab", "volume": "50", "author": "Nagorsen", "year": "2009", "journal-title": "Leuk Lymphoma."}, {"issue": "1", "key": "10.1002/9781118468678.ch17-BIB6|cit6", "doi-asserted-by": "crossref", "first-page": "21", "DOI": "10.1111/j.1365-2567.2012.03564.x", "article-title": "B-cell receptor: from resting state to activate", "volume": "136", "author": "Treanor", "year": "2012", "journal-title": "Immunology"}, {"issue": "4", "key": "10.1002/9781118468678.ch17-BIB7|cit7", "doi-asserted-by": "crossref", "first-page": "283", "DOI": "10.1038/nri1808", "article-title": "ITAM-mediated tonic signalling through pre-BCR and BCR complexes", "volume": "6", "author": "Monroe", "year": "2006", "journal-title": "Nat Rev Immunol."}, {"issue": "6", "key": "10.1002/9781118468678.ch17-BIB8|cit8", "doi-asserted-by": "crossref", "first-page": "787", "DOI": "10.1016/j.cell.2004.05.014", "article-title": "Survival of resting mature B lymphocytes depends on BCR signaling via the Iglalpha/beta heterodimer", "volume": "117", "author": "Kraus", "year": "2004", "journal-title": "Cell"}, {"issue": "1", "key": "10.1002/9781118468678.ch17-BIB9|cit9", "doi-asserted-by": "crossref", "first-page": "55", "DOI": "10.1016/j.immuni.2006.04.014", "article-title": "The B cell receptor promotes B cell activation and proliferation through a non-ITAM tyrosine in the Igalpha cytoplasmic domain", "volume": "25", "author": "Patterson", "year": "2006", "journal-title": "Immunity"}, {"issue": "6", "key": "10.1002/9781118468678.ch17-BIB10|cit10", "doi-asserted-by": "crossref", "first-page": "855", "DOI": "10.1084/jem.20031140", "article-title": "A B cell receptor with two Igalpha cytoplasmic domains supports development of mature but anergic B cells", "volume": "199", "author": "Reichlin", "year": "2004", "journal-title": "J Exp Med"}, {"issue": "6", "key": "10.1002/9781118468678.ch17-BIB11|cit11", "doi-asserted-by": "crossref", "first-page": "1073", "DOI": "10.1016/S0092-8674(00)80373-6", "article-title": "In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death", "volume": "90", "author": "Lam", "year": "1997", "journal-title": "Cell"}, {"issue": "3", "key": "10.1002/9781118468678.ch17-BIB12|cit12", "doi-asserted-by": "crossref", "first-page": "274", "DOI": "10.1038/ni893", "article-title": "Essential role of Src-family protein tyrosine kinases in NF-kappaB activation during B cell development", "volume": "4", "author": "Saijo", "year": "2003", "journal-title": "Nat Immunol"}, {"issue": "6", "key": "10.1002/9781118468678.ch17-BIB13|cit13", "doi-asserted-by": "crossref", "first-page": "1175", "DOI": "10.1182/blood-2012-02-362624", "article-title": "The B-cell receptor signaling pathway as a therapeutic target in CLL", "volume": "120", "author": "Woyach", "year": "2012", "journal-title": "Blood."}, {"key": "10.1002/9781118468678.ch17-BIB14|cit14", "doi-asserted-by": "crossref", "first-page": "573", "DOI": "10.1016/j.cell.2009.08.041", "article-title": "PI3 kinase signals BCR-dependent mature B cell survival", "volume": "139", "author": "Srinivasan", "year": "2009", "journal-title": "Cell"}, {"issue": "1", "key": "10.1002/9781118468678.ch17-BIB15|cit15", "doi-asserted-by": "crossref", "first-page": "128", "DOI": "10.1200/JCO.2012.44.4281", "article-title": "Targeting B-Cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies", "volume": "31", "author": "Wiestner", "year": "2013", "journal-title": "J Clin Oncol"}, {"issue": "11", "key": "10.1002/9781118468678.ch17-BIB16|cit16", "doi-asserted-by": "crossref", "first-page": "2508", "DOI": "10.1182/blood-2008-05-158618", "article-title": "Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target", "volume": "113", "author": "Young", "year": "2009", "journal-title": "Blood."}, {"issue": "4", "key": "10.1002/9781118468678.ch17-BIB17|cit17", "doi-asserted-by": "crossref", "first-page": "2230", "DOI": "10.1182/blood-2007-07-100115", "article-title": "SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma", "volume": "111", "author": "Chen", "year": "2008", "journal-title": "Blood."}, {"key": "10.1002/9781118468678.ch17-BIB18|cit18", "doi-asserted-by": "crossref", "first-page": "132", "DOI": "10.1186/1476-4598-8-132", "article-title": "Anomalous constitutive Src kinase activity promotes B lymphoma survival and growth", "volume": "8", "author": "Ke", "year": "2009", "journal-title": "Mol Cancer"}, {"issue": "24", "key": "10.1002/9781118468678.ch17-BIB19|cit19", "doi-asserted-by": "crossref", "first-page": "6342", "DOI": "10.1182/blood-2011-02-333773", "article-title": "SYK inhibition and response prediction in diffuse large B-cell lymphoma", "volume": "118", "author": "Cheng", "year": "2011", "journal-title": "Blood."}, {"issue": "4", "key": "10.1002/9781118468678.ch17-BIB20|cit20", "doi-asserted-by": "crossref", "first-page": "795", "DOI": "10.1038/leu.2011.248", "article-title": "Involvement of the Syk-mTOR pathway in follicular lymphoma cell invasion and angiogenesis", "volume": "26", "author": "Fruchon", "year": "2012", "journal-title": "Leukemia."}, {"issue": "13", "key": "10.1002/9781118468678.ch17-BIB21|cit21", "doi-asserted-by": "crossref", "first-page": "4156", "DOI": "10.1182/blood-2006-05-026203", "article-title": "Syk-dependent mTOR activation in follicular lymphoma cells", "volume": "108", "author": "Leseux", "year": "2006", "journal-title": "Blood."}, {"issue": "9", "key": "10.1002/9781118468678.ch17-BIB22|cit22", "doi-asserted-by": "crossref", "first-page": "e243", "DOI": "10.1016/j.leukres.2010.03.026", "article-title": "Syk expression patterns differ among B-cell lymphomas", "volume": "34", "author": "Ponzoni", "year": "2010", "journal-title": "Leuk Res"}, {"issue": "13", "key": "10.1002/9781118468678.ch17-BIB23|cit23", "doi-asserted-by": "crossref", "first-page": "2578", "DOI": "10.1182/blood-2009-08-236471", "article-title": "Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia", "volume": "115", "author": "Friedberg", "year": "2010", "journal-title": "Blood."}, {"issue": "2", "key": "10.1002/9781118468678.ch17-BIB24|cit24", "doi-asserted-by": "crossref", "first-page": "369", "DOI": "10.1172/JCI200522094", "article-title": "Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis", "volume": "115", "author": "Contri", "year": "2005", "journal-title": "J Clin Invest"}, {"issue": "1", "key": "10.1002/9781118468678.ch17-BIB25|cit25", "doi-asserted-by": "crossref", "first-page": "49", "DOI": "10.1016/j.antiviral.2012.05.003", "article-title": "Dasatinib therapy results in decreased B cell proliferation, splenomegaly, and tumor growth in a murine model of lymphoma expressing Myc and Epstein-Barr virus LMP2 A", "volume": "95", "author": "Dargart", "year": "2012", "journal-title": "Antiviral Res"}, {"key": "10.1002/9781118468678.ch17-BIB26|cit26", "author": "William", "volume": "116", "year": "2010", "article-title": "Phase I/II Study of Dasatinib In Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)", "journal-title": "Blood"}, {"issue": "12", "key": "10.1002/9781118468678.ch17-BIB27|cit27", "doi-asserted-by": "crossref", "first-page": "6687", "DOI": "10.1073/pnas.110146697", "article-title": "A sensitized genetic system for the analysis of murine B lymphocyte signal transduction pathways dependent on Bruton's tyrosine kinase", "volume": "97", "author": "Satterthwaite", "year": "2000", "journal-title": "Proc Natl Acad Sci U S A."}, {"issue": "2", "key": "10.1002/9781118468678.ch17-BIB28|cit28", "doi-asserted-by": "crossref", "first-page": "279", "DOI": "10.1016/0092-8674(93)90667-F", "article-title": "Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia", "volume": "72", "author": "Tsukada", "year": "1993", "journal-title": "Cell."}, {"issue": "6409", "key": "10.1002/9781118468678.ch17-BIB29|cit29", "doi-asserted-by": "crossref", "first-page": "226", "DOI": "10.1038/361226a0", "article-title": "The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases", "volume": "361", "author": "Vetrie", "year": "1993", "journal-title": "Nature."}, {"issue": "3", "key": "10.1002/9781118468678.ch17-BIB30|cit30", "doi-asserted-by": "crossref", "first-page": "283", "DOI": "10.1016/1074-7613(95)90114-0", "article-title": "Defective B cell development and function in Btk-deficient mice", "volume": "3", "author": "Khan", "year": "1995", "journal-title": "Immunity."}, {"issue": "10", "key": "10.1002/9781118468678.ch17-BIB31|cit31", "doi-asserted-by": "crossref", "first-page": "1745", "DOI": "10.1084/jem.191.10.1745", "article-title": "Bruton's tyrosine kinase is required for activation of IkappaB kinase and nuclear factor kappaB in response to B cell receptor engagement", "volume": "191", "author": "Petro", "year": "2000", "journal-title": "J Exp Med."}, {"issue": "7277", "key": "10.1002/9781118468678.ch17-BIB32|cit32", "doi-asserted-by": "crossref", "first-page": "88", "DOI": "10.1038/nature08638", "article-title": "Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma", "volume": "463", "author": "Davis", "year": "2010", "journal-title": "Nature."}, {"issue": "29", "key": "10.1002/9781118468678.ch17-BIB33|cit33", "doi-asserted-by": "crossref", "first-page": "13075", "DOI": "10.1073/pnas.1004594107", "article-title": "The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy", "volume": "107", "author": "Honigberg", "year": "2010", "journal-title": "Proc Natl Acad Sci U S A"}, {"key": "10.1002/9781118468678.ch17-BIB34|cit34", "author": "Fowler", "volume": "116", "year": "2010", "article-title": "The Btk inhibitor, PCI-32765, induces durable responses with minimal toxicity in patients with relapsed/refractory B-cell malignancies: results from a phase I study", "journal-title": "Blood."}, {"key": "10.1002/9781118468678.ch17-BIB35|cit35", "doi-asserted-by": "crossref", "first-page": "507", "DOI": "10.1056/NEJMoa1306220", "article-title": "Targeting BTK with Ibruitinib in relapsed or refractory mantle-cell lymphoma", "volume": "369", "author": "Wang", "year": "2013", "journal-title": "N Engl J Med."}, {"issue": "26", "key": "10.1002/9781118468678.ch17-BIB36|cit36", "doi-asserted-by": "crossref", "first-page": "5315", "DOI": "10.1182/blood-2009-02-204362", "article-title": "BCL6 modulates tonic BCR signaling in diffuse large B-cell lymphomas by repressing the SYK phosphatase, PTPROt", "volume": "114", "author": "Juszczynski", "year": "2009", "journal-title": "Blood."}, {"issue": "22", "key": "10.1002/9781118468678.ch17-BIB37|cit37", "doi-asserted-by": "crossref", "first-page": "6122", "DOI": "10.1158/1078-0432.CCR-12-0397", "article-title": "Quantitative Immunofluorescence Reveals the Signature of Active B Cell Receptor Signaling in Diffuse Large B Cell Lymphoma", "volume": "18", "author": "Bogusz", "year": "2012", "journal-title": "Clin Cancer Res"}, {"issue": "1", "key": "10.1002/9781118468678.ch17-BIB38|cit38", "doi-asserted-by": "crossref", "first-page": "229", "DOI": "10.1038/leu.2009.198", "article-title": "Inhibition of Syk protein tyrosine kinase induces apoptosis and blocks proliferation in T-cell non-Hodgkin's lymphoma cell lines", "volume": "24", "author": "Wilcox", "year": "2010", "journal-title": "Leukemia."}, {"issue": "5", "key": "10.1002/9781118468678.ch17-BIB39|cit39", "doi-asserted-by": "crossref", "first-page": "1031", "DOI": "10.1084/jem.20092042", "article-title": "The fusion kinase ITK-SYK mimics a T cell receptor signal and drives oncogenesis in conditional mouse models of peripheral T cell lymphoma", "volume": "207", "author": "Pechloff", "year": "2010", "journal-title": "J Exp Med"}, {"key": "10.1002/9781118468678.ch17-BIB40|cit40", "doi-asserted-by": "crossref", "first-page": "6193", "DOI": "10.1158/0008-5472.CAN-08-3719", "article-title": "The ITK-SYK fusion oncogene induces a T-cell lymphoproliferative disease in mice mimicking human disease", "volume": "70", "author": "Dierks", "year": "2010", "journal-title": "Cancer Res."}, {"key": "10.1002/9781118468678.ch17-BIB41|cit41", "doi-asserted-by": "crossref", "first-page": "5497", "DOI": "10.1038/onc.2008.245", "article-title": "PI3 K pathway alterations in cancer: variations on a theme", "volume": "27", "author": "Yuan", "year": "2008", "journal-title": "Oncogene."}, {"issue": "2", "key": "10.1002/9781118468678.ch17-BIB42|cit42", "doi-asserted-by": "crossref", "first-page": "591", "DOI": "10.1182/blood-2010-03-275305", "article-title": "CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3 K signaling and cellular viability", "volume": "117", "author": "Lannutti", "year": "2011", "journal-title": "Blood."}, {"key": "10.1002/9781118468678.ch17-BIB43|cit43", "author": "Furman", "volume": "116", "year": "2010", "article-title": "CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110, demonstrates clinical activity and pharmacodynamic effects in patients with relapsed or refractory chronic lymphocytic leukemia", "journal-title": "Blood (ASH Annual Meeting Abstracts)"}, {"key": "10.1002/9781118468678.ch17-BIB44|cit44", "author": "Kahl", "volume": "116", "year": "2010", "article-title": "Clinical safety and activity in a phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110, in patients with relapsed or refractory non-Hodgkin lymphoma", "journal-title": "Blood."}, {"key": "10.1002/9781118468678.ch17-BIB45|cit45", "author": "Webb", "volume": "116", "year": "2010", "article-title": "Clinical pharmacokinetics of CAL-101, a p110 isoform-selective PI3 K inhibitor, following single- and multiple-dose administration in healthy volunteers and patients with hematological malignancies", "journal-title": "Blood"}, {"issue": "18", "key": "10.1002/9781118468678.ch17-BIB46|cit46", "doi-asserted-by": "crossref", "first-page": "3151", "DOI": "10.1038/sj.onc.1207542", "article-title": "Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression", "volume": "23", "author": "Fingar", "year": "2004", "journal-title": "Oncogene."}, {"issue": "2", "key": "10.1002/9781118468678.ch17-BIB47|cit47", "doi-asserted-by": "crossref", "first-page": "274", "DOI": "10.1016/j.cell.2012.03.017", "article-title": "mTOR signaling in growth control and disease", "volume": "149", "author": "Laplante", "year": "2012", "journal-title": "Cell."}, {"key": "10.1002/9781118468678.ch17-BIB48|cit48", "doi-asserted-by": "crossref", "first-page": "224", "DOI": "10.2174/157018007780077435", "article-title": "mTOR inhibition in lymphoma: a rational and promising strategy", "volume": "4", "author": "Smith", "year": "2007", "journal-title": "Letters in Drug Design and Discovery."}, {"key": "10.1002/9781118468678.ch17-BIB49|cit49", "doi-asserted-by": "crossref", "first-page": "175", "DOI": "10.1016/j.beha.2012.04.008", "article-title": "Targeting mTOR in mantle cell lymphoma: current and future directions", "volume": "25", "author": "Smith", "year": "2012", "journal-title": "Best Pract Res Clin Haematol"}, {"key": "10.1002/9781118468678.ch17-BIB50|cit50", "first-page": "A7532.", "article-title": "Anti-tumor activity of mTOR inhibitor temsirolimus for relapsed mantle cell lymphoma: A phase II trial in the North Central Cancer Treatment Group.", "volume": "18", "author": "Ansell", "year": "2006", "journal-title": "J Clin Oncol."}, {"issue": "23", "key": "10.1002/9781118468678.ch17-BIB51|cit51", "doi-asserted-by": "crossref", "first-page": "3822", "DOI": "10.1200/JCO.2008.20.7977", "article-title": "Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma", "volume": "27", "author": "Hess", "year": "2009", "journal-title": "J Clin Oncol"}, {"issue": "23", "key": "10.1002/9781118468678.ch17-BIB52|cit52", "doi-asserted-by": "crossref", "first-page": "5347", "DOI": "10.1200/JCO.2005.13.466", "article-title": "Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma", "volume": "23", "author": "Witzig", "year": "2005", "journal-title": "J Clin Oncol"}, {"key": "10.1002/9781118468678.ch17-BIB53|cit53", "doi-asserted-by": "crossref", "first-page": "4740", "DOI": "10.1200/JCO.2010.29.2813", "article-title": "Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium", "volume": "28", "author": "Smith", "year": "2010", "journal-title": "J Clin Oncol"}, {"issue": "9", "key": "10.1002/9781118468678.ch17-BIB54|cit54", "doi-asserted-by": "crossref", "first-page": "2534", "DOI": "10.1158/1078-0432.CCR-11-1407", "article-title": "Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma", "volume": "18", "author": "Petrich", "year": "2012", "journal-title": "Clin Cancer Res."}, {"issue": "6", "key": "10.1002/9781118468678.ch17-BIB55|cit55", "doi-asserted-by": "crossref", "first-page": "1649", "DOI": "10.1158/1078-0432.CCR-07-2218", "article-title": "Proteasome inhibitors in cancer therapy: lessons from the first decade", "volume": "14", "author": "Orlowski", "year": "2008", "journal-title": "Clin Cancer Res"}, {"issue": "1", "key": "10.1002/9781118468678.ch17-BIB56|cit56", "doi-asserted-by": "crossref", "first-page": "116", "DOI": "10.1093/annonc/mdl316", "article-title": "A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150", "volume": "18", "author": "Belch", "year": "2007", "journal-title": "Ann Oncol"}, {"issue": "30", "key": "10.1002/9781118468678.ch17-BIB57|cit57", "doi-asserted-by": "crossref", "first-page": "4867", "DOI": "10.1200/JCO.2006.07.9665", "article-title": "Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma", "volume": "24", "author": "Fisher", "year": "2006", "journal-title": "J Clin Oncol"}, {"issue": "3", "key": "10.1002/9781118468678.ch17-BIB58|cit58", "doi-asserted-by": "crossref", "first-page": "520", "DOI": "10.1093/annonc/mdn656", "article-title": "Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study", "volume": "20", "author": "Goy", "year": "2009", "journal-title": "Ann Oncol."}, {"issue": "4", "key": "10.1002/9781118468678.ch17-BIB59|cit59", "doi-asserted-by": "crossref", "first-page": "667", "DOI": "10.1200/JCO.2005.03.108", "article-title": "Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma", "volume": "23", "author": "Goy", "year": "2005", "journal-title": "J Clin Oncol"}, {"issue": "4", "key": "10.1002/9781118468678.ch17-BIB60|cit60", "doi-asserted-by": "crossref", "first-page": "676", "DOI": "10.1200/JCO.2005.02.050", "article-title": "Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma", "volume": "23", "author": "O'Connor", "year": "2005", "journal-title": "J Clin Oncol"}, {"issue": "10", "key": "10.1002/9781118468678.ch17-BIB61|cit61", "doi-asserted-by": "crossref", "first-page": "2955", "DOI": "10.1158/1078-0432.CCR-06-0170", "article-title": "United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy", "volume": "12", "author": "Kane", "year": "2006", "journal-title": "Clin Cancer Res"}, {"key": "10.1002/9781118468678.ch17-BIB62|cit62", "doi-asserted-by": "crossref", "first-page": "1269", "DOI": "10.3109/10428194.2010.483302", "article-title": "Potential biomarkers of bortezomib activity in mantle cell lymphoma from the phase 2 PINNACLE trial", "volume": "51", "author": "Goy", "year": "2010", "journal-title": "Leuk Lymphoma"}, {"key": "10.1002/9781118468678.ch17-BIB63|cit63", "author": "De Vos", "volume": "106", "year": "2005", "article-title": "Bortezomib plus rituximab in patients with indolent non-hodgkin's lymphoma (NHL): a phase 2 study", "journal-title": "Blood"}, {"issue": "8", "key": "10.1002/9781118468678.ch17-BIB64|cit64", "doi-asserted-by": "crossref", "first-page": "773", "DOI": "10.1016/S1470-2045(11)70150-4", "article-title": "Bortzomib plus rituximab versus rituximab alone in pateints with relapsed, rituximab-na\u00efve or rituximab-sensitve, follicular lymphoma: a randomised phase 3 trial", "volume": "12", "author": "Coiffier", "year": "2011", "journal-title": "Lancet Onc"}, {"issue": "25", "key": "10.1002/9781118468678.ch17-BIB65|cit65", "doi-asserted-by": "crossref", "first-page": "3389", "DOI": "10.1200/JCO.2010.32.1844", "article-title": "Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study", "volume": "29", "author": "Fowler", "year": "2011", "journal-title": "J Clin Oncol"}, {"issue": "10", "key": "10.1002/9781118468678.ch17-BIB66|cit66", "doi-asserted-by": "crossref", "first-page": "2807", "DOI": "10.1182/blood-2010-11-314708", "article-title": "The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma", "volume": "117", "author": "Friedberg", "year": "2011", "journal-title": "Blood."}, {"issue": "25", "key": "10.1002/9781118468678.ch17-BIB67|cit67", "doi-asserted-by": "crossref", "first-page": "3396", "DOI": "10.1200/JCO.2010.33.6594", "article-title": "Bortezomib ADDED to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: a phase II study by the National Cancer Institute of Canada Clinical Trials Group", "volume": "29", "author": "Sehn", "year": "2011", "journal-title": "J Clin Oncol"}, {"issue": "2", "key": "10.1002/9781118468678.ch17-BIB68|cit68", "doi-asserted-by": "crossref", "first-page": "190", "DOI": "10.1111/j.1365-2141.2011.08820.x", "article-title": "VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study", "volume": "155", "author": "Chang", "year": "2011", "journal-title": "Br J Haematol"}, {"issue": "14", "key": "10.1002/9781118468678.ch17-BIB69|cit69", "doi-asserted-by": "crossref", "first-page": "2817", "DOI": "10.1182/blood-2012-05-425934", "article-title": "A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma", "volume": "120", "author": "Siegel", "year": "2012", "journal-title": "Blood"}, {"issue": "10", "key": "10.1002/9781118468678.ch17-BIB70|cit70", "doi-asserted-by": "crossref", "first-page": "933", "DOI": "10.1038/ni.2094", "article-title": "Malignant pirates of the immune system", "volume": "12", "author": "Rui", "year": "2011", "journal-title": "Nat Immunol"}, {"issue": "1", "key": "10.1002/9781118468678.ch17-BIB71|cit71", "first-page": "28", "article-title": "Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling", "volume": "11", "author": "Lam", "year": "2005", "journal-title": "Clin Cancer Res."}, {"issue": "4", "key": "10.1002/9781118468678.ch17-BIB72|cit72", "doi-asserted-by": "crossref", "first-page": "293", "DOI": "10.1097/MOH.0b013e32834788cf", "article-title": "Epigenetics and B-cell lymphoma", "volume": "18", "author": "Shaknovich", "year": "2011", "journal-title": "Curr Opin Hematol"}, {"issue": "20", "key": "10.1002/9781118468678.ch17-BIB73|cit73", "doi-asserted-by": "crossref", "first-page": "e81", "DOI": "10.1182/blood-2010-05-285320", "article-title": "DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma", "volume": "116", "author": "Shaknovich", "year": "2010", "journal-title": "Blood."}, {"issue": "4", "key": "10.1002/9781118468678.ch17-BIB74|cit74", "doi-asserted-by": "crossref", "first-page": "558", "DOI": "10.3324/haematol.2010.033167", "article-title": "Methylation profiling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical Hodgkin's lymphoma and primary mediastinal large B-cell lymphoma", "volume": "96", "author": "Eberle", "year": "2011", "journal-title": "Haematologica."}, {"issue": "5", "key": "10.1002/9781118468678.ch17-BIB75|cit75", "doi-asserted-by": "crossref", "first-page": "e19736", "DOI": "10.1371/journal.pone.0019736", "article-title": "Identification of methylated genes associated with aggressive clinicopathological features in mantle cell lymphoma", "volume": "6", "author": "Enjuanes", "year": "2011", "journal-title": "PLoS One"}, {"issue": "6", "key": "10.1002/9781118468678.ch17-BIB76|cit76", "doi-asserted-by": "crossref", "first-page": "631", "DOI": "10.1200/JCO.2011.37.4223", "article-title": "Results from a Pivotal, Open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy", "volume": "30", "author": "Coiffer", "year": "2012", "journal-title": "J Clin Onc"}, {"issue": "21", "key": "10.1002/9781118468678.ch17-BIB77|cit77", "doi-asserted-by": "crossref", "first-page": "3109", "DOI": "10.1200/JCO.2006.10.2434", "article-title": "Phase IIB Multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma", "volume": "25", "author": "Olsen", "year": "2007", "journal-title": "J Clin Onc"}, {"issue": "9", "key": "10.1002/9781118468678.ch17-BIB78|cit78", "doi-asserted-by": "crossref", "first-page": "1544", "DOI": "10.1200/JCO.2007.14.5367", "article-title": "Lenalidomide for the treatment of B-cell malignancies", "volume": "26", "author": "Chanan-Khan", "year": "2008", "journal-title": "J Clin Oncol."}, {"key": "10.1002/9781118468678.ch17-BIB79|cit79", "doi-asserted-by": "crossref", "first-page": "4952", "DOI": "10.1200/JCO.2007.15.3429", "article-title": "Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin lymphoma", "volume": "26", "author": "Wiernik", "year": "2008", "journal-title": "J Clin Onc"}, {"issue": "29", "key": "10.1002/9781118468678.ch17-BIB80|cit80", "doi-asserted-by": "crossref", "first-page": "3688", "DOI": "10.1200/JCO.2013.49.2835", "article-title": "Phase II multicenter study of single-agent lenalidomide in subjects with mantle cell lymphoma who relapsed or progressed after or were refractory to bortezomib: The MCL-001 \u201cEMERGE\u201d study", "volume": "31", "author": "Goy", "year": "2013", "journal-title": "J Clin Onc"}, {"issue": "5151", "key": "10.1002/9781118468678.ch17-BIB81|cit81", "doi-asserted-by": "crossref", "first-page": "1281", "DOI": "10.1126/science.8122112", "article-title": "Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma", "volume": "263", "author": "Morris", "year": "1994", "journal-title": "Science."}, {"issue": "3", "key": "10.1002/9781118468678.ch17-BIB82|cit82", "doi-asserted-by": "crossref", "first-page": "199", "DOI": "10.1007/s11523-012-0227-8", "article-title": "Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma", "volume": "V", "author": "Morales La Madrid", "year": "2012", "journal-title": "Target Oncol"}, {"issue": "25", "key": "10.1002/9781118468678.ch17-BIB83|cit83", "doi-asserted-by": "crossref", "first-page": "4211", "DOI": "10.1200/JCO.2008.21.5020", "article-title": "Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma: a rare clinicopathologic entity with poor prognosis", "volume": "27", "author": "Laurent", "year": "2009", "journal-title": "J Clin Oncol"}, {"issue": "7", "key": "10.1002/9781118468678.ch17-BIB84|cit84", "doi-asserted-by": "crossref", "first-page": "2568", "DOI": "10.1182/blood-2003-03-0786", "article-title": "ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases", "volume": "102", "author": "Gascoyne", "year": "2003", "journal-title": "Blood."}, {"issue": "25", "key": "10.1002/9781118468678.ch17-BIB85|cit85", "doi-asserted-by": "crossref", "first-page": "4124", "DOI": "10.1200/JCO.2008.16.4558", "article-title": "International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes", "volume": "26", "author": "Vose", "year": "2008", "journal-title": "J Clin Oncol"}, {"issue": "8", "key": "10.1002/9781118468678.ch17-BIB86|cit86", "doi-asserted-by": "crossref", "first-page": "775", "DOI": "10.1056/NEJMc1013224", "article-title": "Crizotinib in anaplastic large-cell lymphoma", "volume": "364", "author": "Gambacorti-Passerini", "year": "2011", "journal-title": "N Engl J Med."}], "container-title": ["Targeted Therapy in Translational Cancer Research"], "link": [{"URL": "http://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2F9781118468678.ch17", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2017, 6, 23]], "date-time": "2017-06-23T22:38:15Z", "timestamp": 1498257495000}, "score": 29.799885, "issued": {"date-parts": [[2015, 10, 30]]}, "ISBN": ["9781118468678", "9781118468579"], "references-count": 86, "URL": "http://dx.doi.org/10.1002/9781118468678.ch17", "relation": {"cites": []}}, {"indexed": {"date-parts": [[2019, 11, 19]], "date-time": "2019-11-19T03:39:03Z", "timestamp": 1574134743138}, "reference-count": 0, "publisher": "Oxford University Press (OUP)", "issue": "2", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Neurosurgery"], "published-print": {"date-parts": [[1985, 2]]}, "DOI": "10.1097/00006123-198502000-00027", "type": "journal-article", "created": {"date-parts": [[2004, 8, 16]], "date-time": "2004-08-16T09:51:32Z", "timestamp": 1092649892000}, "page": "257???60", "source": "Crossref", "is-referenced-by-count": 2, "title": ["Currently available shunt systems"], "prefix": "10.1093", "volume": "16", "author": [{"given": "E M", "family": "Post", "sequence": "first", "affiliation": []}], "member": "286", "container-title": ["Neurosurgery"], "language": "en", "deposited": {"date-parts": [[2017, 1, 4]], "date-time": "2017-01-04T20:22:45Z", "timestamp": 1483561365000}, "score": 29.636662, "subtitle": ["a review"], "issued": {"date-parts": [[1985, 2]]}, "references-count": 0, "journal-issue": {"issue": "2"}, "URL": "http://dx.doi.org/10.1097/00006123-198502000-00027", "ISSN": ["0148-396X"], "issn-type": [{"value": "0148-396X", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 22]], "date-time": "2019-11-22T14:29:35Z", "timestamp": 1574432975726}, "reference-count": 0, "publisher": "Oxford University Press (OUP)", "issue": "2", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Neurosurgery"], "published-print": {"date-parts": [[1985, 2]]}, "DOI": "10.1227/00006123-198502000-00027", "type": "journal-article", "created": {"date-parts": [[2010, 5, 30]], "date-time": "2010-05-30T08:58:53Z", "timestamp": 1275209933000}, "page": "257-260", "source": "Crossref", "is-referenced-by-count": 14, "title": ["Currently Available Shunt Systems: A Review"], "prefix": "10.1093", "volume": "16", "author": [{"given": "Elisabeth M.", "family": "Post", "sequence": "first", "affiliation": []}], "member": "286", "container-title": ["Neurosurgery"], "language": "en", "deposited": {"date-parts": [[2017, 1, 30]], "date-time": "2017-01-30T20:37:42Z", "timestamp": 1485808662000}, "score": 29.636662, "subtitle": [""], "issued": {"date-parts": [[1985, 2]]}, "references-count": 0, "journal-issue": {"issue": "2"}, "URL": "http://dx.doi.org/10.1227/00006123-198502000-00027", "ISSN": ["0148-396X"], "issn-type": [{"value": "0148-396X", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T12:56:45Z", "timestamp": 1574513805872}, "reference-count": 0, "publisher": "Elsevier BV", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2012, 11, 1]], "date-time": "2012-11-01T00:00:00Z", "timestamp": 1351728000000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["European Journal of Cancer"], "published-print": {"date-parts": [[2012, 11]]}, "DOI": "10.1016/s0959-8049(12)72067-1", "type": "journal-article", "created": {"date-parts": [[2012, 11, 6]], "date-time": "2012-11-06T22:01:10Z", "timestamp": 1352239270000}, "page": "82-83", "source": "Crossref", "is-referenced-by-count": 0, "title": ["269 Does the Addition of Molecular Targeted Therapy to Standard Treatments Lead to Better or Worse Outcomes Overall? A Systematic Review and Meta-analysis of EGFR-targeted Therapies Used in Combination with Standard Treatments"], "prefix": "10.1016", "volume": "48", "author": [{"given": "J.", "family": "Rauw", "sequence": "first", "affiliation": []}, {"given": "M.", "family": "Ennis", "sequence": "additional", "affiliation": []}, {"given": "M.", "family": "Krzyzanowska", "sequence": "additional", "affiliation": []}, {"given": "S.", "family": "Sridhar", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["European Journal of Cancer"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0959804912720671?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0959804912720671?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 10, 21]], "date-time": "2018-10-21T17:27:57Z", "timestamp": 1540142877000}, "score": 29.435165, "issued": {"date-parts": [[2012, 11]]}, "references-count": 0, "alternative-id": ["S0959804912720671"], "URL": "http://dx.doi.org/10.1016/s0959-8049(12)72067-1", "ISSN": ["0959-8049"], "issn-type": [{"value": "0959-8049", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 21]], "date-time": "2019-11-21T01:36:57Z", "timestamp": 1574300217833}, "reference-count": 20, "publisher": "Springer Science and Business Media LLC", "issue": "1", "license": [{"URL": "http://creativecommons.org/licenses/by/2.0", "start": {"date-parts": [[2009, 5, 13]], "date-time": "2009-05-13T00:00:00Z", "timestamp": 1242172800000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["BMC Cancer"], "published-print": {"date-parts": [[2009, 12]]}, "DOI": "10.1186/1471-2407-9-145", "type": "journal-article", "created": {"date-parts": [[2009, 5, 13]], "date-time": "2009-05-13T19:29:13Z", "timestamp": 1242242953000}, "source": "Crossref", "is-referenced-by-count": 16, "title": ["A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer"], "prefix": "10.1186", "volume": "9", "author": [{"given": "Justin M", "family": "Balko", "sequence": "first", "affiliation": []}, {"given": "Esther P", "family": "Black", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2009, 5, 13]]}, "reference": [{"key": "1479_CR1", "doi-asserted-by": "publisher", "first-page": "508", "DOI": "10.1093/annonc/mdm496", "volume": "19", "author": "W De Roock", "year": "2008", "unstructured": "De Roock W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G, Personeni N, Biesmans B, Van Laethem JL, Peeters M, Humblet Y, et al: KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol. 2008, 19: 508-515. 10.1093/annonc/mdm496.", "journal-title": "Ann Oncol"}, {"key": "1479_CR2", "doi-asserted-by": "publisher", "first-page": "1166", "DOI": "10.1038/sj.bjc.6603685", "volume": "96", "author": "F Di Fiore", "year": "2007", "unstructured": "Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais MP, Bastit L, Killian A, Sesboue R, Tuech JJ, et al: Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer. 2007, 96: 1166-1169. 10.1038/sj.bjc.6603685.", "journal-title": "Br J Cancer"}, {"key": "1479_CR3", "doi-asserted-by": "publisher", "first-page": "374", "DOI": "10.1200/JCO.2007.12.5906", "volume": "26", "author": "A Lievre", "year": "2008", "unstructured": "Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouche O, Landi B, Louvet C, et al: KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol. 2008, 26: 374-379. 10.1200/JCO.2007.12.5906.", "journal-title": "J Clin Oncol"}, {"key": "1479_CR4", "doi-asserted-by": "publisher", "first-page": "3992", "DOI": "10.1158/0008-5472.CAN-06-0191", "volume": "66", "author": "A Lievre", "year": "2006", "unstructured": "Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Cote JF, Tomasic G, Penna C, Ducreux M, et al: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006, 66: 3992-3995. 10.1158/0008-5472.CAN-06-0191.", "journal-title": "Cancer Res"}, {"key": "1479_CR5", "first-page": "25", "volume": "23", "author": "D McBride", "year": "2008", "unstructured": "McBride D: KRAS status predicts response to cetuximab for metastatic colorectal cancer. ONS Connect. 2008, 23: 25-", "journal-title": "ONS Connect"}, {"key": "1479_CR6", "doi-asserted-by": "publisher", "first-page": "471", "DOI": "10.2217/14796694.4.4.471", "volume": "4", "author": "J Stebbing", "year": "2008", "unstructured": "Stebbing J: FLEX data, KRAS and ERCC1 testing in oncology. Future Oncol. 2008, 4: 471-473. 10.2217/14796694.4.4.471.", "journal-title": "Future Oncol"}, {"key": "1479_CR7", "doi-asserted-by": "publisher", "first-page": "1757", "DOI": "10.1056/NEJMoa0804385", "volume": "359", "author": "CS Karapetis", "year": "2008", "unstructured": "Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, et al: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008, 359: 1757-1765. 10.1056/NEJMoa0804385.", "journal-title": "N Engl J Med"}, {"key": "1479_CR8", "doi-asserted-by": "publisher", "first-page": "5900", "DOI": "10.1200/JCO.2005.02.857", "volume": "23", "author": "DA Eberhard", "year": "2005", "unstructured": "Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, Ince WL, Janne PA, Januario T, Johnson DH, et al: Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol. 2005, 23: 5900-5909. 10.1200/JCO.2005.02.857.", "journal-title": "J Clin Oncol"}, {"key": "1479_CR9", "doi-asserted-by": "publisher", "first-page": "e73", "DOI": "10.1371/journal.pmed.0020073", "volume": "2", "author": "W Pao", "year": "2005", "unstructured": "Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005, 2: e73-10.1371/journal.pmed.0020073.", "journal-title": "PLoS Med"}, {"key": "1479_CR10", "doi-asserted-by": "publisher", "first-page": "e17", "DOI": "10.1371/journal.pmed.0020017", "volume": "2", "author": "W Pao", "year": "2005", "unstructured": "Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, Zakowski MF, Heelan RT, Kris MG, Varmus HE: KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2005, 2: e17-10.1371/journal.pmed.0020017.", "journal-title": "PLoS Med"}, {"key": "1479_CR11", "doi-asserted-by": "publisher", "first-page": "289", "DOI": "10.1186/1471-2164-7-289", "volume": "7", "author": "JM Balko", "year": "2006", "unstructured": "Balko JM, Potti A, Saunders C, Stromberg A, Haura EB, Black EP: Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors. BMC Genomics. 2006, 7: 289-10.1186/1471-2164-7-289.", "journal-title": "BMC Genomics"}, {"key": "1479_CR12", "doi-asserted-by": "publisher", "first-page": "3230", "DOI": "10.1200/JCO.2006.10.5437", "volume": "25", "author": "S Khambata-Ford", "year": "2007", "unstructured": "Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, Wong TW, Huang X, Takimoto CH, Godwin AK, et al: Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol. 2007, 25: 3230-3237. 10.1200/JCO.2006.10.5437.", "journal-title": "J Clin Oncol"}, {"key": "1479_CR13", "doi-asserted-by": "publisher", "first-page": "1294", "DOI": "10.1038/nm1491", "volume": "12", "author": "A Potti", "year": "2006", "unstructured": "Potti A, Dressman HK, Bild A, Riedel RF, Chan G, Sayer R, Cragun J, Cottrill H, Kelley MJ, Petersen R, et al: Genomic signatures to guide the use of chemotherapeutics. Nat Med. 2006, 12: 1294-1300. 10.1038/nm1491.", "journal-title": "Nat Med"}, {"key": "1479_CR14", "doi-asserted-by": "publisher", "first-page": "353", "DOI": "10.1038/nature04296", "volume": "439", "author": "AH Bild", "year": "2006", "unstructured": "Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, Joshi MB, Harpole D, Lancaster JM, Berchuck A, et al: Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature. 2006, 439: 353-357. 10.1038/nature04296.", "journal-title": "Nature"}, {"key": "1479_CR15", "doi-asserted-by": "publisher", "first-page": "1288", "DOI": "10.1093/annonc/mdn058", "volume": "19", "author": "M Borner", "year": "2008", "unstructured": "Borner M, Koeberle D, Von Moos R, Saletti P, Rauch D, Hess V, Trojan A, Helbling D, Pestalozzi B, Caspar C, et al: Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK. Ann Oncol. 2008, 19: 1288-1292. 10.1093/annonc/mdn058.", "journal-title": "Ann Oncol"}, {"issue": "Suppl 6", "key": "1479_CR16", "doi-asserted-by": "publisher", "first-page": "vi8", "DOI": "10.1093/annonc/mdm216", "volume": "18", "author": "E Maiello", "year": "2007", "unstructured": "Maiello E, Giuliani F, Gebbia V, Piano A, Agueli R, Colucci G: Cetuximab: clinical results in colorectal cancer. Ann Oncol. 2007, 18 (Suppl 6): vi8-10. 10.1093/annonc/mdm216.", "journal-title": "Ann Oncol"}, {"key": "1479_CR17", "doi-asserted-by": "publisher", "first-page": "110", "DOI": "10.3816/CCC.2008.n.015", "volume": "7", "author": "N Moosmann", "year": "2008", "unstructured": "Moosmann N, Heinemann V: Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer. Clin Colorectal Cancer. 2008, 7: 110-117. 10.3816/CCC.2008.n.015.", "journal-title": "Clin Colorectal Cancer"}, {"key": "1479_CR18", "doi-asserted-by": "publisher", "first-page": "319", "DOI": "10.1586/14737140.8.3.319", "volume": "8", "author": "N Moosmann", "year": "2008", "unstructured": "Moosmann N, Heinemann V: Cetuximab plus oxaliplatin-based chemotherapy in the treatment of colorectal cancer. Expert Rev Anticancer Ther. 2008, 8: 319-329. 10.1586/14737140.8.3.319.", "journal-title": "Expert Rev Anticancer Ther"}, {"key": "1479_CR19", "doi-asserted-by": "publisher", "first-page": "2311", "DOI": "10.1200/JCO.2007.13.1193", "volume": "26", "author": "AF Sobrero", "year": "2008", "unstructured": "Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, Lutz MP, Vega-Villegas ME, Eng C, Steinhauer EU, Prausova J, et al: EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol. 2008, 26: 2311-2319. 10.1200/JCO.2007.13.1193.", "journal-title": "J Clin Oncol"}, {"key": "1479_CR20", "doi-asserted-by": "publisher", "first-page": "2040", "DOI": "10.1056/NEJMoa071834", "volume": "357", "author": "DJ Jonker", "year": "2007", "unstructured": "Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, et al: Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007, 357: 2040-2048. 10.1056/NEJMoa071834.", "journal-title": "N Engl J Med"}], "container-title": ["BMC Cancer"], "language": "en", "link": [{"URL": "http://link.springer.com/article/10.1186/1471-2407-9-145/fulltext.html", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/content/pdf/10.1186/1471-2407-9-145.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/content/pdf/10.1186/1471-2407-9-145", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}, {"URL": "http://link.springer.com/content/pdf/10.1186/1471-2407-9-145.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 1, 21]], "date-time": "2019-01-21T22:58:15Z", "timestamp": 1548111495000}, "score": 29.434158, "issued": {"date-parts": [[2009, 5, 13]]}, "references-count": 20, "journal-issue": {"published-print": {"date-parts": [[2009, 12]]}, "issue": "1"}, "alternative-id": ["1479"], "URL": "http://dx.doi.org/10.1186/1471-2407-9-145", "relation": {"cites": []}, "ISSN": ["1471-2407"], "issn-type": [{"value": "1471-2407", "type": "electronic"}], "article-number": "145"}, {"indexed": {"date-parts": [[2019, 12, 1]], "date-time": "2019-12-01T15:34:06Z", "timestamp": 1575214446409}, "reference-count": 0, "publisher": "PeerJ", "content-domain": {"domain": []}, "published-print": {"date-parts": [[2017, 1, 12]]}, "DOI": "10.7287/peerj.2880v0.1/reviews/1", "type": "peer-review", "created": {"date-parts": [[2017, 12, 24]], "date-time": "2017-12-24T06:46:06Z", "timestamp": 1514097966000}, "source": "Crossref", "is-referenced-by-count": 0, "title": ["Peer Review #1 of \"Resources available for autism research in the big data era: a systematic review (v0.1)\""], "prefix": "10.7287", "author": [{"given": "M", "family": "Lombardo", "sequence": "additional", "affiliation": []}], "member": "4443", "review": {"revision-round": "2", "stage": "pre-publication"}, "deposited": {"date-parts": [[2017, 12, 24]], "date-time": "2017-12-24T06:46:06Z", "timestamp": 1514097966000}, "score": 29.188477, "issued": {"date-parts": [[2017, 1, 12]]}, "references-count": 0, "URL": "http://dx.doi.org/10.7287/peerj.2880v0.1/reviews/1", "relation": {"is-review-of": [{"id-type": "doi", "id": "10.7717/peerj.2880", "asserted-by": "subject"}]}}], "items-per-page": 20, "query": {"start-index": 0, "search-terms": null}}}